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The Acquired Immunodeficiency Syndrome (AIDS), caused by infection with
Human Immunodeficiency Virus (HIV), was only described in 1981 yet there are
now over 600,000 confirmed cases world-wide. In the USA where the illness was
first described 2/3 of the AIDS cases have been in homo/bisexuals and 1/3 have been
injection drug users. In the UK as a whole by mid 1993 over 8000 cases ofAIDS
had been reported, over 70% in homosexuals and only 6% as a consequence of
injection drug use(IDU).
For a variety of socio-economic reasons an epidemic of IDU involving heroin
occurred during the early 1980's in Edinburgh: one third were female, most were
young, unemployed and living on large council estates. At the peak of this IDU
epidemic, HIV arrived and rapidly spread through this community. By July 1989
over 1000 individuals or 0.1% of the population of Lothian (750,000) had been
recognised to have been infected with HIV, the majority via IDU. This is of the same
order as the worst affected region in England (North West Thames). The majority of
these individuals however live in the City of Edinburgh with a population of only
around 300,000 (1981 census). Consequently a realistic prevalence for this
population is actually 0.3% or 3 times the worst affected English region. Thus this
new area ofmedicine has considerable relevance for future medicine in Edinburgh
and Scotland.
The thesis describes the disease, the epidemiology of Injection Drug Use and IDU
related HIV and the early epidemic in Edinburgh. It also describes the clinical
services that were developed at the City Hospital in Edinburgh and the problems that
this new service encountered. The provision of health care for this difficult patient
population facilitated a variety of research projects. The thesis describes some of the
results of these projects particularly those concerned with natural history, clinical
presentation and use of anti-retroviral therapy in IDU related HIV. Lastly the factors
found to affect the transmission ofHIV to the heterosexual partners of the patients
are presented together with their relevance for other populations.
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List of Abbreviations
ACMD Advisory Council on the Misuse ofDrugs
AIDS Acquired Immune Deficiency Syndrome
ALOS Average Length of Stay
AMJ Dr Ann M Johnson
ARC AIDS Related Complex
ARV Aids Related Virus, the name used in San Francisco for the virus now
known as HIV
AUC Area Under the Curve
AZT Zidovudine (Retrovir), a nucleoside analogue and anti-HIV compound
CDC Centers for Disease Control, Atlanta
CDPS Community Drugs Project Sevice, Edinburgh. A psychiatric
service for drug users set up in 1988 to work with drug users via general
practitioners.
CD200 The CD200 diagnosis was defined as the first of two consecutive CD4
counts below 200 or an AIDS diagnosis, whichever was earlier.
CD4 A specific receptor molecule on a T lymphocyte helper cell,
called CD4 after the monoclonal antibodies that specifically




cumm cubic millimetre or mililitre
DDI Dideoxydidanosine, nucleoside analogue and anti-HIV compound
DF118 Dihydrocodeine
DNA Deoxyribonucleic acid
DSS Department of Social Security
DTF a form of liquid methadone
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ELISA Enzyme linked immunosorbent assay
FDA Federal Drug Administration
GAZT 3'-azido- 3'-deoxy-5'-beta-D-glucopyranuronosylthymidine or
the glucoronide metabolite of zidovudine
GG&GD Public Health and Environment Department of Amsterdam
Municipal Medical Health Care Service
GUM Genito Urinary Medicine
HBV Hepatitis B virus
Het Infected with HIV via heterosxual intercourse
HIV Human Immunodeficiency Virus
HLA Human Leucocyte Antigen
HSV Herpes Simplex Virus
HMP Her Majesty's Prison
Ho/bi Homosexual or bisexual
HTLV III Human T lymphotropic Virus III, the name used by Dr Gallo in
Washington USA to describe the virus now known as HIV
ID Infectious Diseases
IDU Injection Drug Use
IDUs Injection Drug Users
IgA Immunoglobulin type A
IgG Immunoglobulin type G
IgM Immunoglobulin type M
Inserm French Medical Research Council
IP Inpatient
ITP Immune thrombocytopenia
ITU Intensive Therapy Unit
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LAV Lymphadenopathy Virus, the name used by Dr Montagnier in France to








MMTP Methadone maintenance treatment programmes
MRIHS Montefiore Rikers Island Health Service
MRC Medical Research Council
NIDA National Institute on Drug Abuse, Washington, USA




PAIS Patient Assessment Information System
PCP Pneumocystis Carinii Pneumonia
PGL Persistent Generalised Lymphadenopathy
PML Progressive Multi Focal Leucoencephalopathy
RNA Ribonucleic acid
RIDU Regional Infectious Disease Unit, City Hospital, Edinburgh
ROI Risk of Infection
RPB Raymond Patrick Brettle
RR Relative Risk
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RW Sister RhonaWyld and Sister Roseana Wightman
RVL Regional Virus Laboratory
SAS A commercial statistical software package
SCODA Standing Committee on Drug Abuse
SD Standard deviation
SE Standard error
SFGH San Francisco General Flospital
SJD Sister Susan Davidson
SPSS/PC A commercial statistical package for social sciences
UK United Kingdom
UTI Urinary Tract Infection
URTI Upper Respiratory Tract Infection
US United States of America
USA United States ofAmerica
TB Tuberculosis
T cell A lymphocyte associated with cell mediated immunity
T4 cell A helper lymphocyte, also known as a CD4 lymphocyte
Tran Infected with HIV via blood products
WHO World Health Organisation
WTE Whole time equivalent
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Summary
This thesis contains an initial introductory section describing the condition ofHIV
and AIDS, injection drug use and injection drug use related HIV particularly the
epidemic that affected Edinburgh.
The second section describes services developed at the RIDU, City Hospital,
Edinburgh in response to the problem of IDU related HIV, compares them with
services developed at other centres in the USA and Holland, evaluates their ability to
attract and retain patients, introduces the concept of harm reduction and the ability of
the services to reduce high risk behaviour.
The third section aims to describe the research work undertaken as a result of
establishing the services at the RIDU in Edinburgh particularly the early use of
zidovudine, the natural history of IDU related HIV. It also reviews the clinical
problems of IDU before describing the clinical problems of IDU related HIV as seen





Human Immunodeficiency Virus and The Acquired Immune Deficiency
Syndrome
Introduction
The original description of AIDS or the Acquired Immune Deficiency Syndrome
appeared in 19811. It described 26 patients with Kaposi's sarcoma (a skin tumour
which until then had only been seen in elderly men, in African races, and in those
with considerable iatrogenic immunosuppression) and 5 men with oral thrush and
Pneumocystis pneumonia which again, was usually associated with iatrogenic
immunosuppression. The connection between the two groups was that the men were
all young male homosexuals with a mean age of 32 years12. The first 9 cases of
AIDS amongst injection drug users were diagnosed retrospectively to have occurred
in 1980 and 4 of these were also homosexuals^. The first case of transfusion
associated AIDS occurred in a young child who had a platelet transfusion^. Between
1978 and 1983 in the United States the risk of acquiring AIDS via blood transfusion
was estimated at 0.6 cases of AIDS per one hundred thousand adults transfused and
2.8 cases ofAIDS per one hundred thousand children transfused^. The risk was
increased by a factor of 32 for adults given more than 10 units of blood and by a
factor of 27 for children given more than 10 units of blood^. The risk with whole
blood, packed cells, platelets or frozen plasma and the mean incubation period from
transfusion to the development ofAIDS was 21 months for children and 31 months
for adults^. The risk of acquiring HIV from an infected blood product appeared to be
about 66% and infection was more likely the closer the donor was to developing
AIDS^. This does rather suggest that infectivity in donors rises as they develop
symptoms. Other "high risk groups" were also soon recognised including
haemophiliacs, the heterosexual partners of patients with AIDS and children^"' 8
At any one time, approximately 50% of the cumulative number ofAIDS cases have
died 19. The current mortality depends upon the index condition at presentation; for
instance those presenting with an opportunistic infection (OI) have a current case
mortality rate of over 50% whereas those with Kaposi's sarcoma have a case
mortality rate of only 33%. Those patients presenting with both an OI and Kaposi's
sarcoma have a current case mortality rate of 63%19. The survival time also varies
with the type of presentation in AIDS, the medium survival time for those patients
with Kaposi's sarcoma in the absence ofOIs varies between 20 and 30 months
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whereas the median survival time for patients with OIs varies between 4 and 11
months20>21
The causative virus involved in AIDS was first isolated in 1983 by Dr. Luc
Montagnier and it was propagated in a cell line by Dr. Robert Gallo in 198422,23 a
variety of names were used for the virus initially, including LAV, ARV and HTLV-
III but these have all now been replaced by HIV24. HIV is a retrovirus i.e. an RNA
virus which utilises an enzyme known as DNA polymerase or reverse transcriptase to
produce a DNA provirus that is able to insert itself into the host DNA It contains 3
major genes, gag, pol and env25.
The gag gene codes for the core or shell proteins that enclose the RNA These
proteins are also known as p24, pi8 and pi5. The pol gene codes for at least 3
enzymes, protease, reverse transcriptase, and an endonuclease. The env gene codes
for the outer spike glycoproteins and transmembrane glycoproteins. These are also
known as gpl20 and gp41. Before leaving a host cell a newly assembled virus takes
with it part of the host cell membrane into which the gpl20 and gp41 viral proteins
have been inserted.
HIV preferentially infects lymphocytes that function as T helper cells. These cells
are distinguished by the presence of a specific receptor molecule known as CD4 after
the monoclonal antibodies that specifically recognise the molecule. The gpl20 viral
protein appears to bind specifically to the CD4 receptor molecule before penetrating
into the cell. In addition to helper lymphocytes this receptor molecule may be found
on 10 - 20% ofmonocytes or macrophages, Langerhans cells in the dermis and
microglial cells in the central nervous system25.
The various viral proteins produced by HIV infection stimulate an immune response
although in many individuals this immune response does not neutralise or protect
against the virus. The major antibody response is against the env gene products or
outer glycoproteins notably gpl20. Antibodies against gpl20 appear about 6 weeks
after infection and persist until the terminal stages of AIDS Soon after this
antibodies against the gag or core proteins, notably p24, appear. High levels of anti
p24 may be protective since low levels predispose to the development of AIDS25.
The commercial assays available for screening purposes detect gpl20 antibodies and
are usually based on a competitive or anti-globulin enzyme linked immunosorbent
assay (ELISA). Commercial assays are now available to detect anti p24 antibody as
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well as antigen. The appearance ofHIV p24 antigen in the circulation together with
the loss of anti p24 antibody is thought to be predictive of progression to AIDS25-28
The Centers for Disease Control Clinical Staging System
The Centers for Disease Control (CDC) in Atlanta introduced a definition to help
collate accurate information about the condition. This definition of AIDS initially
only required the clinical diagnosis of conditions that were moderately predictive of
cellular immunodeficiency without an underlying cause. The definition was revised
in 1987 to take into account serological evidence ofHIV infection and is set out in
full in the appendix to this chapter^.
It was soon recognised that in addition to AIDS there were a number of other
conditions related to HIV infection. The exact inter-relationship and natural history
ofHIV is as yet not known but in an attempt to ease the problem of definition, the
CDC developed a classification system which is descriptive and does not attempt to
define any inter-connections29. it essentially details four mutually exclusive
categories or groups ofHIV infection as shown in Table 1.1.
Table 1.1: Classification of effects of HIV infection
CDC Stage Clinical Description
I acute infection with seroconversion
II asymptomatic infection
III persistent generalised lymphadenopathy
IV Symptomatic HIV disease
IV A constitutional symptoms and disease
IV B neurological disease
IV C immunodeficiency
IV CI 1982 CDC definition ofAIDS
IV C2 infections out with AIDS definition
IV D tumours in CDC definition ofAIDS
IV E Other e.g. Hodgkins, carcinoma, lymphoid
interstitial pneumonia, symptomatic
thrombocytopenia
This classification system for HIV is not meant to suggest that every individual has
to progress through all stages but it is hierarchical i.e. having reached a particular
stage the patients do not revert to earlier stages if the signs or symptoms settle. CDC
stage IV is however further divided into 5 subsections which are not exclusive and
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patients in this group may be included in one or more of the sub groups. The
conditions detailed in stage IV contain all those conditions currently used for the
definition ofAIDS as well as others that indicate clinically significant HIV infection.
A similar staging system was also developed for children but this will not be
described in detail.
Primary HIV Infection
CDC stage I describes those individuals that undergo a self limiting illness whilst
seroconverting for HIV. Primary infection with HIV may be associated with acute
clinical manifestations for example a "glandular fever" like illness or less commonly
an acute neurological illness for instance meningo-encephalitis or peripheral
neuropathy 30-40
Patients with the glandular fever like illness complain of sore throat, non specific
"flu" like symptoms and gastrointestinal disturbances. An erythematous macular rash
is present in around 50% of patients. It is initially prominent in the trunk and later
involves the extremities. Other skin manifestations include urticaria, loss of hair, and
desquamation of palms and soles30-32,36,41 Generalised lymphadenopathy is a
feature in around 75% of patients and in some patients may be associated with
splenomegaly and tender hepatomegaly30,41,42
Patients may present with symptoms of acute aseptic meningitis such as headache,
fever, photophobia and neck stiffness. Cerebrospinal fluid findings are typical of
viral infection30,31 . HIV has been isolated from the cerebrospinal fluid in certain
cases, and also from peripheral blood39. The clinical features ofHIV
encephalopathy during primary infection consist of mood changes, confusion,
convulsion and incontinence. Abnormalities on neurological examination include
altered conscious level, extensor plantar responses, sensorimotor peripheral
neuropathy including facial palsy38,40 other neurological manifestations have
been reported; myelopathy, Guillain-Barre syndrome, and radiculopathy^1-45
The incubation period, defined as the time from exposure to clinical symptoms of
acute HIV infection has been variable ranging from a few days to up to a few
months30>40 it is feh that the incubation period may be longer in sexually
transmitted HIV infection because of a smaller dose of innoculum and the non
parenteral route of transmission 1 >46. However, incubation periods of up to 6
months have been documented via the parenteral route47,48
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Seroconversion is defined as the time from infection to the detection of specific
antibodies and has occurred from 8 days to 10 weeks after the onset of acute
illness30>31,49 IglVl antibodies are first detected by immunofluorescence and an
IgG immunofluorescent antibody test has been found to be more sensitive than either
ELISA or Western Blotting in detecting primary HIV infection. The characteristic
pattern of specific antibody responses to the various viral proteins have been
described^.
Severe immunodepresssion may occur during acute HIV infection^ 1. Oesophageal
candidiasis has been reported in a number of patients during acute HIV infection, and
other OIs e.g. tuberculous meningitis have also been reported 8 weeks after acute
HIV infection52-54,56
Early Manifestations ofHIV Infection
CDC stage II describes those individuals who are essentially well or asymptomatic
but have antibodies for HIV. They may be further subdivided after laboratory
investigations into those with immunological abnormalities and those without,
however this has no prognostic value since at present the natural history ofCDC
stage II is incompletely understood.
CDC stage III describes those individual with enlarged lymph nodes (greater than 1
cm) at two or more non adjacent sites for longer than three months in the absence of
any other illness to explain the findings. This condition is also known as Persistent
Generalised Lymphadenopathy (PGL). Commonly the enlarged nodes are found
down the front and or back of the neck, under the jaw or in the axillae and may not be
noticed by the patient. Massive enlargement can occasionally occur. Unusual sites
for lymph node enlargement do occur for instance at the elbow, behind the knee,
down the front of the thigh, down the side of the chest wall, in the abdominal wall, or
behind the nipples. This lymph node enlargement may be accompanied by other
troublesome symptoms such as tiredness, lethargy, excessive sweating, aches and
pains in muscles or joints.
Late Manifestations ofHIV Infection
CDC stage IV is divided into five further sub- sections labelled A to E and this stage
has to be regarded as being more serious although some individuals may be relatively
well. AIDS Related Complex or ARC is a term which is commonly used, has a
number of definitions but is anyway covered by CDC stage IV.
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Stage IV A describes those individuals complaining of the vague constitutional
symptoms of stage III but with the addition ofmore serious problems such as
unexplained diarrhoea, fever (greater than 38°C) for longer than 1 month or
unexplained weight loss ofmore than 10% body weight.
Stage IV B consists of neurological problems associated with HIV other than those
occurring during CDC stage I. Examples are neuropathy and myelopathy. Disabling
cognitive and or motor dysfunction interfering with occupation or the activities of
daily living can also occur. Patients or relatives may notice loss ofmemory and loss
of skills such as mental arithmetic or decision making. Relatives may notice changes
in personality which early on seem like eccentricities. Frank mental illness, dementia
or loss of consciousness if no other pathogens are found in the setting ofHIV
infection is called HIV encephalopathy and is one criterion for the diagnosis of full
blown AIDS.
Stage IV C describes a number of infections which occur as a result of
immunodeficiency secondary to HIV infection and is divided into two sub groups IV
CI and IV C2.
• CDC stage IV CI includes individuals suffering from one or more of 12 infections
which formed the basis of the original CDC definition ofAIDS.
• Stage IV C2 contains those infections which are commonly associated with serious
HIV infection but are not in the original description ofAIDS. Examples of infections
in stage IV C2 are recurrent and invasive salmonella, extensive herpes zoster or
shingles, recurrent oral thrush or candidiasis, a condition almost unique to HIV called
oral hairy leucoplakia and recurrent severe bacterial sepsis in adults.
CDC stage IV D groups together all those cancers specifically associated with HIV
infection and as with CDC stage IV CI some of these conditions also fulfil the CDC
definition ofAIDS. Examples are the skin tumour Kaposi's sarcoma and cancers of
the lymph nodes such as non-Hodgkins lymphoma or primary lymphoma of the
brain.
CDC stage IV E is designed to cover those conditions not yet described or those not




Until recently the CDC classification was the only viable clinical classification
system used to stage HIV. It is likely that with the increasing use ofCD4 counts a
new WHO/CDC classification system will be utilised in its place5^57.
It essentially consists of three broad clinical stages, well or asymptomatic, HIV
related diseases and AIDS combined with three stages of immunodeficiency as
measured by either CD4 counts (>500 cell/cumm, 200-500 and < 200) or lymphocyte
counts (Table 1.2). When combined in a three way table there are thus 9 possible
stages. In the USA everyone with a CD4 count below 200 is to be classified as AIDS
although this seems unlikely to happen in Europe for the present57. The CDC also
proposed that three new clinical problems be added to the 1987 definition of
AIDS57. These are
• cervical cancer
• two episodes of bacterial pneumonia in a 12 month period
• pulmonary tuberculosis.
These new clinical definitions ofAIDS may be added to the UK definition in the near
future.
Table 1.2: WHO/CDC classification system for HIV
Laboratory Classification Clinical Category*
Absolute CD4 count or Total lymphocyte
count (TLC)
A B C
1 >500/cumm >2000/cumm A1 B1 CI
2 200-499/cumm 1000-1999/cumm A2 B2 C2
3 <200/cumm < 1000/cumm A3 B3 C3
*Definitions ofClinical Groups for Table 1.2
Clinical category A: (Asymptomatic disease) Acute infection with HIV; persistent
generalised lymphadenopathy; asymptomatic. Conditions in Groups B and C must
be absent.
Clinical category B: (Symptomatic disease) Any symptomatic conditions not included
in Category C. Examples are bacterial infections, candidiasis (oral or vulvovaginal)
for > 1 month, cervical dysplasia or carcinoma, constitutional symptoms, oral hairy
leukoplakia. Two distinct episodes ofherpes zoster or involving more than one
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dermatome, idiopathic thrombocytopenia purpura, mycobacterium tuberculosis,
peripheral neuropathy.
Clinical category C: Any condition which meets the 1987 CDC/WHO case definition
for AIDS.
Laboratory Features of HIV Infection
Immunology
AIDS is characterised by a marked depletion of CD4 lymphocytes in the peripheral
blood. Exactly how this depletion takes place is as yet unclear but a number of
possible mechanisms have been suggested including, a direct cytopathic effect of
HIV, syncytia or giant cell formation with subsequent cell death and a form of auto
immunity against lymphocytes using either cytotoxic T cells or other anti
lymphocytic factors^.
The major effect ofHIV infection appears to be damage to cell mediated immune
mechanism resulting in characteristic susceptibility to opportunistic infections. This
susceptibility is usually to intracellular organisms such as latent viruses, fungi or
protozoa. Such organisms require the presence of an intact cell mediated immune
system which relies on T lymphocytes and macrophages. The clinical course of the
illness is associated with a marked depletion of peripheral blood CD4 lymphocytes
which play a key role in initiating and promoting immune responses including the
initiation of a de novo humoral response. Most adults with HIV infection seem to
have reasonable B cell memory although recurrent bacterial infections can occur in
HIV infection. This humoral defect is worst in children where B cell memory is
limited and the patient may be rendered effectively hypogammaglobulinaemic. The
humoral defect also limits the usefulness of serology in the diagnosis ofmany
disorders, for instance latent viruses may exhibit persistent and stable levels of
antibodies and other organisms produce little in the way of an antibody response^.
The marked loss of T cell immunity results in a susceptibility to reactivation of latent
or controlled infections such as CMV, Toxoplasmosis or Tuberculosis (TB) or to
attack by relatively non pathogenic organisms which may be endogenous or common
in the patient's environment. Examples of this type of infection are Pneumocystis
carinii pneumonia (PCP), candidiasis or atypical mycobacteria.
The loss of T cell function also results in only limited macrophage activity. Infection
in these patients often produces little in the way of an inflammatory response and
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consequently little in the way of clinical signs. A number of immunological
abnormalities have been described including:
• leucopenia and lymphopenia.
• loss of T4 lymphocytes from the peripheral blood.
• hypergammaglobulinemia.
• skin anergy.
• decreased in vitro lymphocyte proliferation, cytotoxic T cell response and
antibody production to new antigens.
• elevated levels of immune complexes, interferon and P-2-
microgobulin58.
Haematology
The haematological abnormalities associated with HIV infection vary with the
clinical state of the patient but are commoner as HIV infection progresses. For
instance 12% ofAIDS/AIDS Related Complex (ARC) patients were leucopenic, 20%
were neutropenic, 75% were lymphopenic and 93% were anaemic^9,60 j^e reasons
for these abnormalities are multifactorial and involve the effects ofHIV infection,
drug effects, chronic infection and the effects of opportunistic infections. In a series
of patients who underwent bone marrow examination a number of abnormalities were
noted including:
• reticuloendothelial iron blockade.
• dyserythropoeisis and megaloblastic change.
• erythroid hypoplasia.
• excess histiocytes and viral associated haemophagocytosis^.
Despite the peripheral lymphopenia, bone marrow lymphopenia is uncommon
perhaps because T cells predominate in the peripheral blood whereas B cells
predominate in the bone marrow. Immune thrombocytopaenia (ITP) is usually
associated with children and middle aged women. An ITP syndrome was noted early
on to be an AIDS related condition in homosexuals, injection drug users, and
haemophiliacs61_64 in patients with AIDS about 30% have a depressed platelet
count and it often falls further with treatment for PCP61>65 Jhe platelet count is
generally depressed in HIV infection and ITP has been noted to occur in HIV
infection before the advent ofAIDS61-63_ jn 0ther studies about 5-10% ofPGL
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patients have mildly depressed platelet counts^. The commonest symptoms are
excessive bruising, epistaxis, menorrhagia, gingival and rectal bleeding. Major life
threatening haemorrhage is rare. Platelet associated immunoglobulin has been
demonstrated in the majority of patients studied65.
The General Epidemiology of AIDS and HIV
Transmission ofHIV in the USA and Europe basically involves homo/bisexuals and
injection drug users whereas in Africa it is essentially a heterosexually transmitted
disease^. in the rest of the world transmission ofHIV is mainly as a sexually
transmitted disease from individuals travelling to these areas from areas of high
seroprevalence or occurs because of the importation of infected blood products from
areas of high seroprevalence. These patterns of spread have been designated type I,
II and III respectively by the WHC)67, More recently the importance of bisexuals in
the spread of infection to non drug using heterosexual women has been demonstrated
in South America^.
By end of 1992, 611,589 cases ofAIDS had been notified world wide; 242,146 from
the United States alone and 313083 from the whole of the Americas, 209805 from
Africa, 81,091 from Europe with 6510 from the United Kingdom, 4846 from the
Western Pacific, 1539 from the Eastern Mediterranean and 1225 from South East
Asia (Figure 1.1 and 1.2)69. ^ must be remembered that the cases from Africa are a
gross underestimate of the size of the problem for a variety of reasons but mostly as a
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There appears to be little variation between the risk groups with regard to
presentation. In the USA, figures are available on the 30 632 cases ofAIDS notified
to the Centers for Disease Control by the 9 February 1987^0. These show that
conditions such as Kaposi's Sarcoma (KS) are unusual in the absence of
homo/bisexuality. In drug users, KS, cytomegalovirus and chronic cryptosporidiosis
are all significantly less common than for all other risk groups notified with AIDS;
while Pneumocystis carinii pneumonia (PCP), TB, oesophageal candidiasis and
extra-pulmonary cryptococcosis are more common. The effect of risk group on
presentation in Edinburgh will be discussed in Chapter 17.
The distribution of cases was characteristic of a blood borne or blood associated virus
since transmission occurred via blood contact, via sexual intercourse and perinatally.
Consequently, the patients likely to be affected are:
• homosexuals/bisexuals.
• injection drug users.
• the recipients of blood products either coagulation products or blood
itself, especially prior to 1985 when testing became available in the
United Kingdom and the United States.
• the children of infected females.
• heterosexual contacts of infected patients.
In the United States 70% of the AIDS cases are associated with homosexual
intercourse, 24% with drug use and/or homosexual intercourse, 2% with heterosexual
intercourse, 2% with receiving blood transfusions, and 1% with haemophilia^, in
Europe however, injection drug use is even commoner than in the USA and accounts
for 34.5% of the reported AIDS cases^l. Some 87% of these IDU related cases have
been reported by just three countries i.e. France, Italy and Spain. There is a small but
an increasing number of paediatric cases, the majority of which are associated with
HIV infection in the mother7 1.
In the United Kingdom by 30 September 1993, 74% of the AIDS cases had been
associated with homo/bisexual intercourse, 11% with heterosexual intercourse, 4%
with injection drug use and 6% with blood products (figure 1.3)72. The number of
HIV reports by risk activity also show a predominance of homo/bisexual
transmission (fig. 1.4).
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30September1993
Only 438 or 5.4% of the UK AIDS cases had come from Scotland but 142 of these
were drug users^. By comparison to the UK as a whole, in Scotland, IDU currently
accounts for 32% of the AIDS reports and some 50% originate from Lothian (fig 1.5
and 1.6)73,74 in the UK as a whole, whilst IDU represented only 12% of reports of
those infected with HIV this contrasted markedly with the position in Scotland where
48% of those infected with HIV have implicated IDU and 51% of those reports had
come from Lothian (fig 1.7 and 1.8 )72,73 p^ig dramatic change of risk activity
distribution over time is shown in figure 1.9.
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The surveillance definitions of AIDS
The Centers for Disease Control, Atlanta produced a revised definition ofAIDS in 1987
which is as follows.
I. Without laboratory evidence ofHIV infection.
If laboratory tests for HIV are not available then provided the following conditions (under I
A) are not present a diagnosis ofAIDS can be made provided the disease is diagnosed
definitively (under I B).
I A. Causes of immunodeficiency that disqualify diseases as indicators ofAIDS in
the absence of evidence ofHIV infection.
1. High dose or long term systemic corticosteroid therapy or other
immunosuppressive/cytotoxic therapy for < or = 3 months before the onset of
the indicator disease.
2. Any of the following disease diagnosed for < or = 3 months after the diagnosis
of the indicator disease: Hodgkin's disease, non- Hodgkins lymphoma (other
than primary brain lymphoma), lymphocytic leukaemia, multiple myeloma, any
other cancer of the lymphoreticular or histiocytic tissue, or angioimmunoblastic
lymphadenopathy.
3. A genetic (congenital) immunodeficiency syndrome or an acquired
immunodeficiency syndrome atypical ofHIV infection, such as one involving
hypogammaglobulinemia.
I B. Indicator disease diagnosed definitively:
1. Candidiasis of the oesophagus, trachea, bronchi, or lungs.
2. Cryptococcosis, extra pulmonary.
3. Cryptosporidiosis with diarrhoea for > 1 month.
4. Cytomegalovirus disease of an organ other than the liver, spleen, or lymph
nodes in a patient > or = 1 month of age.
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5. Herpes simplex virus infection causing a mucocutaneous ulcer that persists for >
1 month; or bronchitis, pneumonitis, or oesophagitis for any duration affecting a
patient > or = 1 month of age.
6. Kaposi's sarcoma affecting a patient < or = 60 years of age.
7. Lymphoma of the brain (primary) affecting a patient < or - 60 years of age.
8. Lymphoid interstitial pneumonia and or pulmonary lymphoid hyperplasia
(LIP/PLH) complex affecting a child less than or equal to 12 years of age.
9. Mycobacterium avium complex or M. kansasii disease, disseminated (at a site
other than or in addition to lungs, skin, or cervical or hilar lymph nodes).
10. Pneumocystis carinii pneumonia.
11. Progressive multifocal leukoencephalopathy.
12. Toxoplasmosis of the brain affecting a patient > or = 1 month of age.
II. With laboratory evidence ofHIV infection.
Regardless of the presence of other causes of immunodeficiency outlined above (under I A),
in the presence of laboratory evidence ofHIV infection, any disease listed above (under I B)
or below (under II A or II B) indicates a diagnosis ofAIDS.
II A. The following conditions, diagnosed definitively;
1. bacterial infections, multiple or recurrent (any combination of at least two
within a 2-year period), of the following types affecting a child <13 years of
age: septicaemia, pneumonia, meningitis, bone or joint infection, or abscess of
an internal organ or body cavity (excluding otitis media or superficial skin or
mucosal abscesses), caused by Haemophilus, Streptococcus (including
pneumococcus), or other pyogenic bacteria.
2. coccidioidomycosis, disseminated (at a site other than or in addition to lungs of
cervical of hilar lymph nodes).
3. HIV encephalopathy (also called "HIV dementia", "AIDS dementia", or "sub
acute encephalitis due to HIV").
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4. histoplasmosis, disseminated (at a site other than or in addition to lungs or
cervical or hilar lymph nodes).
5. isosporiasis with diarrhoea persisting >1 month.
6. Kaposi's sarcoma at any age.
7. lymphoma of the brain (primary) at any age.
8. other non-Hodgkin's lymphoma of B-cell or unknown immunological
phenotype and the following histological types:
9. small non cleaved lymphoma (either Burkitt or non- Burkitt type).
10. immunoblastic sarcoma (equivalent to any of the following, although not
necessarily all in combination: immunoblastic lymphoma, large-cell lymphoma,
diffuse histiocytic lymphoma, diffuse undifferentiated lymphoma, or high grade
lymphoma).
11. Note: Lymphomas are not included here if they are of T-cell immunological
phenotype or their histological type is not described or is described as
"lymphocytic", "lymphoblastic", "small cleaved", or "plasmacytoid
lymphocytic".
12. any mycobacterial disease caused by mycobacteria other than M. tuberculosis,
disseminated (at a site other than or in addition to lungs, skin or cervical or hilar
lymph nodes.
13. disease caused by M. tuberculosis, extra pulmonary (involving at least one site
outside the lungs, regardless ofwhether there is concurrent pulmonary
involvement.
14. Salmonella (non typhoid) septicaemia, recurrent.
15. HIV wasting syndrome (emaciation, "slim disease").
II B. The following conditions, diagnosed presumptively;
1. Candidiasis of the oesophagus.
2. Cytomegalovirus retinitis with loss of vision.
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3. Kaposi's sarcoma.
4. Lymphoid interstitial pneumonia and or pulmonary lymphoid hyperplasia
(LIP/PLH) affecting a child < or = 13 years of age.
5. Mycobacterial disease (acid-fast bacilli with species not identified by culture),
disseminated (involving at least one site other than or in addition to lungs, skin,
or cervical or hilar lymph nodes).
6. Pneumocystis carinii pneumonia.
7. Toxoplasmosis of the brain affecting a patient > or = to 1 month of age.
III. With laboratory evidence against HIV infection.
With laboratory test results negative for HIV infection, a diagnosis ofAIDS for surveillance
purposes is ruled out unless:
A. All the other causes of immunodeficiency listed above are excluded and
B. The patient has had either:
1. Pneumocystis carinii pneumonia diagnosed by a definitive method or
2. any of the other disease indicative ofAIDS listed above diagnosed by a
definitive method and





This includes the acute retroviral syndrome of initial infection, the asymptomatic and
those with persistent generalised lymphadenopathy.
WHO Symptomatic
This has been divided into two areas;
WHO Stage 2
• Weight loss < 10% of body weight
• Mucocutaneous manifestations such as seborrhoeic dermatitis, prurigo, fungal
nail infections, recurrent oral ulcerations, angular cheilitis.
• Herpes zoster
• Recurrent upper respiratory tract infections such as bacterial sinusitis.
WHO Stage 3
• Weight loss > 10% of body weight
• Unexplained chronic diarrhoea > 1 month.
• Unexplained prolonged fever (intermittent or constant > 1 month).
• Candidiasis, oral.
• Candidiasis, vulvovaginal for > 1 month
• Oral hairy leukoplakia.
• Pulmonary tuberculosis.
• Severe bacterial infections such as pneumonia or pyomyositis.




• Bed ridden for > 50% of the day during the last month.
• Candidiasis of the oesophagus, trachea, bronchi or lungs.
• Cryptococcus, extrapulmonary
• Cryptosporidiosis with diarrhoea for > 1 month.
• Cytomegalovirus disease of an organ other than the liver, spleen or lymph nodes.
• Herpes simplex infection, mucocutaneous for > 1 month or visceral for any
duration.
• HIV dementia (encephalopathy).
• Isosporiasis with diarrhoea for > 1 month.
• Kaposi's sarcoma
• Lymphoma
• Mycobacterium tuberculosis - extrapulmonary
• Mycobacteriosis- atypical and disseminated.
• Mycosis - disseminated histoplasmosis or coccidioidomycosis.
• Pneumocystis carinii pneumonia.
• Progressive multifocal leukoencephalopathy.
• Salmonella septicaemia (non-typhoidal)
• Toxoplasmosis of the brain.
• Wasting syndrome due to HIV.
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The medical complications of drug use are many and varied and include, the
excessive effects of drugs themselves, the withdrawal effects from drugs, and a
number of associated medical conditions. It is difficult to quantify the workload for
the health service but one survey from Dundee revealed that heroin drug users had
twice the general practice consultation rate ofmatched controls (7/yr. versus
3.25/yr.)l. In Glasgow 0.6% of all consultations at an accident and emergency
facility were by injection drug users and two thirds of these consultations were
deemed medical or surgical and one third "psychiatric" suggesting that the addiction
problems were in a minority^. A second Scottish survey of accident and emergency
referrals revealed that 60% were related to the effects of drugs (37% related to an
excess of drugs or overdoses and 23% related to withdrawal from drugs), 21% to
infections, 8% to trauma and 10% to other medical conditions (fig 2.1 )T As far as
hospital treatment is concerned, in Basel, Switzerland 0.8% of all admissions to a
University Hospital over a 7 year period involved narcotic drug users, 31 % as a
consequence of infection (fig 2.2)4. gy comparison in 1973 a survey of 200
consecutive admissions over a 5 month period to a specialised medical inpatient unit
of a New York Hospital devoted to drug addiction revealed that 58% were related to
infection, 5% as a consequence of drug overdose and 22% for a variety of other
medical conditions (fig 2.3)5. A different spectrum ofmedical problems in drug
users is revealed by a post mortem survey of 1561 narcotic drug users in New York
from 1950 to 1961 in which of the deaths 49% were as a consequence of drug excess
but 19% as a consequence of various infections and the rest as a consequence of
miscellaneous disorders (fig 2.4)6.
Thus whilst the medical problems of drug users reported by the medical profession
vary with the exact location there is no doubt that they account for a significant
number of medical consultations and that infection related to injection drug use forms
a significant part of the clinical spectrum of disease associated with drug use.
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Drug use associated infections usually occur in association with injection drug use
(IDU) although the use of animal excreta as fertiliser in the cultivation ofmarijuana
and the subsequent outbreaks of Salmonella gastro-enteritis is a notable exception^.
IDU related infections occur as a consequence of the use of non sterile equipment
(needles, syringes, spoons, cups etc.) and solutions which allow micro organisms to
overcome the normal defence mechanisms by direct entry into subcutaneous tissues,
muscle or the blood stream. Once the normal defence mechanisms have been
overcome, organisms, whether pathogenic, opportunistic or commensal may then
produce either local or systemic infections.
It is often assumed that IDU is a relatively modern problem but this is certainly not
the case. The injection ofmorphine under the skin by the "hypodermic method" was
described by Dr Lafargue of St Emilion in the 1830's and consisted of a lancet dipped
into a solution ofmorphine inserted beneath the skin^. The use of the hollow
hypodermic needle and syringe to introduce a solution of morphine appeared in the
1 840's7. The first reports of an infection associated with injection drug use were of
tetanus and appeared as early as 1867 8-14 ps occurrence has largely been related to
the practice of subcutaneous injections (or skin popping) of morphine or adulterated
heroin usually in the region of the abdomen and or thighs 14,15,16 initially it was
relatively rare and Doane commented that over an 8 year period he had seen only 3
cases out of 4000 cases of drug addiction^. However by the late 1950's drug
addiction accounted for the majority of cases of tetanus in New York and was the
cause of between 5-8% of deaths in drug users5>14,17,18 The rise incidence was
probably accounted for by a resurgence of subcutaneous drug use as a consequence
of a lack of venous access from prolonged drug usel^. The use of quinine as an
adulterant in street heroin was also considered important since this drug itself could
produce skin abscesses suitable for the growth ofClostridium tetani^. It is possible
that the widespread use of immunisation with tetanus toxoid in childhood has been a
successful harm reduction measure for IDU since in recent surveys tetanus is now a
rare IDU associated infection 1 "4.
The intravenous administration of drugs including opium dates from the seventeenth
century although it was not initially popular7. Intravenous drug use was described in
detail from Egypt in 1929 and the problem was even described in an article by
Beatrix Bellingham in the Illustrated London News of February 1st 193019,20 This
article not only described the problem of drug addiction in Egypt but also noted that
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3.6% of 217 Egyptian heroin drug users rounded up in police raids were injection
drug users suffering from septic sores and abscesses^. The practice was then
reported in the medical literature from a number of cities in the United States in the
early 1930's2fi22
IDU together with the sharing of injection equipment and paraphernalia between
users facilitates the spread of a number of blood borne organisms notably viruses.
Two practices seem to favour this spread; firstly washing the drug out of the syringe
into the blood stream by repeatedly drawing back and injecting the users own blood.
This results in heavy contamination of the equipment with blood which can then be
passed onto the next user. Secondly the practice ofwashing the equipment in a
communal glass or bowl ofwater which rapidly becomes contaminated with blood.
The first blood borne organism associated with equipment sharing was in fact
malaria^ 9-23 An example of inadvertent early harm reduction for IDU may have
been the practice of using quinine as a diluent for street heroin. This became
common in New York during the 1930's such that the problem of artificially
transmitted malaria was not seen in New York after 1943^.
The association of IDU (subcutaneous and intravenous) with Hepatitis B virus (then
known as homologous serum hepatitis) was first described in 195024-27 Qne report
described the spread of hepatitis through a tight knit group of long term users after
one particular individual joined the group28. Multiple attacks of hepatitis initially
attributed to chronic forms of hepatitis were described in drug users in 1960 and it is
now known of course that one form ofNon A non B hepatitis, Hepatitis C, is also
commonly associated with IDU29-31
The sudden and sporadic appearance of injection related infections in IDU
communities has been previously described; for instance the appearance of various
types ofmalaria into Washington drug users^T Malaria which was not endemic in
that area suddenly appeared in drug users in 1943 and until 1946 was of the
falciparum type but in 1947 cases of quartan malaria began to be detected. The high
prevalence of delta agent, another blood borne virus, in drug users from Italy,
Copenhagen, Basel, Dublin and Edinburgh is a further example of the international
spread of blood borne viruses by injection drug users32-35
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Epidemiology of IDU infections
How common are IDU related infections? This is difficult to determine since few
doctors systematically record drug use as an associated factor for infections and it
also depends on the number of drug users in any one particular location. A survey of
the deaths in 1561 narcotic drug users in New York from 1950 to 1961 revealed that
19% were as a consequence of various infections^. Between 1943 and 1947
infection was concerned with 80% of 139 heroin addicts admitted to one Washington
hospital^. This had risen from 6% during the years 1938 to 1942 and was attributed
by the authors to a lack of antisepsis, use of a community needle and in 95% of the
cases occurred in Blacks. This epidemic of drug use and infection has many
similarities to the events that occurred in Edinburgh in the mid 1980's^6-38 The
post mortem survey of narcotic drug users in New York from 1950 to 1961 revealed
that 19% of the deaths were as a consequence of various infections; 44% from
tetanus, 35% from pyogenic infections or endocarditis, 11% from tuberculosis, 10%
from viral hepatitis (fig 2.5)6.
In Basel, Switzerland 0.8% of all admissions to a University Hospital over a 7 year
period involved narcotic drug usersA Of 404 drug use related admissions, 31% were
as a consequence of infection (20% of these infections were as a consequence of viral
hepatitis), 28% were related to drug intoxication, 5% to drug withdrawals and 15% to
other medical conditions (fig 2.5)3. a pre-HIV series from the USA of 200
consecutive admissions over a 5 month period to the medical inpatient unit of a
hospital devoted to drug addiction also revealed that 58% were related to infection,
31% because of acute viral hepatitis and 28% as a consequence of other infections^.
The other infections identified consisted of endocarditis (3.5%), bacteraemia without
an obvious source (11%), chest infections (29%) and skin infections (43.5%) (fig
2.6).
Thus it appears that IDU related medical problems account for between 0.5-1% of all
hospital medical admissions and that IDU related infections account for between 20-
60% of these admissions i.e. 0.1-0.6% of all hospital admissions.
In Edinburgh during 1983/84 there were an estimated 2000 injection drug users and
80 of these attended the accident and emergency department during a 4 month
period2>39. This survey of accident and emergency consultations by drug users
reveals that 21% of the consultations were as a consequence of some form of
infection^. The majority, some 73%, were described as local infections, 17% as
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hepatitis and only 10% as a consequence of systemic infection (fig 2.7). Thus this
data would suggest an incidence of clinical IDU infection of around 2.5% of the drug
using population, 20% ofwhich was viral hepatitis and less than one percent as a
consequence of serious infection.
During 1984 there were 100 admissions to Lothian hospitals for infections such as
hepatitis, endocarditis, pneumonia and skin infections out of a population of 2000
suggesting an incidence of around 5% for IDU infections^9,40 Eighty one percent
of these infections were bacterial and 15% were serious (pneumonia or endocarditis).
Thus the annual incidence of clinical IDU related infection for a drug using
population is probably somewhere between 2.5-5%, around 20% of these infections
being viral hepatitis. The annual incidence for serious life threatening infections
from this data is some where between 0.25-0.75% which is of the same order as the
accident and emergency department survey. If 10-15% of IDU related infections are
serious life threatening systemic infections and 0.1-0.6% of all hospital admissions
are due to IDU related infections one can conclude that the upper limit of hospital
admissions related to serious IDU related infections would be 0.1%.
What are the risks however from the drug users point of view? A general practice
survey in Edinburgh revealed that 50% of drug users had suffered some form of
infection during their IDU career^l. The majority of the IDU infection problems at
that time were hepatitis B (76%) with 14% suffering skin infections and only 10%
having a history of endocarditis. Thus in this particular population the lifetime
chance of a serious systemic infections such as endocarditis for a group was around
5%. This compares with an 80-90% lifetime chance of infection with blood borne
viral infections such as Hepatitis B. What is surprising from these figures is perhaps
how small is the chance of a serious systemic infection such as endocarditis
considering that Edinburgh users were injecting 3-4 times per day. It perhaps
demonstrates how effective the host defence system is, particularly against bacteria,
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Injection Drug Use and HIV/AIDS
The first nine cases ofAIDS amongst injection drug users were diagnosed
retrospectively in 1980 and four of these were also homosexuals^. The number of
cases associated with IDU in the USA increased from 29 in 1981, to 148 in 1982, 324
in 1983, 4500 in 1986 and 26 321 by May 1989 accounting for at least 17% ofAIDS
cases in the USA43. In Europe in 1984 IDU related AIDS accounted for only 2% of
cases but this had risen to 26.8% by 1989 and it had been noted that in Europe IDU
related AIDS was the fastest growing risk group44,45
IDU related HIV and AIDS epidemics are noted for their geographical clustering.
For instance some 75% of IDU related AIDS in the USA has occurred in the New
York City metropolitan area and in Europe 70% of the cases have been reported from
Italy, Spain and France46,47 As yet exact explanations for this clustering are not
forthcoming although there are suggestions that it is linked to the intense sharing of
equipment in localised areas together with mobility of a small number of users48.
IDU related HIV was first noted from retrospective analysis of sera to have begun in
New York in 1978, in Italy in 1979, in Germany in 1982, in Edinburgh, Dublin and
Sweden in 1983, and in Copenhagen in 198447,49-52. The extent ofHIV
seropositivity in drug users is by and large related to the time of introduction ofHIV
into the community. For instance by 1984 in New York and 1985 in Edinburgh, HIV
seroprevalence of drug users had passed 50%37,53,54 The extent and variability of
IDU related HIV seroprevalence is demonstrated in the appendix to this chapter
In these differing communities the spread of IDU related HIV seems to follow two
broad patterns, a slow gradual spread and a rapid explosive spread. The reasons for
the different pattern is probably differing relationships between drug users. In some
areas, drug users remain in tight knit communities often along racial lines. There
may be little mixing between such different groups other than the purchase of drugs.
As such, spread is rapid within groups but not between groups. In other situations
possibly where there is only one racial group there is more dynamic interchange
between users and spread is very rapid.
The scattered pockets of IDU related HIV around Europe may be explained by the
movement of small numbers of very mobile users between areas of varying drug
availability37,48 jn j^aly relatively high seroprevalence amongst drug users around
US Air Force bases has been suggested as one means of entry of the virus into Italy
88
and thus Europe^. This pattern of the sudden appearance of pockets ofHIV
amongst drug users may well be set to continue into developing countries with the
reports ofHIV seroprevalence amongst drug users of 44% in Bangkok, 22%-48% in
Argentina and 54% in North India^2,56-58 The latter report from North India is
reminiscent of the events in Edinburgh during 1983-85. The seroprevalence for HIV
in North India was reported as being 0% of 2322 samples tested in September 1989
but 54% of 1412 drug users tested between October 1989 and June 1990^2.
The HIV epidemic in South East Asia has the potential for an enormous future AIDS
epidemic in that area in about 7-10 years. The current focus of concern in South East
Asia is without doubt Thailand where an explosive HIV epidemic began in 1987 such
that by the end of 1990 there had been 76 cases ofAIDS out of a total identified HIV
population of 25,342, 50% of whom acquired the infection via IDU (personal
communication Mr John K Roberts, Wellcome Thailand Ltd, Bangkok, Thailand and
Dr Surapol Suwanagool, Faculty of Medicine, Siriraj Hospital, Mahidol University,
Bangkok, Thailand). By the end of June 1991, 123 cases of AIDS had been reported
although the estimated numbers ofHIV infected were between 200-400,000
individuals 13 8_ Probably as a consequence of the mobility of drug users and the
heterosexual contact's of prostitutes which has been reported elsewhere in the
world48,1395 HIV is already spreading to neighbouring countries such as South West
China where 29.6% of over 400 drug users were HIV seropositive (personal
communication Professor Y Zeng, Institute of Virology, Chinese Academy of
Prevention, presented at 1 st International Conference on AIDS and Reproduction,
December 1990, Genoa, Italy) and to Malaysia which by December 1990 had 19
cases ofAIDS and over 750 cases ofHIV infection, some 76% acquired via IDU
(personal communication Professor Rokiah Ismail, Faculty of Medicine, University
ofMalaya, Kuala Lumpur).
The risk factors associated with HIV infection amongst drug users have not been well
elucidated. The link with the frequency of equipment sharing is, however, now well
established and in the USA there is also a link with injecting in "shooting
galleries"^,36,59-64 jy[ore recently HIV has been cultured from needles and
syringes collected from a shooting gallery in Miami, Florida confirming the
infection risk^S. Less well recognised is the importance of the type of drug used.
For instance, users inject cocaine intravenously often mixed with heroin and do so far
more frequently than when they inject heroin alone^. Recently a definite link
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between HIV seropositivity and the use of intravenous cocaine has been reported^b-
74.
Lastly, it is difficult to separate out the importance of the spread ofHIV between
drug users by sexual intercourse. However an estimate can be made by comparing
the seroprevalence of injecting drug users and their non drug using sexual partners.
For instance in one Italian study the seroprevalence of double drug using couples was
45% compared to only 8% in non drug using sexual partners75. In Edinburgh whilst
the seroprevalence of injecting drug users was around 50% that in non using partners
was only 15%76. These studies suggest that needle sharing is between three to five
times as efficient at spreading HIV as heterosexual intercourse.
Conclusions
IDU is a small but important cause ofmedical problems and the problem of IDU
related infections continues although the particular organisms involved have varied
over time. The use of unsterile equipment increases susceptibility to bacterial and
fungal infections which is even further increased in the setting ofHIV. The
particular organisms involved tend to vary with injection practices. The sharing of
injection equipment has resulted in a number of problems over the years notably
malaria, various forms of hepatitis and latterly HIV.
IDU related HIV was first reported from New York in 1980 and seems to spread via
two broad patterns i.e. slow and gradual or rapid and explosive. Pockets of IDU
related HIV are found in Northern Europe as a result of the mobility of drug users.
This mobility of drug users is also the likely explanation for the similar explosive
outbreak of IDU related HIV that has recently appeared in South East Asia.
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Appendix
Table 2.1: IDU Related HIV Seroprevalence -British Isles
Location Year %HIV Sample Size Reference
Scotland
Edinburgh 1982 0.0 182 80
1983 14.0 124 80
1984 42.0 205 80
1985 38.0 106 80
1986 51.0 164 36
1986 52.0 191 37
1988 56.0 164 81
1988 64.0 203 77
1992 35.2 378 140
1992 20.3 227 141
Dundee 1986 39.0 251 82
Glasgow 1986 4.5 600 83
1990 2.0 507 144
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Table 2.1 continued: IDU Related HIV Seroprevalence -British Isles
Location Year %HIV Sample Size Reference
England and Wales
E&W 1983 1.5 269 86
1984 2.5 203 86
1985 6.4 236 86
1986 10.0 239 86
1986/87 2.1 2712 87
Manchester 1986 0.0 100 82
Liverpool 1986 0.0 200 82
Southport 1986 0.0 36 82
South London 1985 6.4 236 84
1986 0.6 146 85
1986 6.0 293 84
1987 4.0 313 84
1988 5.0 216 84
London (overall) 1990 12.8 491 142
London (never in
treatment)
1990 20.6 131 142
London (current and
previous treatment)
1990 10.2 354 142
Ireland
Dublin (healthy) 1985 27.0 451 51
Dublin (ill) 1985 37.0 152 51
Dublin (neonates) 1985 55.0 11 51
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Table 2.2: IDU Related HIV Seroprevalence -Europe
Location Year % HIV Sample Size Reference
Italy
Milan 1979 7.0 716 50
1980 6.0 716 50
1981 8.0 716 50
1982 22.0 716 50
1982 24.0 67 88
1983 35.0 716 50
1983 21.0 78 88
1984 45.0 716 50
1985 60.0 716 50
1985 53.0 62 88
1985 69.3 89
Bari 1980 6.0 68 90
1981 10.0 58 90
1982 15.0 47 90
1983 31.0 49 90
1984 53.0 34) 90
1985 76.0 59 90
Pordenone/ Udine 1985 27.0 315 75
Pordenone 1985/86 90.0 63 55
Udine 1985/86 10.0 134 55
Rome 1985 28.0 207 91
1985 52.0 220 92
1986 33.0 120 93
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Table 2.2 continued: IDU Related HIV Seroprevalence -Europe
Location Year % HIV Sample Size Reference
Italy
Padua 1985 43.0 460 94
Naples 1986 14.0 164 93
Sicily 1987 68.4 684 95
Palermo 1980 5.0 20 145
1983 40.0 40 145
1985 62.5 341 145
1986 60.9 271 145
1987 49.4 245 145
1988 44.0 250 145
1989 41.0 234 145
1990 38.5 226 145
Spain
Valencia 1983 11.0 58 96
North Spain 1983 35.0 478 97
1983 71.0 478 97
1984 40.0 174 96
1985 48.0 75 96
Bilbao 1984/85 50.0 479 59
1986 41.9 313 64
Catalonia 1985/88 40.7 55 98
Barcelona 1985/88 70.0 473 99
France
Paris 1984 75.0 8 100
1985 64.0 113 61
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Table 2.2 continued: IDU Related HIV Seroprevalence -Europe
Location Year % HIV Sample Size Reference
France
Tours 1982/83 0.0 52 101
1984 15.0 40 101
Tours 1985 17.0 125 101
Toulouse 1985 51.0 402 102
Holland
Amsterdam 1983 3.4 145 103
prostitutes 1983 23.0 52 104
1986 33.3 52 104
1987 28.3 52 104
1988 27.8 560 104
Austria
Tyrol 1985 44.0 34 105
Vienna 1985 8.5 82 106
Vienna 1986 14.4 159 106
Prisoners 1986 17.0 71 63
Methadone treatment 1988 44.0 136 107
Switzerland
Geneva 1981 7.0 131 108
1985 52.0 131 108
Bern 1979/81 0.0 93 108
1982 16.0 79 86
1983 16.0 49 86
1984 42.0 38 86
1985 32.0 37 86
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Table 2.2 continued: IDU Related HIV Seroprevalence -Europe
Location Year % HIV Sample Size Reference
Switzerland
Bern/Basel/ Geneva/ 1983 36.0 103 109
1984 53.0 55 109
1985 36.0 103 110
Lausanne 1987 47.3 63 111
Sweden
1983 3.0 67 52
1984/86 16.0 32 52
1987 57.0 60 52
Denmark
autopsies 1988 6.0 83 146
1989 11.0 86 146
1990 14.0 90 146
1991 14.0 130 146
Greece
prisoners 1987 2.1 288 112
voluntary screening 1987 2.8 434 113
West Germany
1983 10.1 927 114
1984 17.6 927 114
1985 23.9 927 114
Berlin
autopsy 1985 30.0 114
1986 49.0 114
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Table 2.2 continued: IDU Related HIV Seroprevalence -Europe




1988 38.0 362 115
detoxification 1988 13.0 362 115
prisoners 1988 12.0 362 115
Hamburg
autopsy 1985 0.0 362 115
1986 23.0 362 115
Hamburg 1987 16.0 362 115
1988 13.0 362 115
Portugal
Portuguese 1988 8.0 24 116
foreigners 1988 67.0 86 116
Yugoslavia
Belgrade 1983 10.0 40 117
1987 42.0 19 117
1986/88 44.0 625 118
Zagreb 1985 5.0 140 119
1987 5.9 393 119
Czecho-slovakia
1987 0.0 228 120
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Table 2.2 continued: IDU Related HIV Seroprevalence -Europe




North East 1988 0.0 30 121
Warsaw 1988 2.9 718 122
1989 8.0 718 122
Israel
1988-89 2.3 300 143
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Table 2.3: IDU Related HIV Seroprevalence - American Continent
Location Year % HIV Sample Size Reference
Canada
Manitoba 1988 2.1 627 123
Montreal
hospitalised 1985/88 4.4 294 123





San Francisco 1985 10.0 281 60
Los Angeles 1987 3.4 205 125
Denver 1985 2.0 76 82
1985 5.0 262 82
New Hampshire 1981/83 30.0 283 126
Maimi
in treatment 1988 12.0 127
street users 1988 33.0 500 127
Chicago 1984/85 11.0 35 82
1986/87 33.0 200 128
Baltimore 1988 24.7 441 129
Detroit 1985/86 12.5 96 130
1987/88 15.7 70 130
1988/89 15.5 71 130
99
Table 2.3 continued: IDU Related HIV Seroprevalence - American Continent
Location Year % HIV Sample Size Reference
Minneapolis 1987 1.3 231 131
1988 1.5 325 131








1984 35.0 103 133
drug detoxification 1984 58.0 54
1985 50.0 54
Bronx, New York
Methadone 1985 32.0 445 134
Methadone 1987 59.5 222 125
1987 19.4 31 130
San Antonio 1987 1.3 149 125
South America
Buenos Aires
drug detoxification 1987 22.0 268 57
hepatitis 1987 48.0 97 58
1988 63.9 36 135
1988 60.3 338 136
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Table 2.4: IDU Related HIV Seroprevalence - Oceania
Location Year % HIV Sample Size Reference
Australia
1986 0.8 1905 137
Thailand
Bangkok 1985 0.0 99 138
1986 0.0 75 138
1987 1.0 3180 138
3/88 16.0 1649 138
9/88 43.0 1811 56
6/90 44.0 878 138
4/89 45.0 1020 138
India
North India 9/89 0 2322 32
10/89- 54.2 1412 32
6/90
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CHAPTER 3
Clinical features of drug use and drug use related HIV
Introduction
The extent of the injection drug use (IDU) related HIV epidemic in Edinburgh
requires consideration of the clinical features of IDU as well as those ofHIV since
each may mimic the other. As an example, lymphadenopathy is associated with both
HIV and with the injecting of foreign materials. The fatigue, lethargy and excessive
sweating which are an early feature ofHIV can all, also be caused by mild
withdrawal from opiates. Diarrhoea, a common presentation of early symptomatic
HIV (CDC stage IV A) is unfortunately a common problem with opiate withdrawal.
A history of diarrhoea for longer than 1 month may be elicited via direct questioning
and suggest a possible diagnosis of CDC stage IV A. Such as history would also
require a search for specific pathogens such as Cryptosporidium which are seen in
AIDS. However early morning diarrhoea is common for those on methadone and is
simply a symptom of early opiate withdrawal. Weight loss and sweating are both
key symptoms of constitutional disease (CDC stage IV A) as well as mycobacterial
infections, yet both are associated with heavy opiate use or the use of stimulants
(amphetamines or cocaine).
Epileptic fits in patients with HIV requires consideration of cerebral toxoplasmosis
but the intermittent use of benzodiazepines can also cause seizures. The regular
monitoring of CD4 counts and toxoplasma serology helps to identify those patients at
risk of toxoplasmosis and consequently reduces the number of CT scans required.
The excessive use of cannabis and benzodiazepines interferes with memory and other
cognitive functions in a similar manner to HIV although in the former dramatic
improvement occurs with reduction or cessation of drugs. Thus early dementia
which might be detected in other risk groups by psychometric testing is extremely
difficult to diagnose in current drug users especially since reducing drugs will also
help the dementing patient to improve function in the activities of daily living.
Syncopal attacks in AIDS are often associated with an autonomic neuropathy or a
failing adrenal cortex. This problem however is associated with the use or misuse of
antidepressant tricyclic drugs such as amitriptylene. Lastly shortness of breath and a
persistent cough are common early symptoms of PCP but can occur with
endocarditis, bacterial pneumonia, excessive smoking, recurrent bronchitis and
obstructive airways disease.
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The medical conditions associated with IDU include asymptomatic abnormalities of
pulmonary function tests, life threatening infections, or immunological problems
such as polyarteritis nodosa. The advent of IDU related HIV has not only widened
the spectrum of disease seen in drug users but has also increased the frequency of
some existing conditions. As a consequence the differential diagnosis in a patient
with IDU related HIV is extensive. Further examples are detailed in Table 3.1.
Because of the difficulties with interpreting the history and the extensive differential
diagnosis if there is evidence of current drug use, a short period of admission is often
the only way to clarify the situation.
Table 3.1: Comparison of Drug, IDU and HIV related problems
Symptom Complex Drug related problems HIV related problems
Pulmonary
Recurrent sinusitis




































Table 3.1 continued: Comparison of Drug, IDU and HIV related problems




"Bad fix" or endotoxaemia
CDC stage IV A, PCP and
OI's such as MAI,
Night sweats Opiate withdrawals CDC Stage III, IV A, or
early 01
Weight loss Heavy addiction, poor diet
and use of stimulants such
as cocaine or
amphetamines
CDC stage IV A, TB or
other 01
Gastroenterology
Diarrhoea Opiate withdrawals CDC stage IV A or enteric
pathogen
Sore mouth Thrush OHL etc.
Sores around mouth /nose poor diet, snorting or
sniffing glue or cocaine
HSV
Abdominal pain Intra-abdominal pathology




CMV, lymphoma, KS etc.
Abnormal liver function
tests
Acute hepatitis type A, B,
C, D
Paracetamol overdose
Recurrence of B, C or D
hepatitis, drug reactions
e.g. anti TB drugs and
MAI
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Table 3.1 continued: Comparison ofDrug, IDU and HIV related problems
Symptom Complex Drug related problems HIV related problems
Neurological




Toxic confusional state Drug use or infection Bacterial infections, OI's,
HIV encephalopathy




Peripheral nerve paralysis IDU related traumatic
nerve damage
Seroconversion illness of
HIV, CDC stage IV B





Purpura IDU, endocarditis HIV related
thrombocytopaenia
Itching and scratching Opiates and stimulant use Seborrhoeic dermatitis,
scabies, HIV related
papular urticaria






Pulmonary hypertension Talc granuloma's HIV related pulmonary
hypertension
Complications ofDrug Use - non infection related
The medical complications of IDU which are not related to infection are summarised
in Table 3.2.
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Table 3.2: Medical (non infection) problems of Drug Use
Problem Medical complications
Drug effects
Excess Opiate Narcosis, coma, small pupils, respiratory depression,
aspiration pneumonia, and rhabdomyolysis secondary to
pressure
Opiate withdrawal
Simulates a mild "URTI" (sweating, coryza, lacrimation),
pupillary dilation, insomnia, nausea, vomiting, diarrhoea,
lethargy, muscle weakness, myalgia, muscle twitching,
tachycardia and hypertension
Excess cocaine Apprehension, dizziness, syncope, blurred vision,
dysphoric states, paranoia, confusion and aggressive
behaviour
Seizures, coma, hyperthermia, respiratory depression,
apnoea, sudden death, spontaneous rhabdomyolysis
Excess amphetamine Headaches, anorexia, nausea, tremors, dilated pupils,
tachycardia and hypertension
Stimulant withdrawal Sleepiness, lethargy, increased appetite, food binging,
depression or even suicide
Trauma
Frequent injecting Track marks and skin scars
Lack of veins and thrombophlebitis
Deep venous thrombosis
Persistent peripheral oedema, venous stasis and ulcers
secondary to chronic venous obstruction
Misplaced injections Arterial damage and insufficiency with secondary tissue
damage, muscle compartment syndrome and traumatic
rhabdomyolysis
False aneurysms and pulmonary emboli
Traumatic neuropathy
119










Respiratory depression, coma and pneumonia




Opiates or cocaine Pulmonary oedema






Abnormal pulmonary function e.g. reduced DCO
Restrictive defect due to interstitial lung disease
Smoking of tobacco,
heroin, marijuana
Abnormal pulmonary function e.g. reduced DCO
COAD
"Snorting" stimulants Chronic rhinitis, rhinorrhoea, anosmia, atrophy of the
mucosal membranes, ulceration and perforation of the
nasal septum
"Snorting" opiates Recurrent sinusitis
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Table 3.2 continued: Medical (non infection) problems ofDrug Use
Problem Medical complications
Cardiology
Cocaine Cardiac arrhythmia's such as sinus tachycardia,






Cardiac arrhythmia's and death
Endocrinology
Opiate use Increase prolactin levels and gynecomastia
Amenorrhoea (may be secondary to weight loss)











IDU Enlarged lymph nodes
Elevated serum IgM
False positive syphilis serology
As with IDU itself, measuring the frequency of the medical complications of IDU is
difficult and may well be underestimated, because the drug use is often not declared
on contact with the health service. A pre HIV survey of admissions in the 1970's to a
specialised medical inpatient unit of a New York Hospital devoted to drug addiction
revealed that although nearly 60% were due to infection, 21% were for general
medical conditions; diabetes 7.5%, pulmonary disease 6%, cardiovascular disease
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4%, and gastro-intestinal disease 3.5%1. The pulmonary problems noted were
pulmonary fibrosis (obstructive or restrictive), carcinoma of the lung, chronic
bronchitis, pleural effusion, pulmonary emboli, and bronchial asthma. Heavy
cigarette smoking was regarded as a probable cause ofmany of the problems
although the injection of inert material was also thought to be a contributing cause of
the pulmonary fibrosis. The cardiovascular problems included congestive heart
failure, cardiomyopathy and viral pericarditis. The gastro-intestinal disorders
included, ulcers, gastritis, small bowel dysfunction and cirrhosis 1.
A survey of narcotic related deaths in New York in the 1950's which found that
nearly 50% of the deaths were related to drug excess, also noted that 20% were due
to infections, 18% to medical conditions (including 7% because of respiratory
problems other than pulmonary oedema and drug overdose)^. A few of the lungs
studied contained microscopic granulomas of the foreign body type which were
thought to have occurred because of a reaction to injected foreign particulate matter
which adulterates "street heroin". Particles of cotton fibres used to filter drugs before
injection were also been seen within these granulomas^.
Drug effects
Prior to the advent ofHIV, drug use itself had a relatively low mortality with
alternating periods of abstinence and drug use. Probably the commonest
complication of opiate use is either an excessive dose with subsequent narcosis or
coma and respiratory failure or withdrawal effects. It had been estimated that opiate
overdoses killed around 1% of drug users each year but this was before the
description ofHIV^-?. The clinical features of excessive doses of opiates include
coma of varying severity, small pupils and depressed respiration. This state may or
may not be associated with a respiratory infection. There is an absence of focal
neurology, poor peripheral circulation and possibly a fever whilst investigations may
reveal a reduced oxygen tension and possibly hypercapnia. Early withdrawal from
opiates simulates a mild upper respiratory tract infection with sweating, coryza,
lacrimation and even a slight fever. In a known drug user, sweating, involuntary
sniffing and pupillary dilation are helpful physical signs of early withdrawal from
opiates. Later the patient may suffer insomnia, nausea, vomiting, diarrhoea, lethargy,
muscle weakness, myalgia, muscle twitching, tachycardia and hypertension.
The excessive use of stimulants such as cocaine produces apprehension, dizziness,
syncope, blurred vision, dysphoric states, paranoia, confusion and aggressive
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behaviour^. Seizures, coma, hyperthermia, respiratory depression, apnoea and
sudden death have also been reported^. Cardiovascular problems can occur after
apparently small doses notably cardiac arrhythmias such as sinus tachycardia,
ventricular tachycardia and fibrillation as well as asystole. Myocardial infarction,
even in teenagers, severe hypertension and cerebrovascular accidents have all been
notedWithdrawal from stimulants such as cocaine, produces sweating, irritability,
hypersomnia, depression or even psychosis. Excess amphetamines produce
headaches, anorexia, nausea, tremors, dilated pupils, tachycardia and hypertension.
Withdrawals form amphetamines result in sleepiness, lethargy, increased appetite,
food binging, depression or even suicide.
Inhaling or smoking cocaine has also been associated with a decreased diffusing
capacity for carbon monoxide^. The commonest abnormality of pulmonary function
in injection drug users is a reduction of the carbon monoxide transfer factor which
occurred as the sole abnormality in 38% of one series (in 42% the reduction was to
less than 75% of the predicted value). Obstructive lung disease (asthma or chronic
bronchitis) was observed in 6% and a restrictive defect due to interstitial lung disease
in 7%. Radiological evidence of pulmonary hypertension was not observed in any
patient. The authors concluded that alterations of pulmonary function due to foreign
body emboli were common but that significant respiratory symptoms were unusual.
Unfortunately follow up was not attempted and whether there are long term
pulmonary problems of injection drug use has yet to be determined^.
Regular smoking ofmarijuana (3-4 cigarettes per day) is associated with the same
frequency of symptoms of acute and chronic bronchitis as well as the same type and
extent of epithelial damage in the central airways as the regular smoking of 20
tobacco cigarettes per day 10. The different methods of smoking marijuana compared
to tobacco cigarettes results in a greater quantity of smoke particulate and noxious
gases being delivered to and deposited in the lungs during the smoking of marijuana
and this probably explains the greater propensity for lung damage associated with
marijuana. In one study smoking marijuana was associated with a five fold
increment in the blood carboxyhaemoglobin, a three fold increase in the amount of




Heroin related pulmonary oedema is a rare complication of heroin use if one
considers the fact that most users inject 3-4 times each dayl M2 It was reported in
association with morphine by Osier as early as 1880 which was 18 years before
heroin was first manufactured^. The majority of reports however have incriminated
recreational injections of heroin which may result in sudden unexpected death often
with the needle and syringe still in siftA14,15 jn one series this problem accounted
for 48% of all deaths in narcotic drug users in New York^. Estimates of 1 death per
150,00 injections have been made which is less than for penicillin anaphylaxis^.
Since opiate related pulmonary oedema was originally associated with sudden death
in those injecting recreational opiates a number of theories were suggested including
bacterial or endotoxin contamination 12. However it has also been described with
sterile medical injections of opiates as well as with orally administered opiates. Two
cases ofmethadone associated pulmonary oedema were reported in 1972 in
individuals without previous drug use and unassociated with injection drug use^. It
would therefore appear to be some form of idiosyncratic reaction, possibly as a result
of activation of histamine releasing cells!6,17 Investigations have revealed that the
pulmonary wedge pressure is normal and the resulting oedema fluid is rich in protein
supporting the hypothesis that it occurs because of altered capillary permeability and
should therefore be considered as a form of adult respiratory distress syndrome or
ARDS16>17.
Trauma
A common complication of IDU is traumatic damage to tissues and organs secondary
to injections although it's frequency is difficult to determine; much of it is sub¬
clinical, it depends on a number of factors which are difficult to quantify; local drug
practices, the skill of the injector and the susceptibility of the individual, since the
frequency of thrombophlebitis varies with individuals.
The commonest trauma associated with IDU is the physical damage from frequent
injecting also known as tracking or track marks - the hall mark of IDU23>15. This
cutaneous stigmata of IDU may also be associated with pigmentation of the skin or
even scarring around superficial blood vessels7^, 15 There are often also scars of
superficial abscesses which are more common with subcutaneous injections (skin
popping) of drugs than with intravenous drug use73,15 The associated abscesses
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may be extensive and infected with micro-organisms or a purely chemical reaction to
the substances injected^? 15_
Individuals who lose superficial venous access may turn to injecting the deep limb or
neck veins with more consequent increased risks of damage to adjacent tissues. For
instance the use of the femoral veins, a technique often learnt from the physician who
cannot obtain blood for investigations, may result in damage to the femoral nerve
with a subsequent pressure neuropathy or arterial damage and anoxic damage to
distal tissues. The physical signs of a femoral neuropathy include muscle wasting,
pain and sensory loss in the limb. False aneurysms of the femoral artery may
complicate intra-arterial injections and these false aneurysm may become infected
and produce life threatening haemorrhage^. The inadvertent injection of drugs into
the arterial circulation may result in vascular spasm with loss of distal tissue due to
anoxia. This may be complicated by infections (gas gangrene or tetanus), muscle
swelling (compartment syndrome) and rhabdomyolysis which may lead onto renal
failure. Such complications often require surgery in the form of decompression of
muscle compartments or amputation depending on the severity^.
Excessive tissue damage has been associated with the injection of one particular
drug, temazepam, in its varying oral formulations^. Its injection intravenously was
originally made easy by the fact that it was marketed in a liquid form contained
within a capsule. The drug alone is capable of producing considerable tissue damage
especially to vascular endothelium either if it extravasates from vessels or is injected
intra-arterially. In an attempt to reduce this practice the manufacturers introduced a
solid gel formulation. However attempts to inject this formulation have continued by
heating the capsules usually with hot water which temporarily rendered the gel into a
liquid form. The present formulation whilst harder to inject seems to cause more
damage possibly because the macrogols used to increase the viscosity are also
capable of damaging vascular endothelium. This practice seems to have the ability to
cause massive venous thrombosis leading to oedema and venous gangrene^.
Other possible traumatic complications of IDU depend on the site of injection but
may include air embolus or blindness. Lastly a pyrogenic reaction or bad fix may
occur depending upon the substances injected and their endotoxin content.
Lung damage in the form of spontaneous pneumomediastinum and
pneumopericardium have been associated with inhaling or smoking free base
cocaine. This method of drug use is associated with deep, forced and prolonged
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inspiratory efforts together with a Valsalva manoeuvre which produces a sudden rise
in intra-alveolar pressure and subsequent alveolar rupture^.
Sinusitis
The use of the nasal mucosa, also known as "snorting", to absorb drugs is associated
with a number ofmedical problems. The frequency of these upper airway problems
is unknown amongst "snorters" but is probably fairly common. The use of
amphetamine or cocaine has been associated with chronic rhinitis, rhinorrhoea,
anosmia, atrophy of the mucosal membranes, ulceration and perforation of the
septum presumably as a consequence of intense vasoconstriction and necrosis of
tissue^' 15. Snorting as a cause of upper airway symptoms is well worth considering
in injection drug users with limited access to injecting equipment but not drugs e.g.
inmates of prisons.
Polyarteritis nodosa
In 1970, 14 injection drug users were described with a necrotizing angiitis
indistinguishable from polyarteritis nodosa. At that time it was thought to be an
idiosyncratic reaction to the use of amphetamines^ 1. However it is possible that this
was in fact an example of polyarteritis nodosa complicating chronic Hepatitis B
surface antigen carriage which was described around that time22-24 Pneumonitis
and pulmonary oedema are possible pulmonary presentations of this condition.
Pulmonary hypertension
Post-mortem studies have revealed foreign body emboli, thrombosis and granulomas
in pulmonary arterioles6>25,26 jn 1950 a pattern suggestive of pulmonary fibrosis
was noted on the X ray of a middle aged white male morphine addict who eventually
died of congestive right heart failure^. The post-mortem demonstrated numerous
foreign body emboli in and around the pulmonary arterioles. Many of the pulmonary
arterioles contained thrombi in various states of organisation and canalisation. The
right ventricle was hypertrophied and dilated.
A number of particular foreign bodies have been associated with these granulomas
including cotton fibre and talc. The majority of granulomas are apparently
asymptomatic or sub-clinical in life but there have been reports of pulmonary
hypertension in drug users. In 1964 Wendt et al reported pulmonary hypertension
secondary to arteritis and thrombosis of small pulmonary arteries, arterioles and
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capillaries??. These changes were associated with granulomatous reactions
secondary to crystals induced by the injection of various drugs. Whilst this report
may also be an example ofpolyarteritis nodosa secondary to hepatitis B the clinical
features were not typical and subsequently similar pathological features were found
after injecting rabbits with drugs containing talc?8. it thus appears that tablets
containing talc are able to induce this reaction when injected intravenously.
Evidence that granulomas may have some clinical effect comes from a case report of
a 32 year old drug user who presented with a one day history of low grade fever,
dyspnoea and dizziness. The chest X-ray showed diffuse bilateral miliary infiltrates.
It appeared that these symptoms recurred each time he injected intravenously a
mixture of drugs containing talc. Investigations failed to reveal any pathogens but a
transbronchial biopsy revealed talc granuloma?^.
Immunology
Autopsy reports of long term injection drug users prior to the introduction ofHIV
reported hyperplasia of the reticuloendothelial system; enlarged lymph nodes
particularly in the porta hepatitis and persistence of the thymus^. Elevated serum
IgM levels and false positive syphilis serology were also noted*?.
Endocrinology
The use of cannabis has been associated with reduced testosterone, oligospermia,
impotence and gynaecomastia™'?1. The mechanisms may be via increase prolactin
levels or via increased peripheral conversion of testosterone to oestrogen? ?. Opiates
also suppress the secretion of leutenising hormone and enhance the release of
prolactin although at present they have not alone been reported to be associated with
gynaecomastia??. The author has however seen cases which in all probability were
related to oral methadone. Drug use during pregnancy has been associated with
decreased foetal growth and or an increased foetal death rate.
Sexual dysfunction has been associated with cocaine use. Whilst at low doses
cocaine delays ejaculation, prolongs an erection and heightened sensory awareness
long term users may have difficulty maintaining an erection or ejaculating^.
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Neurological effects
A persistent psychopathology has been described amongst long term drug users; 55%
of stimulant users developed psychotic reactions like schizophrenia and 57% of
depressant users developed a severe depressive illness although no long term opiate
users had any measurable psychopathological effects^. Opiate use itselfwas not
associated with any direct toxic effect on the brain whilst nearly one third of sedative
users had evidence of brain damage. A variety of psychiatric problems have been
reported in users of cocaine including paranoid psychosis and severe depression
although it is difficult to establish causality^. Psychiatric illness may also be the
presenting feature of cocaine abused
Complications ofDrug Use - IDU related infections
The significant IDU related infections are summarised in Table 3.3
Table 3.3: IDU related infections
Infection related problems associated with unsterile technique
Gas gangrene
Tetanus










Epidemiology andfrequency ofIDU related infections
The detailed history, epidemiology and frequency of IDU related infections was
described in detail in Chapter 2 although a brief summary of the frequency of
infections is provided here for the sake of continuity. Prior to the advent ofHIV,
19% of narcotic related deaths were as a consequence of various infections^. The
infection related deaths were mainly bacterial sepsis such as endocarditis (34.5%),
tetanus (44%) as well as viral hepatitis (10%). In 1973 58% of drug related
admissions to a New York hospital were related to infection 1. At that time acute
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viral hepatitis (30.5%) was the single largest reason for admission and other
infections noted (27.5% of the admissions) were endocarditis (3.5%), bacteraemia
without a source (11%), chest infections (29%) and skin infections (43.5%). With
the advent ofHIV, 31% of admissions in Basel, Switzerland were infection related;
24% were due to lower respiratory tract infections, 20% were as a consequence of
viral hepatitis, 6% were soft tissue infections and 3% were secondary to bacteraemia
including endocarditis^.
In Edinburgh during 1983/84 the incidence of clinical IDU related infection requiring
medical attention was 3.5% (20% of which was viral hepatitis and less than one
percent as a consequence of serious infection)5>36 During 1984 there were 100 IDU
related admissions to Lothian hospitals for soft tissue infections, hepatitis,
endocarditis and pneumonia out of a population of 2000 drug users; an incidence of
5% for IDU infections that required admission (see Chapter 4). Between 1977 and
1986 there were 252 IDU related admissions for infections to Edinburgh hospitals;
15% were for hepatitis B, 9% for pneumonia, 5% for endocarditis and 71% for
subcutaneous infections.
Specific infections
The commonest organisms found in IDU associated endocarditis are coagulase
positive staphylococci (50-86%), enterococci and or gram negative bacilli and
candidal?,38 jn the case of bacterial pneumonia the predominant organism
isolated tends to be pneumoccoci in between 30-50% of cases, followed by
Haemophilus influenzae (2-10%), Staphylococcus aureus (2-5%) or Klebsiella
species3>35,38
Candida infection is a rare but well recognised complication of intravenous heroin
use and disseminated candidiasis has been reported among intravenous heroin users
world-wide in small epidemics^9-42 This syndrome caused by Candida albicans is
characterised by cutaneous, ocular, osteoarticular, and pleuropulmonary involvement
alone or in combination^. At least 160 cases have been described in the literature
many of which have indicated the epidemic nature of this condition, the largest
occurring in association with Iranian or brown heroin42-44
In disseminated candidiasis, all patients describe sudden onset fever, shivers,
myalgia, headaches and profuse sweating shortly after the intravenous injection of
heroin. The fever usually lasts between one to three days, and is followed by
cutaneous signs in more than 90% of cases^l. These are numerous painful nodules
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0.5 to 1 cm in diameter occasionally surrounded by some erythema and usually
located in the scalp and hairy parts of the body. Untreated they gradually resolve
within four weeks generally leaving an area of alopecia. Sometimes, the nodule can
discharge thick yellow pus. Painful pustules are also present in some patients; they
are 2 - 3 mm in diameter on an inflamed base from which the Candida can be easily
identified. These can be found disseminated over the body and may appear like
streptococcal or staphylococcal folliculitis. Patients often have high titres of anti-
Candida albicans antibodies but Candida albicans is readily isolated from the skin
lesions^O. Pleuropulmonary involvement was recorded in 8% of cases in one study
but Candida albicans was always isolated in conjunction with other pathogens such
as Staphylococcus or other saprophytes for instance Torulopsis glabrata^-.
The first blood borne infection identified in association with IDU was malaria,
although the blood borne viruses are now, more likely to be identified in association
with IDU45-48 The association of IDU (subcutaneous or intravenous) with
Hepatitis B virus (also known as homologous serum hepatitis) was described
between 1950 and 196049-54 Qne report described the spread of hepatitis through a
tight knit group of long term users after one particular individual joined the group^T
Multiple attacks of hepatitis initially attributed to chronic forms of hepatitis were
described in drug users in 1960 and it is now known of course that one form ofNon
A non B hepatitis, Hepatitis C is also commonly associated with IDU^5,56 jhe
levels ofHepatitis B and C in drug users are usually higher than those reported for
HIV; up to 65% of a group of drug users may be positive for the core antibodies of
hepatitis B and possibly 80% of injection drug users have antibodies for Hepatitis
£58-62 a high prevalence of delta agent, another blood borne virus, has also been
reported in drug users from Italy, Copenhagen, Basel, Dublin and Edinburgh^,64
Two retroviruses, HTLV-I/II have been shown to be endemic in some population
groups ofNorth America, the Caribbean southern Japan and the northern parts of
South America. There is no agreement at present on the effect of this infection on
human health other than to suggest an association with adult T-cell leukeamia-
lymphoma and tropical spastic paraparesis/myelopathy^. In the USA the prevalence
ofHTLV-I is reported to be 0.025% among asymptomatic blood donors although the
prevalence is higher amongst IDUs and patients in STD clinics65. As with HIV, the
highest seroprevalence is found among blacks and Hispanics^S. in Europe most
individuals with HTLV-I are migrants from endemic areas^ and the seroprevalence
in blood donors was reported to be of 0.011% in France and 0.00036% in London^.
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The virus is spread in a similar way to HIV except that vertical transmission can
occur via maternal HTLV-I infected T cells in breastmilk^. As far as sexual
transmission is concerned, male to female, male to male and rarely female to male
have been described. Parenteral infection via blood transfusions and IDU related
infections as a consequence of sharing contaminated equipment have been
described67-69 Whilst the transmission routes are similar to HIV HTLV-I seems
less infectious since HTLV-I cannot be transmitted by cell free body fluids^.
Reports of infection in drug users have come from the USA and Italy although
without as yet a particular associated clinical syndrome or a clear idea on an effect of
mortality^.
Susceptibility ofdrug users to infections
The underlying explanation for an increased susceptibility of drug users to infection
is not well understood. Obviously IDU itself by breaching the defences of the skin
increases susceptibility to infection. Unsterile IDU exposes the individual to
recurrent episodes of bacterial infection. Opiates, however administered are known
to reduce or depress the cough reflex which increases the susceptibility of the
individual to aspiration pneumonia. In addition opiates also impair the immune
system. Morphine given to mice reduced the numbers of neutrophils and
macrophages as well as their efficiency in phagocytosing and killing Candida
albicans. Morphine treated mice succumbed more rapidly to Klebsiella pneumoniae
peritonitis and a depressed lymphoproliferative response to mitogens was noted in
the presence of opiates70>71. Morphine treated mice also develop marked atrophy of
the spleen, thymus, lymph nodes and bone marrow as well as a reduced lymphocyte
helper/suppressor ratio within 24 hours. The effects were maximal at three days but
took 20 days to reverse completely^.
The effect ofHIV on IDU problems
Effect ofHIV on Non infective IDUproblems
There have been reports of pulmonary hypertension associated with HIV and
although some have been drug users it has also been noted amongst non drug using
homosexuals. Six patients with AIDS, 4 homosexuals and 3 drug users developed
moderate or severe pulmonary hypertension associated with right ventricular
hypertrophy and cardiac failure. The authors estimated an incidence of pulmonary
hypertension of 0.5%73. The patients presented with dyspnoea on exertion,
hypoxaemia, restrictive lung disease, reduced transfer factor for carbon monoxide
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and pulmonary hypertension. The most distinguishing feature was right ventricular
hypertrophy in the electrocardiogram. The diagnosis was often obscured by the fact
that the features developed during an episode of an opportunistic infection although
the symptoms and signs did not settle with treatment. Histology revealed that in 2
patients in addition to PCP medial hypertrophy of the small pulmonary arteries and
arterioles, endarteritis obliterans, intimal fibrosis of the pulmonary veins,
lymphohistiocytic infiltration of the interstitium associated with interstitial fibrosis,
thickened alveolar septa, and honeycombing was present.
In a prospective evaluation of patients with HIV, 8% had pulmonary hypertension
with elevated right ventricular systolic pressures as demonstrated by Doppler
echocardiography^. This amounted to an incidence of 0.5% in a cohort of 1200
HIV infected patients. In the latter series the problem occurred in both early or late
HIV and did not seem related to the level of immune deficiency. Five of the six
patients were drug users but post-mortem in two did not reveal evidence of foreign
body embolisation suggesting it is distinct from the problem reported previously in
drug users. In addition there were no signs of inflammatory vessel changes and the
pathology like the others in the literature consists ofplexiform lesions typical of
primary pulmonary hypertension.
In Edinburgh where over 70% of the HIV patients are IDU related, 7 (4%) had
isolated right ventricular dilation^. Follow up scans revealed that 4 of the patients
reverted to normal after treatment of their chest infections although the abnormality
persisted in 3 (1.7%) patients. One had definitive pulmonary hypertension
demonstrated by Doppler echocardiography suggesting an incidence of pulmonary
hypertension of at least 0.6%.
Emphysema like pulmonary disease in association with HIV has also been reported.
Four patients presented with dyspnoea (none were drug users), none had prior lung
infections and the chest X rays did not show infiltrates^. They were all late stage in
that the mean CD4 count was 100 cells/cumm. No organisms were detected by
bronchio-alveolar lavage and the pulmonary function tests suggested emphysema
with air trapping, hyperinflation and markedly reduced diffusion capacity. Only
minimal airflow obstruction was present. Three of the patients had high resolution
computed tomographic scans of the chest which revealed emphysema like bullous
changes.
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Effect ofHIV on IDU related infection problems
Amongst drug users, data collected on narcotic related deaths revealed that AIDS
cases greatly under represented serious IDU related HIV disease. In New York there
was a rapid increase in both AIDS and non AIDS narcotic related deaths between
1978-86 such that for every AIDS related death in a drug user, there was one other as
a consequence of conditions such as tuberculosis, endocarditis and bacterial
pneumonia^?. Similar data have also been reported from Europe but there had been
no increase in the non infective causes of death noted^8'79 [pqj related bacterial
infections are very likely to become more common since susceptibility to ordinary
bacterial infections is increased by HIV infection^^-92 As an example in New
York the rate of pulmonary tuberculosis was 4% amongst HIV positive as opposed to
0% in HIV negative drug users**3. The 36% increase in reported cases of TB
between 1984 and 1986 in the USA has been largely ascribed to infection amongst
HIV positive drug users**^.
IDU related HIV patients in the USA also have a higher incidence of bacterial
infections such as pneumonia; 12% with a mortality of 2.2% compared to 3% with a
mortality of 0% in HIV negative drug users**6. The annual incidence of pneumonia
was nearly 10% for HIV seropositive drug users compared to under 2% for a
population ofmainly homosexual males with AIDS**7>****. The rising mortality from
pneumonia in young adults in New York City is primarily as a consequence of IDU
related HIV and other cities in the USA are showing similar trends^,90. The
morbidity and mortality of bacterial endocarditis in HIV seropositive individuals has
been reported to be greater than for seronegative individuals; a mortality of 24%
compared to 4%. The poorer outcome was related to more frequent embolisation, a
greater diversity of organisms, more prolonged fever, persistent bacteraemia and
greater immunological dysfunction. It was not related to recognised opportunistic
infections^ 1'92 Another study however showed no increase in mortality and no
unusual organisms^. The mortality was not surprisingly higher for those with
greater immunological dysfunction.
The combined effect of progressive immunodeficiency and attempts at harm
reduction has had an influence on the predominant medical problems of drug users.
A survey ofmethadone maintenance patients from the Bronx, New York from 1986-
87 revealed that infection now accounted for 62% of the admissions but infection that
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might be related to injecting such as endocarditis or skin cellulitis only accounted for
17% of admissions^.
Estimates of the effect ofHIV on IDU admissions from Edinburgh, where the
epidemic of IDU peaked in 1983-84^4,95(ancj Chapter 4) and HIV in drug users did
not occur before 1983^^(and Chapter 4) also reveal increased susceptibility for
bacterial pneumonia. The annual admission rate for pneumonia during 1986 for
individuals aged 15-44 was 0.6/1000; in drug users aged 15-44 the rate rose from
1.4/1000 between 1983-85 to 12/1000 by 1985-89, an 8 fold increase by 5 years after
patients were infected with HIV??. The commonest single identifiable reason for an
HIV admission in Edinburgh was because of a respiratory tract infection (29% of the
admissions)^?. Unlike other UK centres only 27% of these respiratory admissions
were for PCP whilst 54% were for a bacterial chest infection^. Despite the fact that
51.5% of the patients were regarded as being asymptomatic as far as their HIV was
concerned the respiratory tract infections were serious; 50% had radiological
pneumonia, 43% were hypoxic, 28% were hypercapnic and the average length of stay
was 10 days reflecting the complicating factor of susceptibility to infection and drug
use. Interestingly Haemophilus influenzae rather than Streptococcuspneumonia was
the commonest organism isolated from these bacterial chest infections.
The reasons for the increased susceptibility to bacterial infections amongst HIV
patients are not entirely clear. Although unsterile IDU exposes an individual to
episodes of bacterial infection the susceptibility is not specific for drug users since
bacteraemia is also increased in HIV positive individuals in Africa^. In San
Francisco where IDU related HIV is unusual the increase of pneumococcal
bacteraemia in all HIV individuals has been shown to be 100 times that of the general
population^. In drug users and Africa it might be argued that access to medical
services is an additional contributory factor. However antibody production is
impaired in HIV infected patients, and low levels of IgG2 have been associated with
bacterial infection^,99. Additional susceptibility factors for drug users may be that
opiates themselves depress the cough reflex as well as the immune system?0-72,100
Interestingly despite the absence of a definitive symptom complex associated with
the retroviruses HTLV-I/II, drug users infected with both HIV-1 and HTLV-I/II were
three times more likely to die ofAIDS during the follow up period in Florida^ 1.
However the infection again could not be associated with any particular clinical
134
syndrome and the association could simply represent those patients who had been
infected the longest with HIV-1.
Medical problems of HIV infected drug users
As far as the clinical problems specific for HIV itself, there appears to be little
variation between the risk activities with regard to presentation. In the USA, figures
available to the Centers for Disease Control show that conditions such as KS are
unusual in the absence of homo/bisexuality. In drug users, KS, cytomegalovirus and
chronic cryptosporidiosis are all significantly less common than for all other risk
groups notified with AIDS; while PCP, tuberculosis, oesophageal candidiasis and
extra-pulmonary cryptococcosis are more common102 The clinical problems of
IDU related HIV in Edinburgh will be discussed in more detail in Chapter 17.
Conclusions
There are a number of important medical problems, both non infective and infective
in nature, associated with drug use. The advent ofHIV requires practitioners to have
not only knowledge of these latter medical conditions but also both the infection and
non infection related HIV related medical conditions associated with IDU since they
may mimic each other. A variety ofmicro-organisms are associated with the non
sterile nature of IDU whilst a number of blood borne viruses, including retroviruses
such as HIV, are easily transmitted to individuals involved in the sharing of injection
equipment. Prior to the advent ofHIV the mortality rate in drug users was of the
order of 1 % per annum.
As far as the clinical problems specific for HIV itself, there appears to be little
variation between the risk activities with regard to presentation. In the USA
conditions such as KS appear to be unusual in the absence of homo/bisexuality. In
drug users PCP, tuberculosis, and oesophageal candidiasis seem to be more common.
HIV has now been reported to cause some of the non infective problems previously
seen in IDUs particularly pulmonary hypertension, cardiomyopathy and emphysema.
In addition the literature suggests that a number of conditions which occur commonly
in drug users such as tuberculosis, pneumonia and endocarditis are affected by the
presence ofHIV in the host. The underlying mechanism behind the increased
susceptibility to, and mortality of, bacterial infections is not as yet clear.
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CHAPTER 4
Injection Drug Use related HIV Infection in Edinburgh
Unlike the USA, by 1989 82% of the patients with AIDS notified in the United
Kingdom had involved homosexuality or bisexuality alone and only 2% of such
reports had implicated IDU alone as a high risk activity 1. Only 3.8% of the AIDS
cases had come from Scotland and only 11 of these were drug users2-4 in the UK as
a whole IDU represented only 16% of reports of those infected with HIV and this
contrasted markedly with the position in Scotland in which 54% of those infected
with HIV had implicated IDU and nearly 60% of those reports had come from
Edinburgh2_4.
The first indications that Edinburgh had a particular HIV problem came with the
finding that 15/34 or 44% of a group of haemophiliacs had acquired HIV antibody
between 1983 and 1984 after being treated solely with locally produced Factor VIII^.
In 1985 and 1986 surveys found that between 38% and 52% of Edinburgh and 40%
ofDundee drug users had been infected with HIV^'9 By comparison only 4.5% of
drug users in Glasgow and 10% in England and Wales were infected with HIV 10,11.
Whilst fewer IDU related HIV infections have occurred in England and Wales all
areas have now reported cases. A follow up study on a cohort of drug users revealed
that the known HIV seropositivity rate had risen to a maximum of 64% by 198812.
The initial United Kingdom drug problem in the 1960's was centred around relatively
affluent individuals in London with smaller numbers in other cities. In the late
1970's and early 1980's, coincident with the arrival of relatively cheap brown heroin
from Iran and then Pakistan, a different user appeared - unemployed individuals from
large council estates^. An epidemic of IDU occurred in Edinburgh starting around
1980 and peaking in 1983-8414-16^ancj see results below). There is supportive
evidence of this epidemic of IDU from a variety of sources and unfortunately HIV
was introduced into this community at the peak of the IDU epidemic^' 17. This
chapter details what was discovered about the Edinburgh epidemic of IDU and HIV
via interviews with drug users attending a counselling and screening clinic as well as
via other sources of information concerning morbidity and mortality.
Method
A voluntary self referral clinic was established in the Edinburgh Regional Infectious
Diseases Unit (RIDU) to provide open access counselling and HIV antibody testing
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(see Chapter 5)6. The Clinic started on October 16th, 1985 to coincide with the
commencement of testing of all blood donations by the National Blood Transfusion
Service. As part of the pre test counselling assessment a series of questions were
asked concerning injection drug use such as year of first injection, frequency of
current injection drug use etc. The responses to these questions were analysed for
drug users attending the clinic up to the end of 1987. Where possible, assuming the
individual agreed to undergo an HIV test, the results were cross tabulated with the
HIV test result. Initial testing of specimens was by competitive or anti-globulin
enzyme linked immunosorbent assay (ELISA). All reactive sera were considered
positive if confirmed by methodologically distinct assays. The Information Service
Division of the Common Services Agency were asked to provide data on admissions
to Lothian Hospitals with first or second diagnosis of medical conditions such as
pneumonia, endocarditis etc. and or drug misuse.
Results
A total of 368 injection drug users provided a year of first injection drug use and
these results together with their HIV result are shown in table 4.1 and figure 4.1. The
numbers starting IDU each year were not constant (%^(22)= 368.6, p <0.000) with a
peak occurring in 1983, thereafter the numbers decline sharply. An analysis of the
relationship between the year of starting IDU and HIV infection revealed that this
was also not constant (x^(22)= 279.5, p <0.000). The relationship between year of
starting IDU and HIV infection was further analysed and the results are shown in
table 4.2. An HIV positive drug user was more often associated with starting IDU
before or during 1983 than in subsequent years (x^(3)==8.3, p<0.05). There was a
significant association between the frequency of needle sharing and HIV infection (x
2=4.24, p<0.05, table 3.3). In addition there was also a significant association
between markers of past or present infection with another blood borne virus,
Hepatitis B virus and HIV infection (x^=4.81, p<0.05 table 4.4).
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Table 4.1: Frequency and HIV infection of individuals by year of entry to
injection drug use in Edinburgh as reported to Counselling Clinic





1965/66 2 0 0
1967 6 1 17
1968 3 0 0
1969 5 2 40
1970 2 2 100
1971 6 2 33
1972 4 0 0
1973 5 3 60
1974 6 1 17
1975 10 4 40
1976 9 7 78
1977 13 9 69
1978 21 11 52
1979 25 16 64
1980 33 20 61
1981 43 25 58
1982 46 23 50
1983 59 35 59
1984 34 12 35
1985 22 2 9
1986/87 14 0 0





































































































Table 4.5: Injection Drug Use related illness: hospital discharges for Lothian
1976-86





1976 0 0 0 0 0 0
1977 0 0 4 0 0 4
1978 0 2 3 0 0 5
1979 0 0 2 0 0 2
1980 1 2 5 2 36 46(7)
1981 0 4 13 2 55 74(11)
1982 2 0 23 3 53 81(12)
1983 1 4 46 9 53 113(16)
1984 7 8 66 19 83 183(26)
1985 1 2 7 1 93 104(15)
1986 1 0 9 3 69 82(12)
Total(%) 13(2) 22(3) 178(26) 39(5) 442(64) 694(100)
Supplied by Information and Statistic Division ofCommon Services Agency
(Scotland)
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The distribution ofHIV infected individuals around Edinburgh was not uniform and
was concentrated in and around particular areas of Edinburgh. These areas were
centred on 4 areas with considerable multiple deprivation, namely Muirhouse (EH4
and EH12), Leith (EH6), Craigmillar (EH 15,16,17) and Wester Hailes (EH11 and
14). In 157 attendees of the City Hospital Counselling and Screening Clinic in whom
post codes were available there was a statistically significant increase in the number
ofHIV infected in those areas 7.67, p <0.01). These particular areas were
also known from other work to have been heavily affected by the IDU epidemic^.





HIV + 32 5 37
HIV- 97 23 120
Total 129 28 157
X^-7.67, p<0.01
Despite the fact that the majority of individuals involved in drug use in Edinburgh
were born in the area, interviews revealed that many had travelled to other areas and
had shared injecting equipment in those areas. The extent of this mobility is largely
unknown but an idea of its extent is revealed in Table 4.7 which documents the range
ofmovement for 122 drug users interviewed after their return to Edinburgh. The
number failing to return to Edinburgh is not known.
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Table 4.7: The location of needle sharing in drug users returning to Edinburgh
(individuals shared in more than one location)









































Table 4.7 continued: The location of needle sharing in drug users returning to
Edinburgh (individuals shared in more than one location)






It is likely that this mobility of a sub group of drug users was the origin of the
epidemic ofHIV in Edinburgh. Four individuals reported sharing injecting
equipment in Edinburgh as well as Southern Europe where it is now known that the
HIV epidemic began 2-3 years earlier (see Chapter 2). One particular individual
arrived back in Edinburgh from Spain in early 1983 and developed an episode of
clinical hepatitis B. When referred to the clinic in 1987 by his general practitioner
because ofHIV it was determined from stored specimens taken by his general
practitioner, that he had seroconverted for HIV between December 1982 and January
1983. This is to date the earliest known positive specimen from an injection drug
users in Edinburgh. This individual remained in Edinburgh for a further 6 months
during 1983 and many individuals with whom he shared equipment were shown to
have seroconverted around August 1983^. Thus the source of the Edinburgh HIV
epidemic was probable the heroin and HIV epidemic which affected Southern Europe
from around 1979 20
Discussion
An epidemic of IDU occurred in Edinburgh, starting in the late 1970's and peaking in
1983-84. The evidence for this epidemic comes from a variety of sources. Self
reported data from individuals asked about when they first started IDU at the City
Hospital Counselling Clinic, revealed that the year of starting IDU was not evenly
spread over the years. More individuals began IDU in the late 1970's and early
1980's. What is perhaps of interest is the fact that the epidemic peaked well before
any medical sources were aware of the problem. The reasons for the decline in
individuals initiating IDU after 1985 are largely unknown. The response of the
police to the epidemic may have influenced the epidemic or IDU may have exhibited
the phenomena of saturation in that only a certain number of young individuals may
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be attracted at any one time into the activity. For what ever cause the number of new
individuals entering IDU fell steeply after 1985.
The other evidence for the existence of an IDU epidemic comes from an analysis of
drug use related medical conditions in Lothian Hospitals over the same time period.
Drug related problems such as opiate overdoses, drug related soft tissue infections,
pneumonia and endocarditis all showed similar explosive increases. In addition
reports of IDU related clinical hepatitis B, a blood borne virus infection with similar
transmission characteristics to HIV were also increased with a peak occurring in
1985.
The epidemic of IDU was also documented in a variety of non medical statistics. For
instance from Home Office and Police Statistics it can be seen that the number of
notified addicts both new, old and those receiving treatment peaked in 1984/85^. in
addition a similar epidemic of drug offences, drug related arrests and convictions all
occurred in Lothian. Whilst most of these figures relate to the Lothians and the
Borders areas 75% consistently relate to the Lothian area. Interestingly 69% of these
offences were found to occur within the same postal district as that of the accused
suggesting that the activity was very much a local community event. The seizure of
drugs also showed a dramatic rise over this period^.
In 1985 drug users were generally unemployed, around 25 years of age, started their
drug use around the age of 17-20 and at least one third were female 19,21 They
were concentrated in 4 areas ofmultiply deprived areas of Edinburgh (Muirhouse,
Leith, Craigmillar and Wester Hailes) These individuals often had no tradition of
heroin use and knew little about how to avoid some of the complications. They were
using at least once daily if not more often and in most cases preferred to administer
the drugs by injection^. Comparisons of self reported habits between Edinburgh
and Glasgow or Edinburgh and London reveal considerably more sharing of needles
and syringes in Edinburgh 17,21. For instance, the sharing of equipment occurred 46
times per month in Edinburgh compared to only 15 times per month in Glasgow. In
addition sharing occurred with twice as many individuals, 14 versus 7 per month^.
Of 78 Edinburgh injection drug users 42% shared daily and 63% weekly by
comparison to only 14 or 31% of 45 South London injection drug users who admitted
to sharing within the last 3 months^l.
Historically, drug users report that needles and syringes were in short supply in
Edinburgh from around 1981/82 to 1985 when a surgical supplies shop ceased
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trading and pharmacists were generally unwilling to supply users22-24. Users also
report that equipment was commonly removed from them by the police during
searches and then destroyed. Possession of equipment contaminated with heroin may
be used as evidence of illicit use and users might then give evidence against a
supplier. This resulted in suppliers forcing users to use drugs on site so that on
leaving the premises they were free of any incriminating evidence. Unfortunately,
because of the limited supply of equipment considerable sharing occurred with
possibly only one or two sets of equipment for all the pushers' clients which could
number 20-40. There were also large gatherings of users, anything from five to 20, in
the style of American 'shooting galleries' where one set of equipment was passed
around the group.
The reason Edinburgh was so important in the Scottish heroin epidemic is in part
related to the geography of Scotland. Heroin tended to be smuggled in to the UK
from Europe via the East coast and Edinburgh, unlike Glasgow, has a radial
communication network to the rest of Scotland which eased the distribution of the
product around Scotland. With this background it is perhaps not entirely surprising,
therefore, that when in 1983 HIV was introduced into Edinburgh it spread rapidly as
a consequence of the habit of equipment sharing^ 19. Those involved in IDU in
1985 were around 25 years of age and were injecting drugs at least daily if not more
often. Commencing IDU in the years 1983 or before was associated with an
increased risk ofHIV infection as was more frequent injecting drugs, younger age,
infection with other blood borne viruses and living in particular areas of Edinburgh.
The origins of the IDU related epidemic ofHIV in Edinburgh have been traced to the
unexpected mobility of a small number of injection drug users who travelled to
Southern Europe to access greater quantities of heroin. The variety of locations
where Edinburgh drug users shared equipment and then returned to Edinburgh
effectively demonstrates the method by which blood borne viruses such as Hepatitis
B delta virus, Hepatitis C and HIV are spread geographically via IDU25-29
By 1989 over 1700 HIV infected individuals had been identified in Scotland and over
1000 in Edinburgh^ 9. Estimates of the size of the drug abuse community in
Edinburgh are poor but it is thought that there are probably at least 2 - 2,500' 5. The
3 series of investigations from Edinburgh on HIV infection in injection drug users
suggested a level of 50% infection in those individuals injecting drugs in the early to
mid 1980's. These two pieces of information when combined suggest that there were
at least 1,000 individuals infected by IDU in Edinburgh^, 19
155
By July 1989 over 1000 or 0.133% of the population of Lothian (750,000) had been
found to be infected with HIV the majority by injection drug use™. The worst
affected area in England (North West Thames) has a known rate ofHIV infection of
0.089%31. The majority of infected individuals in Edinburgh live in the City with a
population of only around 300,000 (1981 census). Thus the realistic prevalence for
the City ofEdinburgh is 0.3% or 3.74 times the worst affected English region. Some
77% of the infected individuals in Edinburgh are in the 15 to 35 age group (120,000
in the 1981 census) and therefore a more realistic prevalence rate for HIV is 1 in
every 150 (0.64%) of the 15-35 population. Edinburgh may therefore have the worst
density ofHIV in the UK or at the very least as bad as the region most affected in
England Wales (North West Thames).
Could there be even more infected individuals from IDU in Edinburgh? At the peak
of the IDU epidemic it was estimated by Standing Committee on Drug Abuse
(SCODA) that the prevalence of opiate injecting drug use was 6 per 1000 or 0.6% of
individuals aged 15-3515 Reports from 1985/86 suggest that between 50-65% of
injection drug users were infected with HIV and this would therefore suggest that a
minimum of 360-480 individuals or 0.3-0.4% of adults aged 15-35 in Edinburgh are
now infected with HIV. In fact to date 490 individuals infected with HIV via IDU
have been identified in Edinburgh^. Thus the calculated and observed numbers of
HIV infected patients are very similar and confirm the serious nature of the problem
for Edinburgh. The data also suggests that there is not as yet a large undetected
population ofHIV infected individuals.
Whilst the overall prevalence rate of opiate drug use was 6 per 1000 of the
population aged 15-35 it was 8.4 per 1000 for males and 3.6 per 1000 for females.
Within these estimates there were however considerable variations. For instance the
prevalence of problem opiate drug use for males was 36 per 1000 of the 15-35
population in Leith, 29 in Muirhouse and 20 for Craigmillar^. Similarly the female
prevalence of problem opiate drug use was 22 per 1000 for the population aged 15-35
in Leith, 11 for Muirhouse and 9 per 1000 for Pilton^. Utilising the various opiate
drug taking estimates the HIV seroprevalence may obviously vary from 0.3% to as
much as 1.8-2.3% for males in Leith. The general practice in Muirhouse has
documented the fact that 1 in 10 males between the ages of 15-35 are infected^. By
comparison in the Bronx the HIV seroprevalence ofwomen attending for termination
was 2% and 4.6% for patients attending hospitals in general^.
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Conclusions
For a variety of reasons an epidemic of IDU began in Edinburgh in the late 1970's
and peaked again for unknown reasons between 1983-85. A clinically unrecognised
epidemic ofHIV began abruptly in Edinburgh in 1983 and rapidly spread through
drug using cohorts. It is likely that this epidemic originated in Southern Europe and
came to Edinburgh as a consequence of the unexpected mobility of a small number of
injection drug users. The transmission ofHIV via IDU was associated with more
frequent equipment sharing and evidence of an other blood borne viruses namely
hepatitis B.
This dramatic and rapidly spreading epidemic ofHIV was the first of its type to be
described in the world and unfortunately despite the relatively small number of drug
users in Edinburgh it resulted in a large number of individuals infected with HIV.
Per head of population the density ofHIV infection in the 15-44 age group was
certainly as great as any where else in the UK. Unlike other areas such as the USA
the epidemic was detected within 2 years of its onset when the majority of infected
individuals were asymptomatic and as a consequence there was the opportunity to
develop specific services for HIV before the onset ofHIV related ill health or AIDS
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SERVICES FOR THE HIV/AIDS
EPIDEMIC
As a consequence of the knowledge of the HIV epidemic a number of new services
were developed at the RIDU, City Hospital and the following chapters describe these
services together with an assessment of their effect. Prior to the advent ofHIV, drug
use was considered as a psychiatric problem and there was no medical service
dedicated to managing the medical problems of drug users on a long term basis.
The aims of the service were to initiate and maintain contact and the success or
failure of the service should be judged against these aims. Society has two basic
methods of coping with the problem ofHIV. One method is to identify and control
the spread ofHIV by coercion. The alternative approach is to provide positive
incentives for patients with HIV to enter the health care system and this was the
approach adopted in Edinburgh. Whilst many may consider the services as lavish
they need to be judged against the objective of attracting individuals into the health
care system.
For the asymptomatic patient with HIV their own problems take priority over those
of society; those who are homeless or addicted are not likely to worry about their
physical health or the dangers of viral transmission. Consequently medical care for
HIV particularly IDU related HIV, requires a multi-disciplinary approach.
Demonstrating a practical approach to the patient's problems of drug use, housing,
low income etc. is a necessary method of working with the patient until he or she can
begin to concentrate on the problem ofHIV.
The aim of the service was however not only to care for the individual but also to
care for society i.e. by understanding and reducing transmission ofHIV. Helping
individuals to realise that they are infected with HIV is important if health education
is to alter their behaviour. This need to be in contact with as many HIV positives as
possible in the hope of gradually altering their behaviour, was an important
underlying theme in the service developed at the City Hospital. Consequently some
assessment of behaviour change is an important part of the results of the service.
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CHAPTER 5
Counselling and screening of HIV infected patients
Introduction
The most immediate consequence of the HIV epidemic for society as a whole was the
threat to the confidence of society in blood transfusions. The Government's response
when antibody testing became available in early 1985 was to introduce mandatory
screening of all donated blood in October 1985. In Edinburgh the HIV positivity rate
amongst voluntary blood donors was 1/13074 and this compared with 1/41598 in the
West of Scotland and 1/50000 for the UK as a whole^. The screening of blood
donations could only be successful if it was combined with a programme of "donor
deferment" to direct individuals in high risk groups away from the Blood Transfusion
Service since such individuals could be infectious before developing detectable HIV
antibody^. It was, therefore, necessary to provide voluntary confidential screening
and counselling at alternative testing centres to prevent the Blood Transfusion
Services being used as a diagnostic facility.
Since the majority of individuals infected with HIV in Edinburgh were current or
past injection drug users it was important that an alternate test site be both
experienced in handling drug users as well as acceptable to those drug users. A
decision was therefore made to establish an alternate test site at the City Hospital
with 6 months of funding from the Chief Scientist's Office. Thereafter funding was
provided by the Lothian Health Board.
Experienced counselling is important to avoid the fear and ignorance surrounding
HIV. Headlines such as "Dying mum's baby has AIDS" are a direct result of bad
counselling and inexperience on the part of the legal and medical professions. In the
extreme, poor or ineffective counselling may result in suicide whilst at the very least
it results in the patient losing contact with services. This removes the chance for the
service to influence and educate about high risk behaviour. Counselling also
provides the opportunity for those not infected with HIV to be educated about
reducing high risk behaviour. Consequently pre and post test counselling are
important in establishing a relationship between individuals (whether infected or not)
and the health service which may eventually be used for health education or harm
reduction (see Chapter 8). Poor pre-test counselling or non voluntary testing might
eventually also lead to legal claims as a result of difficulty in obtaining life assurance
or a mortgage.
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The City Hospital Counselling and Screening Clinic
A voluntary self referral clinic was established in the Edinburgh Regional Infectious
Diseases Unit to provide open access counselling and HIV antibody testing. The
Clinic started on October 16th, 1985 to coincide with the commencement of testing
of all blood donations by the National Blood Transfusion Service.
Apart from self referrals, patients were also referred by social workers, drug self help
groups, General Practitioners and other hospitals. The HIV antibodies were detected
by a competitive ELISA system and confirmed by a conventional ELISA system.
Doubtful positives were confirmed by immunofluorescence or Western blotting.
The clinic was supervised by a consultant in Infectious Diseases (RPB) and continues
to be held in the Out Patient Department of the RIDU, Edinburgh. It initially
operated for a four hour session, five times per week and each session was staffed by
a Medical Officer, Nurse Counsellor and a receptionist/secretary. Whilst the initial
cost of staffing was only one part time medical officer and one part time
nurse/counsellor the sessions were shared by three medical officers and two nurses.
The clinic had its own telephone line with an answering machine which informed out
of hours callers of clinic hours. Most patients were offered an appointment within 1 -
2 days of calling. The clinic presented a relatively non-medical image since it did
not set out to conduct a full clinical examination and assessment. Because of the
expectation that a majority of the patients would be injection drug users it was
necessary initially to have a medical officer present at all times because phlebotomy
might be difficult.
From the outset, the aim of the clinic was to offer a confidential service and to this
end all records were kept within the clinic and there was no other record of
attendance unless they took up the offer ofmedical screening. The aim was always
to persuade patients of the advantages of informing their general practitioner of their
HIV antibody status. Initially the clinic was often left with results not knowing
whether or not to inform other doctors. It then became necessary to obtain written
consent to inform general practitioners of the HIV results. The results were otherwise
only given out in person at a clinic attendance. Contact tracing was not undertaken
but the patients were encouraged to bring their sexual or needle sharing partners to
the clinic. When the clinic opened there was no literature specifically for injection




Each patient was allocated at least 30 minutes for their initial appointment although
in practice strict adherence to such a timetable did not occur. The patients received a
simple sheet which explained the advantages and disadvantages ofHIV antibody
testing and this was discussed at the counselling session. The main objectives of the
pre test counselling were general education regarding HIV including modes of
transmission, risk activities and risk reduction. Individual specific risk activities were
assessed and advice provided. In view of the high default rate and the almost
invariable lack of comprehension following a positive result as much information as
possible was provided at the first visit.
As a consequence of the prolonged incubation period for seroconversion the policy
was to offer repeat testing for up to one year after an individual's last risk activity and
during that time the client was advised to assume seropositivity in terms of risk
reduction measures. Contraceptive advice and supplies were also available. The
implications of the test were then explored and if the patient decided to proceed,
blood was taken for HIV antibody and hepatitis B marker tests. A further
appointment was given for one week later when a confirmed result would be
available. No other specific screening was undertaken, for instance to exclude
sexually transmitted diseases, however, if the medical officer considered it necessary
referrals were arranged to genito-urinary medicine, dermatology, psychiatry etc.
One important function of the clinic was to act as a point of contact for providing
advice and information to Health Care Workers, Social Workers, Occupational
nurses and foster mothers, as well as worried individuals whether or not they were in
identified high risk groups. The clinic staffwere, therefore, an important resource for
the dissemination of information to many individuals other than those directly
concerned with this infection.
Post test counselling
At the return visit patients with a negative antibody test were given advice which
depended upon their suspected exposure time and risk factors. If there had been a
high risk activity within the past twelve months, the patient was advised to re attend
the clinic for further testing in six to twelve months time.
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Patients with a positive test were counselled in relation to relevant risk reduction
with the initial emphasis on reducing progression of the disease in the individual and
spread of the virus in the community. Depending upon the circumstances this would
include advice on safe sex, safe drug use, advice with regard to sexual and needle
sharing partners, advice with regard to diet and physical activity as well as
reassurance about lack of transmission to non sexual or non needle sharing partners.
It also would encompass for men and women the risks of pregnancy.
Further Management
Patients with a positive HIV antibody result were offered further counselling
appointments as well as an appointment for a medical examination. With one third
of the affected patients being female it was one important aim to offer medical
services for both mother and child at one clinic in an attempt to overcome the
problems of a haphazard and chaotic lifestyle. One session initially was devoted to
the follow up of those children identified as at risk ofHIV infection and utilised the
services of a nurse counsellor from the Screening Clinic, a Consultant in Community
Child Health, an Infectious Diseases physician and a liaison Health Visitor to help
co-ordinate follow up. The mothers were encouraged to attend routine baby clinics
but the clinic co-ordinated their immunisations and medical care.
The dental health of drug users is generally poor and their attendance at dentists is as
irregular as all other medical services. In Edinburgh there was already a mechanism
for dealing with patients with Hepatitis B and with the help of the Lothian Area
Dental Service treatment was also offered for these patients.
Results of the first year of the service
A total of 441 new patients had been counselled at 980 clinic attendance's by the 30th
September 1986 and there were 402 (41%) non attendance's. Three hundred and
forty five (78%) of the patients were from the City of Edinburgh, 55 (12.5%) were
from the rest of the Lothian Region, 27 (6%) were from the rest of Scotland, 3 (0.5%)
were from England and 11 (3%) gave no address.
A total of 30 (6.8%) individuals declined HIV testing after pre test counselling and
not surprisingly those with the least risk were more likely to refuse testing (Table
5.1).
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test (% of risk
group)
IDUs 191(44) 100(52) 5(3)
Sex with an IDUs 88(20) 6(7) 3(3)
Ho/bi 40(9) 4(10) 3(8)
Heterosexual 53(12) 0(0) 5(9)
Other 69(16) 4(6)* 14(20)
Total 441(100) 114(26) 30(7)
* all related to iatrogenic blood products
Risk groups
IDUs injection drug users
Ho/bi homosexuals or bisexuals
Sex with an IDUs sexual intercourse with a known IDUs
Heterosexual heterosexual intercourse other than with IDUs
One hundred and fourteen (26%) HIV positive individuals were counselled, 100
(88%) of whom were current or ex injection drug users. There were a total of 191
patients who admitted to injection drug use, 119 (62%) males and 72 (38%) females
and the seropositivity rate was 52%. None of the drug users admitted to
homosexuality. The mean age of drug users was 26 years, 25 years for those found
to be seropositive and 27.5 years for those found to be seronegative (p<0.01). The
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mean age of onset of injection drug use was 20 years, 18 years for those found to be
seropositive and 22 years for those found to be seronegative (p<0.0001). The
Male/Female ratio was 1.6/1, 1.3/1 for those found to be seropositive for HIV and
2.1/1 for those seronegative. Forty three (60.5%) of the females were HIV antibody
positive compared to 57 (49.5%) of the males but this difference was not significant.
On 1st January 1986 the family clinic for seropositive mothers and their new-born
children was established and by 30th September 1986, 23 at risk babies and their
mothers had been counselled and examined.
The total cost of this counselling and screening service in the first year was £27,000
made up of £18,500 in salaries, £3,000 in initial equipment, £2,500 in consumables
and £3,000 for HIV and Hepatitis B testing. The cost per patient in the first year was
therefore, £61.22 or £27.55 per attendance. The total number of hours available for
counselling per year were 2080. Allowing approximately one hour for counselling
each patient, a 15% time loss for holidays and 40% for default appointments,
approximately 1000 patients could have attended. This number of patients in
subsequent years would cost £21,000 for counselling and £7,300 for HIV/Hepatitis B
testing or £28.3 per patient. A more compliant population would reduce costs even
further to approximately £20 per patient made up of £12 for counselling and £8 for
HIV/Hepatitis B testing.
Discussion
The demand for this type of facility was confirmed by the fact that 441 new patients
attended in the first year, 64% being either injection drug users or their sexual
contacts. In Edinburgh 5 of 7 HIV positive donors identified by the Blood
Transfusion Service were ex- injection drug users and this further emphasises the
importance of alternative testing sites^. The clinic had counselled a total of 114
(26%) HIV positive individuals 88% ofwhom were injection drug users. It
confirmed the fact that HIV infection was commonplace (52%) amongst drug users
but less so amongst their sexual contacts (7%). This supported previous work
suggesting that this infection in drug users was spread by needle sharing rather than
as a sexually transmitted disease^.
Those affected in Edinburgh are characteristically younger, have markers of current
or past infection with Hepatitis B virus and are more likely to share needles/syringes
frequently^.
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Not surprisingly those individuals with the least risk were most likely to decline the
test after counselling, 20% in the miscellaneous group versus 2.6% in drug users.
Overall 7% declined testing compared to 16% in the USA where the positivity rate
was 17% compared to Edinburgh's 26%^. The post testing default rate was 21%
which compared favourably with 30% in the USA^. An overall default rate of 42%
is a matter of concern, since this means that counsellors are under-utilised. Cost and
distance appear not to be factors in the default rate and it may be a feature of either
lifestyle or the anxiety associated with screening for this particular virus.
The majority ofHIV counselling and screening in the United Kingdom had been
undertaken by Genito-Urinary Medicine clinics and since this had been an additional
workload separate costing had not been readily available. This HIV counselling and
screening clinic was set up de novo for a particularly difficult risk group. For a
variety of reasons it was felt necessary to have a medical officer on site at all times
and this obviously added to the expense. A realistic estimate of the cost ofproviding
a counselling and screening service was however possible as a result of setting up a
new service. In the first year the cost was £61.22 per patient without taking into
account the cost of premises which were available at no extra cost to the Health
Board. This cost could fall with increased numbers of patients and a better default
rate to around £20 per patient
Conclusions
The demand for an alternate site HIV counselling and testing facility was confirmed
by the attendance of over 400 patients in its first year of operation, 64% being either
injection drug users or their sexual contacts. It confirmed the fact that HIV infection
was commonplace (52%) amongst drug users but less so amongst their sexual
contacts (7%).
Not surprisingly those individuals with the least risk were most likely to decline HIV
testing after counselling. The post testing default rate compared favourably with that
reported from the USA but the high overall default rate was a matter of concern,
since this meant that counsellors were under-utilised and costs increased. The cost of
attendance and or distance appeared not to be factors in the default rate and it may be
a feature of either lifestyle or the anxiety associated with screening for this particular
virus are the most important factors.
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CHAPTER 6
Hospital Health care for HIV Infection with particular reference to Injecting
Drug Users - a review of services outside the UK
Introduction
Models of health care developed for HIV and AIDS tend to reflect the experience of
San Francisco or London where the majority of affected patients have been
homosexual or bisexual The services developed in such areas may not
necessarily apply to injection drug users. As a group injection drug users exhibit
poor utilisation of existing services although some of this chaotic behaviour is more a
characteristic of their community than drug use per se^. The medical services
dealing with drug users have, until recently, concentrated on and or specialised in
their addiction rather than their physical problems. Health care services have not
been developed to manage chronic ill health in drug users and behaviour change with
respect to HIV in drug users has been modest and rather difficult to initiate4-6. in
view of the problems associated with IDU related HIV, which are both physical and
psychological, the experience of other centres in developing services was important.
This chapter details IDU related services, some experienced in HIV others not, in
three other centres.
Method
During October and November 1988 the author undertook a travel fellowship to
compare and contrast medical services for injecting drug users with particular
reference to HIV and AIDS. During this fellowship I visited Amsterdam and a
number of centres in the USA notably the Montefiore Medical Centre, Beth Israel
Hospital, St Lukes-Roosevelt Hospital, Memorial Sloan Kettering Cancer Hospital,
Beth Abraham Hospice and Bailey House residential facility in New York as well as
the University of California San Francisco Medical Centre, San Francisco General
Hospital and San Francisco Department of Health. Whilst there are many centres
dealing with the problem of IDU related HIV I chose Amsterdam because of their
model of care for IDU, San Francisco because of their model of care for AIDS and
New York because of the size and length of their experience with IDU related HIV.
Results
The shape of any medical service is very much related to local demography and as a
consequence the services for AIDS have developed along different lines in New York
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and San Francisco. In New York City, IDU has been implicated in 34% of the male
and in 60% of the female patients whereas in San Francisco only 1.7% of San
Francisco's cases have been in drug users although a further 11.5% have involved
drug use in homosexual/bisexuals?A New York has had to cope with over 3 times
as many patients with very different characteristics? In San Francisco 82% of the
patients have been white, 99% male, 97% gay and only 1.7% heterosexual drug
users^. By comparison in New York only 46% of the patients have been white, 90%
male, 64% gay and 28% heterosexual drug users^. The medical problems are also
very different for instance, 15% of IDU related AIDS have developed tuberculosis
and this obviously requires very different nursing facilities^. In addition there has
been a dramatic increase in non-AIDS deaths such as pneumonia, tuberculosis,
endocarditis etc. amongst injecting drug users 10.
It is estimated that New York has some 200,000 injecting drug users for its 7.5
million inhabitants and that around 50% have been infected with HIV?. There are
around 35,000 places for drug treatment, approximately 30,000 Methadone treatment
slots and about 5,000 drug free treatment slots^. San Francisco by comparison to
New York has a much smaller injecting drug problem of approximately 14,000 users
for a population of 750,000^ 1. As in New York however the majority are Black or
Hispanic.
Methadone maintenance treatment programmes (MMTP) in the USA are regulated
by the Federal Drug Administration (FDA) and perhaps the most stringent rule is that
for every 50-60 patients attending a programme there should be one drug counsellor.
In addition it is required that there be various support services such as day
programmes. By law MMTP must also provide patients with an admission medical
examination as well as an annual medical examination. The medical examinations
vary however from a few minutes to 45-60 minutes depending upon the centres. The
majority of patients attend daily to receive their methadone dose on site. In order to
get into MMTP the patients need a one to two year history of drug use from court or
medical reports, previous failed detoxification attempts and have to be greater than
18 years of age. For most patients there is a 3-4 month waiting list and at the
admission physical the doctor will then decide on the dose of Methadone which was
usually about 30 mg. He will also decide on the final dose depending upon the pa¬
tient's history and every two to three days the dispensing nurses can increase the dose
by 10 mg provided the patient is having withdrawal symptoms backed up by clinical
signs such as dilated pupils, sweating etc. The doctors in the clinic provided primary
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care and refer to local hospitals if the patients are at all ill. Payment for the MMTP
service is according to income. The support system used relies on role model
counselling, from ex-addicts or stable addicts. The underlying philosophy is re
socialisation and to this end they are allowed take home privileges as far as
Methadone was concerned in an attempt to re stabilise or re socialise the
patients9'12.
Whilst New York City has had the largest number ofAIDS patients in the USA, it
was in San Francisco that an AIDS dedicated medical service began which is
described below.
San Francisco
The San Francisco General Hospital (SFGH) AIDS Care system goes back to 1979-
80 when Dr Abrams and Dr Volberding began a clinic for gay men with unexplained
lymphadenopathy. The AIDS Clinic was set-up in Ward 86 of the SFGH in 1981-82
initially as an oncology clinic and then also as an opportunistic infection clinic.
In 1988 it was open 5 days per week, had 2000 attendance's per month, over 120 staff
and provided the following functions; a Nurse Screening Clinic, an AIDS/ARC
Clinic, an Opportunistic Infection Clinic, a Kaposi's Sarcoma Clinic and a
Prescription Refill Clinic. In addition procedures such as blood transfusions,
intravenous rehydration, intravenous chemotherapy etc. were undertaken in the clinic
in order to avoid the need for admission^.
Whilst injecting drug users did receive medical and HIV care at this clinic, because
of Federal regulations they also had either to attend a separate clinic in the same
building for methadone or alternatively a methadone clinic elsewhere in the City.
Not surprisingly therefore the follow up of injecting drug users was made more
difficult by the need for multiple attendance's^.
In 1983 the in-patient Unit was established initially with 12 beds and latterly because
of the increased workload with 18 beds. The hospital had about 30 AIDS patients in
each day (or 27% of medical beds) and the AIDS Unit was virtually always full 14.
Patients were admitted via the AIDS clinic or arrived via the emergency room and
were admitted under the care of one of the general medical teams. There were eight
such teams providing medical care for general as well as AIDS patients. The
Consultants for the medical teams rotated monthly and provided inpatient care for
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between 2-4 months of each year. Thus patients with multiple admissions were
under different medical teams for each admission^.
In 1985-86 SFGH created an inpatient AIDS Team made up of an AIDS Specialist
(from the AIDS clinic) together with a third year resident (usually a visiting elective
resident from another medical school) and visiting medical students. The AIDS
Team provided back-up advise for the general medical teams and the AIDS Specialist
did 2 ward rounds per week with these teams 14.
By comparison the rest of the care provided for the AIDS patients was very much via
dedicated workers. For instance there were specialised social workers, counsellors,
drug counsellors, physiotherapists, psychologists etc.
It is important to remember that SFGH is a City Hospital and therefore many patients
with private health insurance would not utilise these inpatient services until they had
exhausted their medical insurance. Patients with private health care insurance might
utilise the expertise of the AIDS clinic but still attend their private physician and be
admitted to private hospitals for their inpatient care 14.
New York
In March 1988 1513 or 6.4% of the acute medical and surgical beds in the municipal
or voluntary hospitals were occupied by AIDS patients. At that time the Municipal
system was caring for 36% of the AIDS patients although in fact it only had 16% of
the medical and surgical beds in the City. Whilst overall only 13% ofAIDS patients
in New York hospitals were related to IDU, in the Health and Hospital Corporation
facilities 75% of the cases were related to IDU. Thus a disproportionate share of the
IDU problems gravitated to the Municipal hospitals^.
In 1986 the New York State Department of Health proposed a system of Specialised
AIDS Units. The idea was to provide a comprehensive care model for AIDS patients
and by 1988 22 Specialised AIDS Units had been designated together with their
associated AIDS Teams. In order to persuade hospitals to set up AIDS Units and
Teams the Department of Health offered an increase rate of reimbursement if the
patients were consulted on by an AIDS team.
In setting up AIDS centres the New York State Department of Health formulated a
set of standards which facilities had to meet in order to be designated an AIDS unit.
Essentially in order to claim increased reimbursement for the care of AIDS patients
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hospitals had to designate a Unit for the care ofAIDS patients which could provide a
24 hour emergency service and an outpatient facility. These units were expected to
offer a broad range of services for a range ofAIDS patients with differing needs
including diagnostic services, inpatient care, hospice and residential care, counselling
and educational programmes. The care of the patients in the Units was to be via a
multi-disciplinary team providing individual case management. The Units were also
expected to participate in clinical research and provide educational programmes for
the general public including those at increased risk of acquiring HIV 15.
The teams were headed by an AIDS specialist who would rotate monthly but the rest
of the staffwere dedicated full time to the AIDS patients. There were social workers
and nurse practitioners on all teams but the rest of the teams composition then
depended upon the particular Unit. Most teams had dieticians, psychiatrists and or
psychologists, the Unit head nurse and an administrator the latter because of the
importance of identifying AIDS patients in the hospitals in order to obtain increased
reimbursement. Others also had occupational therapists or lawyers (because of the
problems ofDo Not Resuscitate Orders and or living wills).
St Lukes and Beth Israel Hospital utilised dedicated medical staff that rotated
monthly but other Units such as at the Montefiore Medical Centre in the Bronx did
not have dedicated medical staff and as in SFGH each general medical team cared for
its own AIDS patients in the Unit. In both systems there were a large number of
Consultants involved in the care of the patients and the AIDS team co-ordinated their
care 14,15,16,17
Some Units such as at Montefiore utilised a written admission policy not only for
AIDS but also for substance users, whilst others did not. They all tended to admit the
sickest and most difficult patients or any patient that might benefit from admission to
the Unit. Because the Units were designated as AIDS wards all patients had to
volunteer for admission because it revealed their diagnosis.
Security was a problem for many Units and it was not uncommon for the hospitals to
have security guards who might visit the Units as often as two hourly. The security
staffwere however rarely called upon and in fact had a good relationship with many
of the patients. Their presence was however appreciated by the staff.
The out-patient AIDS clinics in New York provided care for the non-private patients.
The New York Health Department's plan was to provide a similar structure to the
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inpatient model of care for out-patient care but by December 1988 most of the AIDS
Units had not fully established these specialised clinics. In general anyone not being
followed by a private physician or a Methadone Treatment Programme was seen after
discharge in an AIDS clinic.
Amsterdam
By 1988 Holland had reported 605 AIDS patients and of these 2.5% were drug users
in 1986, 5% in 1987 and 8% in 1988. There were no special facilities available for
AIDS in Amsterdam and at that time none were planned1 8,19
The Municipal Medical Health Care Service had 5 major departments, one of them
known as the Public Health and Environment Department (GG&GD) which had the
function of running out-patient clinics, offering vaccinations, controlling infectious
diseases, running laboratory services, combating AIDS and drug treatment for drug
users.
Amsterdam's programme of drug treatment had 3 levels described as low, middle and
high threshold. The Methadone bus was the low threshold system, the Methadone
clinics were the middle system and drug detoxification, therapeutic communities etc.
the high threshold system. The low level system had little in the way of regulations
whilst the high level system was very strict as far as the use of other drugs was
concerned. The GG&GD estimate that they reached 70% of the 6000-8000 addicts in
Amsterdam (approximately 1/3 of Dutch users) and 40% of these were injecting
drugs. Eight hundred individuals or 1/3 of the injecting drug users in Amsterdam
had been found to be seropositive and were in touch with authorities. Approximately
50% of these were German or Italian^,19
The Health care system of the Netherlands was based on an insurance system such
that if one was in receipt of social security then the social security system directly
paid for the services used by the patient. There were however a large number of
uninsured individuals (very often foreign drug users) and if admitted to hospital then
the insurance was initially paid by the social services only if it was a life threatening
illness. As the patients get better however they become liable for the bills and
therefore often self discharge.
A team of psycho-social nurses visited all the drug users in the general hospitals and
saw between 300 and 400 patients per year. The team provided crisis intervention
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for the patient during the first 2-3 hours in order to avoid a lack ofmethadone and
because the patient's drug problem was usually of such a long standing nature they
tried to persuade the staff not to embark on detoxification™.
The patients might well have aggressive, paranoid features or even frank psychiatric
problems. The psycho-social nurses evaluated the drug history, the psychiatric
history and the social circumstances as well as managed numerous crises between
patients and staff. The major problems seen in hospitals with drug users centred
around their visitors, their interaction with other patients and continued injection
drug use. The nurses tried to place patients in treatment programmes and whilst
previously they discharged them as soon as they left the hospital, with AIDS patients
they offered outpatient follow up.
Some years ago Amsterdam experienced the effects of poisoned heroin and all those
cases were managed in one ward to facilitate care. Thus they had developed a model
for how to deal with drug users in hospital utilising a concentrated model of care but
in 1988 they had not utilised this model for AIDS or HIV infection^. Similarly the
methadone bus and clinics were not directly involved in HIV health care.
Discussion
The accepted model of health care for HIV and AIDS was developed in San
Francisco and London and was based on a homosexual or bisexual population. The
evolving HIV health care system was characterised by the involvement of voluntary
groups, most but not all from the homosexual community, an emphasis on home
and/or community care to return the patient to a non-hospital environment, a rapidly
evolving health consciousness over HIV and a positive response to risk reduction
measures.
This model of care does not necessarily apply to injecting drug users since the
current drug user may have a continuing involvement in illegal or criminal activities,
manipulative tendencies in dealing with statutory agencies, a dislike or distrust of
official organisations and a similar dislike or distrust by those organisations of the
clients. As a group they exhibit poor utilisation of existing services although some of
this chaotic behaviour is more a characteristic of their community than drug use per
se. There are in addition a relative lack of self help groups within the community and
a relatively weak community voice. Their home environment is often not ideal or
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suited to home care and to date behaviour change with respect to HIV has been
modest and difficult to initiate^.
The medical care of patients with AIDS is complicated by a number of medico-social
problems which are further compounded by the problem of IDU. Homelessness is
extremely common in New York and San Francisco, and the accommodation of those
that are not homeless is often unsatisfactory in relationship to their medical
condition. Thus the existing situation is simply worsened with the development of
AIDS and consequently many patients remain in hospital solely because of their
unsatisfactory accommodation.
In the USA continuity of care does not necessarily occur within the voluntary or
municipal medical system unless the individual has private medical insurance.
Private medical insurance ensures that the same doctor cares for the individual as
both outpatient and inpatient but this is not the case for those lacking insurance.
Deteriorating health often results in an inability to generate an income or eventual
unemployment. When combined with high medical costs this often results in a lack
of basic health insurance. Amongst injecting drug users there is not only the problem
of the high cost ofmedical care but also a lack of initial basic health care insurance.
This lack of health insurance further reduces continuity of care because individuals
may move from hospital to hospital using false names in order to avoid the problem
of payment. Without doubt in both New York and San Francisco, as in the rest of the
world, the cracks in the medical system are exposed by drug users. Continuity of
care in New York or San Francisco was almost non existent for IDU related HIV
unless the patients were in a methadone programme and in this respect those enrolled
in programmes may be better off than the ex-users or heterosexuals with HIV.
The inability to generate an income however affects not only those in regular
employment but also those with an illegal income. In the case of an injecting drug
user this might be because of an inability to continue criminal activities. The
resulting poverty often precipitates an additional crisis when the individuals can no
longer afford their drug habit. Consequently IDU related AIDS and HIV patients
were more often in need of drug treatment programmes as their health deteriorated.
As a consequence of the shortage of places in methadone treatment programmes and
the priority given to IDU related AIDS or HIV these programmes are rapidly being
saturated. Since these programmes were not established to deal with medical
problems it created further problems for an over stretched service. In addition it
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further reduced the available places for the uninfected drug users and this in turn
further reduced the effectiveness of the prevention aspects ofmethadone
programmes.
The San Francisco model for AIDS care whilst providing excellent continuity of care
for out patients did not provide continuity of care for the numerous in-patient
admissions unless the patient had private medical insurance. The SFGH inpatient
model of care was adopted because it was felt that AIDS should be looked after by
general physicians (despite the presence of an AIDS clinic). It was an attempt to
avoid burnout in the carers and to educate more doctors in the principles of care of
AIDS patients. Flowever it did not address the problems of the patients. Continuity
of care could not be provided by the Consultants since they were only on service for
an average of about 2 months per year. The junior doctors also rotated frequently
and thus it was quite possible for an individual to have a number of admissions and
to be looked after by a variety ofmedical teams.
The New York health care system provided some continuity of care via the AIDS
teams but even here the AIDS specialists rotated. Thus true continuity of care for
inpatients was not available because subsequent admissions were under different
Consultants. This contrasts with the UK medical care system where Consultants are
on service for the majority of the year and provide both inpatient and outpatient care.
A lack of continuity of care or its provision has not been evaluated as a possible
factor in the difficulties of delivering health care to injecting drug users.
At present there are relatively few specialised AIDS out patient services in New York
but the AIDS teams were an improvement on the way patients are generally managed
in the United States in the public sector system. When viewed from this perspective
it was of course an extremely good system. However when viewed from a private
health care system or a European perspective there is no doubt that it had
considerable deficiencies which could be remedied. For instance the creation of
dedicated inpatient medical teams supervised by AIDS specialists as seen in some of
the New York AIDS Units would provide better care for the patient without
sacrificing the training of staff.
As a consequence of the enormous psycho-social problems, the drug dependence
problems and the relative lack of a community network or movement to deal with
these problems, more than any other group, the management of IDU related HIV
requires a multi-disciplinary approach. IDU related HIV is a chronic debilitating
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disease of the young who are in addition socio-economically deprived and their care
is as much about HIV as about how to deliver that care in the presence of extreme
poverty.
The USA experience does emphasises the importance of dedicated HIV services to
cope with the problems. The San Francisco experience suggests that it is more
efficient to provide all the relevant specialities in one area; thus the specialities of
Infectious Diseases, Oncology and Neurology will all be required in the HIV/AIDS
outpatient department.
The Amsterdam Municipal Medical Health Care Service provided excellent
continuity of care for drug problems but had not yet been utilised for IDU related
HIV problems. This despite the fact that Amsterdam had previously used a
specialised inpatient service for an epidemic of poisoned heroin. The SFGH and
Amsterdam experience of using specialised substance abuse counsellors or psycho¬
social nurses to help the patients and staff seems to be well worth considering for
General Hospitals in the UK. Alternatively inpatient services which are experienced
in the care of both HIV and injection drug use are required because the problems and
solutions are so different from the services already established.
Conclusions
The model of health care for HIV and AIDS has been developed from the experience
of San Francisco and London where the majority of patients have been homosexual
or bisexual. This model of care did not apply to injecting drug users who have very
different characteristics to other risk groups affected by HIV.
The medical care of patients with AIDS and HIV is complicated by a number of
medico-social problems which are further compounded by the problem of IDU. In
the USA continuity of care did not necessarily occur unless the individual had private
medical insurance and was almost non existent for IDU related HIV unless the
patients were in a methadone programme. The San Francisco model for AIDS care
provided excellent out patient medical care but continuity of care was not available
for the numerous in-patient admissions unless the patient had private medical
insurance. The New York health care system provided some continuity of care via
the AIDS teams but even the AIDS specialists rotated. Thus true continuity of care
for inpatients was not available because subsequent admissions were under different
Consultants. This is in contrast to the UK system where Consultants were and are on
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service for the majority of the year and provide both inpatient and outpatient care.
The USA experience did however emphasise the importance of a dedicated HIV
service. The San Francisco experience suggested that it was more efficient to
provide all the relevant specialities in one area.
The Amsterdam Municipal Medical Health Care Service provided excellent
continuity of care for drug problems but it had not been utilised for IDU related HIV
problems. The SFGH and Amsterdam experience of using specialised substance
abuse counsellors or psycho-social nurses to help the patients and staff seems to be
well worth considering for General Hospitals in the UK. Alternatively inpatient
services are required experienced in the care of both HIV and injection drug use
because the problems and solutions are so different from the services already
established.
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Outpatient medical care of HIV Infection with particular reference to Injecting
Drug Users
Introduction
Unlike other UK centres, in the early 1980's Edinburgh had little in the way of
specialist services for drug users 1. Whilst Edinburgh had a voluntary sector for
dealing with injecting drug users, during the 1970's and early 1980's there had been a
gradual reduction in the prescribing of substitute drugs by general practitioners and
psychiatrists based on the assumption that spontaneous resolution of addiction would
occur with a small overall mortality of around 1% per year2-5.
The Advisory Council on the Misuse of Drugs (ACMD) report in 1988 noted that in
Scotland, and in Edinburgh in particular, there were four notable features of the drug
services. Firstly a dearth of psychiatric input with virtually no specialist support
which undoubtedly contributed to the unwillingness of general practitioners to
provide care for drug users, secondly a limited range of treatment options, thirdly
limited community based services and lastly pilot syringe exchange schemes which
were not "user friendly" 1. Thus when the epidemic of injection drug use occurred in
the early 1980's there were little or no medical provisions for dealing with the
problem and as a consequence the initial management of IDU related HIV in 1985
and 1986 utilised only the offer ofmedical care. In addition the recognised models
of health care for HIV and AIDS were based on clinics where the majority of patients
affected had been homosexual or bisexual^.
The aims of an IDU related service should be to initiate and then maintain contact,
but this may require diverse initiatives such as methadone, pyschological and social
provisions as well as medical care. This concept has recently been more widely
advocated by the ACMD 1. However to date there has been little if any assessment of
the success or failure of IDU related HIV medical services in achieving these aims,
the majority of papers proposing various theories of care but rarely providing factual
evidence of success or failure.
The aims of medical care are to reduce if possible progression to AIDS , to initiate
the early treatment and prevention ofOIs and where possible to initiate anti-retroviral
therapy. In order to achieve some of these goals regular immunological monitoring
of the patients is important in order to provide both the patient and the service, of an
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early warning of deterioration. Lastly having established contact an attempt is made
to reduce the spread ofHIV by behaviour modification achieved via health
education.
Since 1985, services for individuals with HIV or AIDS have been developed at the
RIDU, City Hospital, Edinburgh. The considerable psychosocial and physical
problems associated with HIV infected patients necessitated the development in
Edinburgh of a multi-disciplinary team able both to manage patients and co-ordinate
their care. This chapter describes that team, its approach to the care ofHIV infected
drug users and, perhaps more importantly, the results.
Patients and Methods
The RIDU has since the early 1960's provided Urinary Tract Infection (UTI) clinics
which are held on one specific day staffed primarily by the Consultant staff. On
other days there were Infectious Disease (ID) clinics providing outpatient
consultations and care for patients with suspected infections including patients
returning from abroad. These clinics were staffed by Consultants and junior medical
staff. The HIV medical clinics were also established in October 1985. Initially a
single clinic was held in the Out Patient Department of the RIDU of the City
Hospital, Edinburgh staffed by one Consultant (RPB) and one part time medical
officer^. In November 1986 an all day clinic was established and staffing gradually
increased to a research registrar and another full time medical officer. In May 1989
an additional consultant (CLSL) was appointed and specific clinics on other days
were established
A retrospective analysis of out patient records was undertaken from 1985-90 to
assess the effectiveness of this service. In addition to providing medical care some
assessment of risk behaviour modification was also made at each clinic visit by
recording self reported IDU behaviour. Those patients who did not attend for more
than one year were flagged with the Registrar General to provide ongoing
information concerning date and cause of death.
In order to re-arrange an appointment it was and remains necessary for defaulting
patients to contact the clinic since appointments are not routinely sent out by post.
Because the phenomenon of re-attendance after missed appointments is so common,
patients were defined as lost to follow up if they had not re-attended before the 31 st
December 1991 and were not known to have died.
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A confidential prospective database containing an assessment of clinical staging,
injection drug use, oral drug use, weight as well as biochemical, haematological and
immunological parameters is maintained on all patients attending the City Hospital.
The patients are identified on the database by hospital number only and the cross link
between hospital number and name is stored on a separate database file which is kept
on a removable "floppy disc".
HIV service at the City Hospital
The general RIDU clinics had been faced with large numbers ofHIV infected drug
users with no management options for their addiction other than abstinence. There
were very few general practitioners or psychiatrists, with notable exceptions, willing
to prescribe oral opiate substitutes and it was obvious that the previous philosophy of
awaiting spontaneous resolution of addiction was no longer practicable with the
advent ofHIV. In 1986 it was also suggested that continued IDU was associated
with an accelerated loss of CD4 lymphocytes in HIV infected patients and therefore,
as an HIV management strategy, the prescribing of oral methadone was
commenced^.
Patients were evaluated for their HIV problems and those found to be injecting drugs
were offered a methadone maintenance programme. Methadone, initially in daily
instalments of "DTF" 1 mg/ml solution (an elixir which includes chloroform to
induce vomiting if injected), was provided via a hospital prescription which could be
taken to any dispensing pharmacist. The cost however was paid for by the hospital
rather than the general practitioner budget. The majority of initial prescriptions were,
and still are, written for daily dispensing but variations such as two or three times per
week are also used. No other drugs of addiction such as dihydrocodeine,
buprenorphine, prochloperazine or benzodiazepines were provided. Initially the
majority of patients were in receipt of hospital methadone prescriptions, but with
time, more general practitioners have taken on long term opiate substitute
prescribing.
As a consequence of the lack of drug services in Edinburgh there was a rise in the
number of uninfected injection drug users seeking treatment, until in June 1987 they
accounted for over one third of the referrals. Unfortunately, the response of the
management to this problem was to restrict the service at the City Hospital to only
HIV seropositives rather than to increase the available resources. This created a two
tier system such that it was easier to obtain oral drugs if infected and resulted, not
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surprisingly, in critical comments from the ACMD^. Eventually this illogical
situation was rectified with the creation of the Community Drug Problem Service or
CDPS in April 198810.
Patients were provided with other medication such as zidovudine, antibiotics etc. as
necessary. Initially Pneumocystis carinii pneumonia (PCP) prophylaxis was
organised using inhaled pentamidine via the district nurse service although latterly
cotrimoxazole has been used more extensively. Generally, however, other than
methadone and zidovudine, the majority of prescribing was done by general
practitioners with advice from the hospital clinic.
As a consequence of disruption to the general clinics and the large number of missed
appointments it was decided in November 1986 to provide IDU related HIV medical
care at a separate all day clinic . Provided the patients attend at some time on that
day, they are seen by a doctor. This overcame the problem of patients arriving late
for morning clinics and being sent away. The busiest time for the clinic was between
11 am and 3 pm and consultations often continued through lunch time. Additional
help came from the establishment of a voluntary organisation to offer practical help
for HIV positive individuals (including transportation to hospital appointments so
that ambulances have not been required except for emergencies).
Patients were offered routine medical surveillance for their HIV infection, methadone
maintenance therapy where necessary, as well as advice on their drug problems. As
far as possible a number of other facilities such as counselling, contraceptive advice
and supplies, inhaled pentamidine, dental care and refunding of bus fares were also
provided on site. Paediatric follow up was available in the community or via a
combined family HIV clinic from the same out patient department.
The majority of IDU related AIDS or HIV problems have, when necessary, been
admitted to the RIDU and were generally nursed in single rooms. There was no
written admission policy and there were no security staff. There was however a
dedicated HIV team, both medical, paramedical and nursing, but no other specialised
drug dependence staff. In general, the problems associated with drug using patients
have settled with time. Many of the early admissions allowed patients and staff to
get to know each other such that by the time the patient were seriously ill an
understanding and trust have developed. Each week there were two multi-
disciplinary meetings, one for inpatients and the other for outpatients, which were
attended by the team together with inpatient and out patient nurses. The consultant
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staff provided medical continuity of care for both in and out patients. Continuity of
nursing care was achieved wherever possible by re-admitting patients to the same
ward.
The majority of the paediatric HIV patients in Edinburgh had also been admitted to
the paediatric ward of the RIDU, initially under the care of the Infectious Disease
Consultants but latterly under the care of the Community Paediatrician who also
provided the paediatric HIV out patient care. On occasions this allowed both mother
and child to be admitted to the same unit. However, when the mother had advanced
or serious disease, she was usually too ill to care for the child. Whilst, in emergency
situations, an admission to the Unit was offered for the child, the preferred solution
was identification, via Social Services, of long term voluntary foster mothers
available at short notice.
All these changes were introduced gradually over the time period and are probably
also important in maintaining contact. Unfortunately it was more difficult to measure
their effect on either attendance and or the missed appointment (MA) rate.
The problems encountered on the wards were more to do with drug use than HIV.
The concern about HIV amongst general patients was not so much of a problem as
the unsociable and disruptive behaviour connected with drug use which caused
considerable distress to other patients as well as difficulties for the staff. The need
for specialised AIDS Units may be as much to do with this difficult behaviour as the
need to provide specialised HIV medical care. Continued non prescribed drug use
either orally or by injection cannot be eliminated whatever the level of supervision.
Not surprisingly it was less of a problem the more seriously ill was the patient but
even then total immediate withdrawal was impossible despite respiratory failure.
Unlike Drug Detoxification Units, restricted visiting and body searches were not
possible for visitors and or patients who were seriously ill.
Other major problems were verbal abuse towards other patients and staff, unsociable
behaviour at unsociable hours, theft from other patients, as well as the ward's
property and violent behaviour. This later problem was not often directed towards
the staff. Commonly there were old scores to settle between patients and
unfortunately staff have been injured in the attempts to halt the fighting.
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Results
By the end ofMarch 1990 contact had been made with 470 HIV seropositive
patients, 77% (363) ofwhom were IDU related, 13% (60) were homosexual and 8%
(37) were heterosexually related. The male to female ratio was 2:1 (312/158), the
median length of follow up at that time was 21.5 months and 25% of the patients had
been followed up for at least 36 months. Only 49 (10%) patients had attended for
only a single clinic visit whilst 274 (58%) patients had attended for at least 5 and 48
(10%) patients for at least 20 clinic visits.
One hundred and sixty nine or 47% of the drug using individuals were considered to
be definitely injecting at their initial clinic visit compared to 36 (10%) at their last
clinic visit. One hundred and twenty nine (36%) of the drug users were in receipt of
methadone prescribed from the clinic at their last clinic visit.
An additional 71 HIV seronegative but at risk individuals had also been seen during
this time, 66% (47) of whom were drug users, 4% (3) were homosexuals and 21%
(15) were heterosexuals mostly the partners of seropositive patients. The male to
female ratio for seronegative patients was 1.8:1 (46/25).
The overall mean age of the patients was 27.5 years (SD. 6.5, range 16-57) and 90%
of the patients were between 19 and 39 years of age. The mean age of the patients
was 27.7 years for the HIV seropositives compared to 26.8 years for the HIV
seronegative patients. The mean age for male HIV seropositives was 28.6 years
compared to 25.9 years for the HIV seropositive females. This difference was largely
accounted for by the fact that the mean age for the male homosexuals was 34.5 years.
The mean age for IDU related HIV seropositive patients was 26.9 years for males and
26.0 years for females.
There were 158 (25%) patients who had failed to attend for at least 1 year and 83
(15%) patients who had not attended for 1.5 years by the end of March 1990.
However a total of 79 patients were known to have reappeared after a 1 year absence
and 37 patients after a 1.5 year absence. The cumulative loss to follow up ofHIV
seropositive patients between 1985 and 1988 was 20%. Thirty four (6%) patients
were also known to have died, 20 after the diagnosis ofAIDS, 12 of drug overdoses
and 2 of unknown causes.
Of the living patients 80 (18%) patients had been classified as being in CDC stage II,
187 (43%) in CDC stage III and 142 (33%) in CDC stage IV at their last clinic visit.
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Initiating andMaintaining Contact
The total attendance for two months (May and November) of each year from 1985-89
together with the number ofmissed appointments (MA) are shown in Table 7.1. In
November 1985 HIV appointments accounted for only 3% (13/426) of the outpatient
workload but by November 1989 this had risen to 39% (246/637). The MA rate for
the HIV clinic was not constant (x2(8) =52.6, P<0.001) whereas over the 4 year
period the MA rate had remained constant for the UTI (x2(8) = 10-26) and ID (x2(8)
= 3.12) clinics. Whilst there was a significant linear trend in the reduction of the
HIV missed appointment rate (x2(l) = 21.6,P<0.001) there was also a highly
significant departure from linearity (x2(7) —31, P<0.001).
The data were examined to see if the MA rate changed significantly after the
introduction ofmethadone and an all day HIV clinic. The change in the MA rate
after November 1986 was significant (x2(l) =38.94, PO.OOl). The introduction of
methadone and the all day clinic explains the observed variation (residual variation
X2(7)=13.7, P>0.05).
Table 7.1: Actual and missed appointments (MA) for 2 months of each year,
1985-1989
UTI Clinics ID Clinics HIV Clinics
Month Total MA (%) Total MA (%) Total (MA
(%)
Nov. 85 359 52 (14) 122 16(13) 19 6(32)
May 86 306 52(17) 123 21 (17) 28 17(61)
Nov. 86 304 38 (13) 127 20(16) 77 27 (35)
May 87 283 47(17) 103 12(12) 172 31 (18)
Nov. 87 275 55 (20) 112 13 (12) 152 26(17)
May 88 321 50(16) 63 8(13) 192 42 (22)
Nov. 88 269 34(13) 153 24(16) 213 36(17)
May 89 225 33 (15) 152 21 (14) 300 45 (15)
Nov. 89 244 32(13) 205 26(13) 294 48 (16)
X2(8) 10.26 3.12 52.6
P< NS NS 0.001
UTI = Urinary Tract Infection, ID = Infectious Diseases, HIV = Human
Immunodeficiency Virus, MA = Did Not Attend, NS = Not Significant
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The data were examined in more detail for the time period November 1985 to May
1987 (Table 7.2). There was no homogeneity of the MA rate across the 19 month
time period (x^(18) = 83.96, PO.OOl). As far as the time periods November 1985-
June 1986, (no methadone), July 1986-November 1986 (methadone) and December
1986-May 1987 (methadone and an all day clinic) were concerned there were
significant differences (x^(2) = 61.26, PO.OOl) not explained by the introduction of
methadone alone (residual variation after allowing for methadone and the all day
clinic X^(16) = 83.96-61.26 = 22.7, NS at 10% level; residual variation after allowing
for methadone alone X^(17) = 83.96-52.05 = 31.91, pO.02).
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Table 7.2: Monthly HIV appointments and missed appointments (MA),
November 1985-May 1987
Month Total appointments Missed appointments
or MA(%)
Nov. 85 19 6(32)
Dec. 85 21 13 (63)
Jan. 86 27 12 (44)
Feb. 86 19 8 (42)
Mar 86 32 14(44)
Apr. 86 70 31 (44)
May 86 28 17(61)
Jun. 86 62 30 (48)
Jul. 86 51 16(31)
Aug. 86 55 16(31)
Sep. 86 57 18 (32)
Oct. 86 56 17(30)
Nov. 86 77 27 (35)
Dec. 86 78 16(21)
Jan. 87 97 22 (23)
Feb. 87 102 34 (33)
Mar. 87 172 36(21)
Apr. 87 138 30 (22)
May 87 172 31 (18)
X2(18) 582.8 83.96
P 0.001 0.001
As a consequence of the problems of trying to manage chaotic drug users in routine
clinics considerable disquiet amongst the non drug using patients developed and
therefore it was necessary to consider the effect of relatively large numbers of drug
users on the other clinics.
Table 7.3 documents the total number of appointments and the number ofMA for the
two six month periods of 1986 and the first six month period of 1987. There was a
significant decline in the total number ofUTI appointments (x2(2) = 21.3, P<0.001),
a highly significant increase in the total number ofHIV appointments (x2(2)=442,
PO.OOl) but little change in the total number of ID appointments. The MA rates
were unchanged for the UTI clinic (x2(2) =2.45) and decreased for the HIV clinic (x
2(2) = 57.7, PO.OOl) as previously noted.
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The MA rate for the ID clinic significantly increased for the second half of 1986 and
then returned to the previous level (x^(2) = 11-28, PO.Ol). This coincided with the
increased attendance of IDU related HIV patients in the general ID clinics which
occurred after the introduction of methadone prescriptions between June 1986 and
November 1986. The decline in the MA rate in the general ID clinics coincided with
the introduction of the all day clinic for HIV infected drug users in November 1986
which was held on one particular day with no additional ID or UTI clinics running
concurrently.
Table 7.3: Total appointments made and missed appointments (MA) for each 6
month period from 1986-1987
Time UTI Clinic ID Clinic HIV Clinic
Month Total MA (%) Total MA (%) Total MA (%)
1/86-6/86 2179 349 (16) 726 77(11) 238 112 (47)
7/86-
12/86
1978 322 (16) 797 124(16) 374 110(29)
1/87-6/87 1894 336(18) 725 77(11) 865 192 (22)
XZ(2) 21.3 2.45 5.12 11.28 442 57.7
P< 0.0001 NS 0.1 0.01 0.0001 0.001
Table 7.4 details the numbers of new patients referred to the UTI and ID Out Patient
Clinic between 1985-89. There appears to be a significant decline in the number of
new patients referred to the UTI clinics over the period 1985-1989 (x^(8) = 60.72,
P<0.001). The decline in the UTI new patients was non linear (x^(7) = 22.04,
PO.Ol) being accentuated after June 1988. The decline in patients referred to the
general ID clinics over the same period was only just significant (x^(8) = 17.96,
PO.05) and less remarkable in terms of clinical workload. The six monthly
acquisition of new HIV patients (Table 7.4) was not at a constant rate over the period
(X^(8) = 36.3, PO.OOl). Much of the variation was however contributed by the first
and last time periods. The number ofHIV negative but at risk patients (mainly HIV
negative drug users seeking methadone) rose significantly until June 1987 and then
ceased. This coincided with a management decision that the prescribing of oral
methadone should be restricted to HIV seropositive individuals.
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Table 7.4: Number of new patients referred to the RIDU by half year 1985-1989
Time period New Patient Category
Half year UTI ID HIV + ve HIV-ve high
risk
July-Dec. 85 108 119 21 0
Jan.-June 86 142 102 47 3
June-Dec. 86 116 130 58 16
Jan.-June 87 107 122 65 24
July-Dec. 87 105 107 40 3
Jan.-June 88 114 114 56 6
July-Dec. 88 61 96 43 6
Jan.-June 89 85 85 63 7
July-Dec. 89 56 88 33 2
X2(8) 60.72 17.96 36.3 70.6
P< 0.0001 0.05 0.001 0.0001
By the end of 1990 contact had been initiated with 511 HIV positive individuals and
68 HIV negative individuals, 75% IDU related. However 64 of the HIV positive and
3 of the HIV negative individuals had died by the end of 1990. As detailed above a
significant reduction in the ratio ofmissed appointments to total appointments
booked, had occurred between 1986 and 1989 coincident with the introduction of
methadone and an all day clinic . However between 1989 and 1990 the MA rate rose
again from 17% to 25%, but a significant increase in the number ofMA was not seen
amongst patients attending the all day clinic (x^(3) - 1.91) only amongst patients
booked for other clinics (%^(3) = 121.3, p<0.001, Table 7.5).
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Table 7.5: HIV appointments by half year during 1989 and 1990
Time All Day Clinic
Half year Actual MA(%) Total
Jan.-June 89 818 164(17) 982
July-Dec. 89 836 153(15) 989
Jan.-June 90 889 182(17) 1071
July-Dec. 90 864 186(18) 1050
Total 3407 685(17) 4092
X2(3)=1.91
Time Other Clinics
Half year Actual MA(%) Total
Jan.-June 89 556 87(14) 643
July-Dec. 89 551 166(23) 717
Jan.-June 90 562 228(29) 790
July-Dec. 90 564 345(38) 909
Total 2233 826(27) 3059
X2(3)=T21.29, p< 0.001.
There was, however, no significant change in the number of patients who missed
medical appointments between 1989 and 1990 (Table 7.6). In 1989, 263 (65%) of
436 individuals missed 537 (29%) appointments out of 1826 visits where laboratory
monitoring occurred (mean number of missed appointments = 2/patient with MA,
range 1-8). In 1990, 254 (60%) of 454 individuals missed 621 (24%) appointments
out of 2556 visits where laboratory monitoring occurred (mean number ofMA =
2.4/patient with MA, range 1-12). There were in addition 19 new patients in 1989
and 14 new patients in 1990 who were referred to the clinic but never attended.
There was no male/female difference in the population with missed appointments
(data not shown). Only 68 of the patients who missed appointments in 1989 (26% of
those patients with missed appointments or 15.5% of the total patients attending in
1989) accounted for 50% of the total number ofmissed appointments. Looked at
another way, 39.5% missed no appointments and 45% missed only one or two
appointments per year and only 34/436 (8%) of the patients failed to receive any
laboratory monitoring during 1989 at the City Hospital (Table 7.6). During 1990, 88
of the defaulting patients (34.5% of those patients with missed appointments or 19%
of the total patients attending in 1990) accounted for 62% of the missed
appointments. Again 44% missed no appointments, 36% missed only one or two
appointments in the year and only 25/454 (5.5%) of the patients failed to receive any
laboratory monitoring during 1990 at the City Hospital.
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An analysis of patients who missed appointments in both 1989 and 1990 is shown in
Table 7.8. This analysis does not include a number of patients; any new patients who
first attended in 1990, those that attended in 1989 but had no visits or requests for
appointments in 1990, those dying in 1989. Essentially 45% of the patients who
missed appointments were consistent in their behaviour, 29% improved their
attendance behaviour and 26% worsened over the two years. Ofpatients who
attended in both years only 2.5% with 3 or more missed appointments in a year had
no missed appointments in the other year and only 2% accounted for 3 or more
missed appointments in both years. In addition, 58% of these patients in 1989 and
64% in 1990 missed appointments in the other year.
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Table 7.8: Cross tabulation of the number of patients attending during 1989 and
1990 categorised by the number of missed appointments during 1989-90
1990
0 1-2 >3 Total (%)
1989
0 69 44 21 134 (36)
1-2 77 66 33 176 (47)












The number of individuals lost to follow up during 1986-90 varied between 8-11%
per year and did not change significantly over time (Table 7.9, x^(4)=l -21). The
cumulative lost to follow up rate between 1986-90 was 124/582 or 21%. This figure
includes the lost to follow up patients who died after missing appointments at the
clinic. Amongst the HIV negative individuals the overall lost to follow up rate was
worse at 51/68 or 75% whilst for the HIV infected individuals the overall loss to
follow up was actually 73/511 or only 14%. A total of 64 HIV infected patients had
died by the end of 1990, a rate of 64/511 or 12.5%. Amongst the HIV negative
individuals the rate was 3/68 or 4.4%. The deaths in the HIV negative patients were
in fact all drug users and a comparison of death rates amongst drug users revealed
38/385 deaths or 10% in HIV infected drug users and 3/50 deaths or 6% in
uninfected drug users.
The number of lost to follow up are those patients not seen by 31/12/91 and not
notified as having died by the Registrar General Scotland. By the end of 1990
232/511 (45%) patients had commenced treatment with zidovudine and of these 166
(72%) had acquired HIV by IDU.
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Table 7.9: Annual number of patients lost to follow up by year
Year Number patients lost(%) Total patients seen in year
1986 10( 7) 143
1987 28(11) 258
1988 30( 9) 330




The self reported injecting behaviour of drug users attending the clinics each year is
documented in Tables 7.10, figures 7.1 and 7.2. Amongst HIV infected patients the
percentage reporting injecting at more than 50% of the visits during a year fell from
42% in 1986 to 6.5% in 1990 (x2(4) = 93.75, p<0.001) and those reporting injecting
at one visit during a year fell from 51% in 1986 to 23% in 1990 (x2(4) ~ 60.9,
p<0.001). Amongst the uninfected drug users the percentage reporting injecting at
more than 50% of the visits during a year fell from 73% in 1986 to 35% in 1990 (x
2(4) = 7.6) and those reporting injecting at one visit during a year fell from 72% in
1986 to 50% in 1990 (x2(4) = 12.99, p<0.05).
Table 7.10: Drug users attending the City Hospital assessed as injecting more
than 50% of the visits during the year or at least once during the year









1986 47/111(42) 8/11(73) 58/114(51) 10/13(77)
1987 51/159(32) 13/27(48) 94/174(54) 21/29(72)
1988 50/228(22) 7/21(33) 96/235(41) 5/18(28)
1989 40/286(14) 3/13(23) 94/289(33) 6/15(40)
1990 20/307 (7) 6/17(35) 67/295(23) 8/16(50)
X2(4)= 93.75 7.6 60.9 12.99
P <0.0001 =0.1 <0.001 <0.05
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The self reported use of opiates is documented in Tables 7.11. Amongst HIV
infected patients the percentage reporting opiate use for more than 50% of the visits
during a year rose from 54% in 1986 to a peak of 70% in 1989 (x^(4) = 10.22,
p<0.05) and those reporting opiate use at least once during the year rose from 57% in
1986 to a peak of 75% in 1989 (x^(4) = 14.3, p=0.006). Amongst the uninfected
drug users the percentage reporting using opiates for more than 50% of the visits
during a year rose from 50% in 1986 to a peak of 100% in 1990 (x^(4) = 9.63,
p=0.054) and those reporting opiate use at least once per year rose from 50% in 1986
to a peak of 100% in 1989 (x^(4) = 9.6, p=0.05).
Table 7.11: Drug users attending the City Hospital assessed as using opiates
more than 50% of the visits during the year and at least once during the year









1986 51/95 (54) 3/6 (50) 55/97 (57) 3/6 (50)
1987 95/144(66) 16/18(89) 101/150(67) 17/19(89)
1988 110/184(60) 5/9 (56) 116/188(62) 5/9(56)
1989 164/233(70) 9/9(100) 178/238(75) 9/9(100)
1990 153/237(65) 7/9 (78) 167/240(70) 7/9(78)
XZ(4)= 10.22 9.3 14.3 9.6
P <0.05 =0.054 =0.006 =0.05
Discussion
Traditionally health care for drug users has been based on psychiatric models
developed for the management of addiction and has not concentrated on the physical
aspects of care. Models for the treatment of drug addiction have utilised a variety of
different regimens including contracts, therapeutic communities, substitution therapy
etc. Whilst such regimens have been evaluated for the treatment of addiction this has
not been the case for the management of IDU related HIV. In addition, unrealistic
behaviour change is sometimes expected of drug users such as cure of addiction,
before offering treatment modalities like zidovudine. Similar constraints on the
behaviour of other risk groups are not however imposed before offering medical care.
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The aim of any IDU service should be to initiate and maintain contact in order to
deliver health care and health education. This initiation and maintenance of contact
may require a variety of initiatives such as needle exchange, methadone, social
provisions as well as medical care which may have to be delivered in ways that fit in
with the injection drug users life style.
Problems ofhealth care for drug users
The difficulties of engaging drug users however should not be underestimated. IDU
has a number of characteristics which provide problems for any health service. For
instance it is an illegal, often violent and expensive activity. It may be funded by
theft, cheque book or credit card fraud, drug dealing on a minor or major basis or via
prostitution. Depending upon the geographical location in general around 2/3 of
drug users are male and 1/3 are female. Up to 70% of drug users in Edinburgh may
have a criminal record and or be "working the system" i.e. committing DSS fraud.
They have a manipulative tendency in their dealings with individuals and society.
The particular problems that make engaging drug users difficult for a health service
are a crisis type of life style with little planning other than for the next supply of
drugs. Since on average heroin drug users require 3-4 doses per day their horizons
may be limited to at the most 24 hours. They are not health conscious as
demonstrated by their overwhelming addiction and injection drug use which is
demonstrably a dangerous life choice. Lastly they have a tendency for a highMA
rate in terms of the health care system probably because the priorities of addiction
come before all else.
The consequences of IDU related HIV are also important to bear in mind because
they interact with the health care system. As illness occurs the patients suffer a
falling income because they are less physically fit, mentally slower and consequently
are more likely to be apprehended in criminal activities. This produces what could
be described as "criminal unemployment" which results in difficulties of funding a
habit. Consequently as HIV progresses there may be a need to become "legal" as
regards the DSS in order to obtain some revenue. There may also be considerable
pressure to prescribe drugs from the NHS. There is certainly a continual pressure to
find other sources of income and this may result in further difficulties for the health
service such as drug dealing in hospitals, requests for help in making fraudulent DSS
claims or even just for inappropriate hospitalisation because this saves money which
would be spent on food, heating etc.
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IDU related HIV is accompanied by physical weakness and mental slowing which
may result in the patient being victimised and or exploited possibly because of their
previous position in the drug culture. This can result in an inability to cope out of
hospital but difficulty in accepting a hospital regime. This unwillingness or inability
to adapt to changed circumstances results in revolving door type admissions to
hospital with considerable frustration for patient, relatives and staff.
In managing HIV patients it may also be necessary to manage the problems of a
patients' visitors. There may be unexplained absences from wards by patients,
frequent self discharges and perhaps most importantly for the ward routine the
problem of day/night reversal as a result of drug use. In addition the ward and areas
dealing with drug users are faced with the problems of theft, frequent noise
disturbance, victimisation of patients, manipulation of staff or other patients and
attention seeking behaviour, aggression or assaults both verbal and or physical on
staff and other patients. Other problems noted are those of self medication and drug
dealing in the wards by both patients and visitors. Staff are naturally alarmed by the
problems of patients carrying offensive weapons such as knives and even on rare
occasions guns. This is however usually because of fear of peers rather than staff. It
is often not appreciated that the patients are more frightened of each other rather than
the staff. Many sworn enemies such as rival drug dealers may be bought together by
HIV and the need to visit the hospital. The staff of course may be entirely unaware
of these ongoing difficulties.
Edinburgh model ofcare for HIV infected drug users
The initiation and maintenance of contact in Edinburgh has relied on the use of
combined medical and drug clinics which are able to deliver both drug services,
physical health care and psycho-social services at the same site. The drug services
developed at the RIDU in Edinburgh are generally based on the principles of harm
reduction. This has meant providing injecting equipment (needles etc.) when
requested but mostly it has meant providing an oral non injectable substitute i.e.
methadone.
The health care delivered has consisted of routine medical care for HIV and drug
problems, prison medical care, dental service, colposcopy, contraception and other
services. The psycho-social services consist of counselling and support for infected
and affected individuals, welfare rights, social services, child care etc. and other
services.
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A review of the systems developed in Edinburgh and at the Montefiore Medical
Centre in the Bronx of substitute drug prescribing and HIV services delivered from
the same site by the same doctors (Chapter 6) suggested that this was the most
effective model of care for injecting drug users . It would appear that a particular
skill mix is required of psycho-social and physical care which is accentuated for HIV
infected drug users. The San Francisco and Amsterdam experiences ofproviding
services at two distinct physical sites seemed to provide either a poor medical and or
a poor HIV service for drug users - possibly by not achieving the best skill mix .
Whilst combined clinics appeared to be the most efficient service they had not been
systematically evaluated. This current analysis of the Edinburgh service supports the
contention that combined medical and drug services are able to deliver care to drug
users.
In Edinburgh, the initial lack of specialised medical services for drug users required
the development of a service which provides not only inpatient and outpatient
continuity of care but also delivered both drug and HIV services at the same site. In
June of 1986 evidence suggesting that accelerated loss of CD4 cells was associated
with continued IDU was presented at the 2nd International Conference on AIDS in
Paris^. It had also become obvious that it was necessary to provide a drug service
before being able to provide health care for HIV. The provision of oral methadone
from the HIV clinics after June 1986 improved not only the numbers attending but
also the MA rate achieving the aims of initiating and maintaining contact with IDU
related HIV.
As a consequence of the disruption to the general ID clinics and the continuing high
MA rates for the HIV patients it became necessary to offer IDU related HIV medical
care on separate days from the ID clinics. The use of a specific IDU related HIV
clinic which lasted for the whole day, was not only associated with improved total
attendance but also a reduction in the MA rate. From an analysis of the MA rates it
appears that the organisational changes made in the HIV clinic are as important if not
more important than the introduction of methadone in explaining the heterogeneity of
the MA rate. Thus the MA rate amongst injection drug users has been steadily
reduced by a number ofmeasures including the use of a dedicated all day clinic, on
site prescribing of substitute methadone for opiate addiction and a multi-disciplinary
approach to care.
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As a consequence of the almost total lack of drug services in Edinburgh there was a
rise in the number of uninfected injection drug users seeking treatment at the City
Hospital. In June 1987 the response of the management to this problem was to
restrict the drug prescribing service to only known HIV seropositives rather than to
increase the available resources. This not surprisingly created a two tier system such
that it was easier to obtain prescribed oral drugs if infected and resulted in critical
comments from the ACMD^.
"In practice this has led to the absurd position whereby treatment involving
substitute prescribing is mostly available only to those already infected with
HIV. Its use to prevent a seronegative drug misuser from engaging in HIV risk
behaviour and acquiring the virus is virtually non- existent".
The illogical and damaging situation for the spread ofHIV via TDU was rectified
eventually with the creation of the Community Drug Problem Service in April of
198810.
Evaluation ofthe Aim ofInitiating andMaintaining Contact
Despite the difficulties, the measures adopted have enabled us to initiate and
maintain contact with large numbers ofHIV positive patients, 77% IDU related and
at least half injecting at their first visit. This is surprising in view of what is known
of drug users and the health care system. The reasons for the loss to follow up are
not totally known but seem to include unforeseen prison sentences, dislike of the
methadone being prescribed, a dislike of being associated with an HIV clinic for fear
of losing confidentiality, and a dislike of currently chaotic drug users.
The subsequent rise in the number ofmissed appointments between 1989 and 1990
was of some concern but on further analysis was only significant in those patients not
utilising the all day clinic. This rise may have occurred because more clinics are now
available and are being utilised by the most chaotic patients or because of increasing
ill health of the cohort associated with more difficulties in attending hospital.
Despite the fact that non attendance occurred in 24% of booked appointments in
1990, laboratory monitoring ofHIV was still achieved in 95% of the patients who
missed appointments. In fact an analysis of the MA pattern for 1989 and 1990
revealed that a relatively small number of the total patients (15-19%) accounted for
between 50-60%% of the missed appointments. In addition, around 60% of these
patients missed appointments in both years but only 2% of such patients consistently
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miss 3 or more appointments per year. This supports the idea that a particular sub
group of patients account for most of the problem ofmissed appointments. In both
years an average of 41% of the patients attending missed only 1-2 appointments per
year which seems acceptable and 45% of the patients were consistent in their
behaviour from year to year. Thus a relatively inefficient system from the health
service point of view does achieve laboratory monitoring ofHIV in even the most
difficult drug users.
The annual lost to follow up rate for individuals of around 8-11% seems very
acceptable and has remained constant since the clinic opened. The long term follow
up on these patients and the loss to follow up rate is now not significantly different
from the non HIV clinics. The phenomena of re-attendance even after a number of
years explains the lower than expected cumulative lost to follow up rate of 14%. Not
surprisingly it is lower than the 81% lost to follow up rate in HIV negative patients
since the clinic system is very much geared towards HIV infected individuals. The
lost to follow up rate amongst HIV negative patients also of course reflects the
establishment of an alternative substitute prescribing clinic (the CDPS) in Edinburgh.
It does however suggest that clinics offering medical care for drug users can achieve
reasonable follow up provided they are adapted to the patient's needs. The flagging
of defaulters with the Registrar General has allowed us to be very confident that the
lost to follow up rate is accurate and is not obscured by covert deaths.
The effect ofHIVClinics on other medical services
The establishment of an IDU related HIV medical service however appeared to have
an effect on existing medical clinics. The success ofmethadone prescribing resulted
in an influx of chaotic drug users into the general ID clinics. Until the establishment
of a specific IDU related HIV clinic day there was an increase in the MA rate of
general ID patients presumably as a consequence of the disruption at these clinics
since no change was noted in the MA rate for the UTI clinic which is held on a
separate day. The establishment of a specific all day IDU related HIV clinic
appeared to reverse this trend by removing chaotic drug users from the ID clinics.
Over a 4 year period a gradual decline in the number of new patients referred by
general practitioners for both the ID and UTI clinics was noted suggesting a possible
reluctance by doctors to refer to, or patients to attend, the Unit. This was particularly
notable from the second half of 1988 and might be as a consequence of the City
Hospital, and the RIDU in particular, being identified with AIDS. It was also more
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notable for the UTI patients and one might expect such patients to be accommodated
more easily in other medical/surgical units. The new patient referral rate for general
ID clinics seemed to have been affected less and this was perhaps because these
services were not duplicated elsewhere in the region. Thus the establishment of an
IDU related HIV service appears to have an effect on other patient services and in
order to avoid either separate facilities or separation of clinics, much more in the way
of education for the general public is required.
Risk Behaviour
An assessment of risk activity based on self reported behaviour suggested that IDU
declined between 1986-90 and that this decline was more common in HIV positive
than HIV negative drug users. The decline in IDU can only be attributed in part to
the medical clinics since there has also been general campaign in Edinburgh to
reduce IDU. During the same time period the use of oral opiates increased
suggesting a change of route of administration rather than abstinence.
Conclusion
Whilst there are considerable problems for a health care service in engaging drug
users it is possible. In three areas an IDU related HIV medical service delivering
substitute drugs and HIV medical services at the same site has been demonstrated to
be effective: the ability to initiate contact, the ability to maintain that contact and the
ability to help modify high risk IDU. Other proposed systems which separate
addiction from HIV medical care should also evaluate their results in order that
medical care for HIV infected drug users can be based on facts rather than dogmas.
A medical care system which is experienced in the care of both HIV and injection
drug use is able to deliver health care to injection drug users. The system used at the
Montefiore Medical Centre in the Bronx and in Edinburgh of drug prescribing and
HIV services delivered from the same site by the same doctors seems to provide the
best model of care for injecting drug users. The San Francisco and Amsterdam
experience of providing these services at two distinct physical sites reveals this to be
an inefficient system providing either a poor medical and or a poor HIV service for
drug users. Thus HIV and drug dependency specialists need to exchange and acquire
each others skills as well as utilising the primary care services.
It is possible to adapt an existing health care system to be more "user friendly" for the
lifestyle of injection drug users fulfilling the important aims of initiating and
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maintaining contact with health care services although there may be effects on the
established service in terms ofMA rate for existing patients and the referral of new
patients.
Dedicated clinics offering both drug management and medical care are able to initiate
and maintain contact with drug users as well as reduce their high risk IDU behaviour.
Although there was a large number ofmissed appointments, the majority of these
were in fact related to less than 10% of the patient population. Whilst such a system
is inefficient from the health services point of view, it may be necessary in order to
maintain contact with the most difficult drug users.
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Harm Reduction for IDU Related HIV
Introduction
Drug use related HIV is a continuing problem not only for important areas of the
developed world such as the USA and Europe but also for the developing world such
as South East Asia and South America. It is a crucial issue because Drug Use related
HIV in some areas of the world is the fastest growing risk group and in addition it is
associated with a substantial amount of vertical and heterosexual spread ofHIV. A
number of studies in the USA and the United Kingdom have shown that between 60-
100% of heterosexually acquired HIV is related to IDU and at least 40% of injection
drug users are in relationships with non users ^"4. Approximately one third of
injection drug users are female and vertical spread to new-born children occurs^.
Consequently the reduction and control ofDrug Use related HIV can have a
substantial impact not only on transmission amongst drug users but also on the
heterosexual and vertical spread ofHIV.
The major public policy issues concerning the prevention of Drug Use related HIV
are,
• persuading society and governments that Drug Use is a key element in
the spread ofHIV,
• that AIDS is a greater threat than Drug Use itself,
• that harm reduction as a strategy in preventing the acquisition ofHIV is
compatible with the aim of primary Drug Use prevention and
• that there is no one single measure, such as methadone, needles or
bleach, that makes up a harm reduction strategy i.e. harm reduction must
be multi faceted.
The importance of drug use in the spread ofHIV was underlined by the Presidential
Commission on HIV in the USA which recognised that "the future course ofthe HIV
epidemic depends greatly on the effectiveness ofour nations ability to address IV
drug use"7. In the UK the Advisory Council on the Misuse of Drugs (ACDM) in its
report on AIDS and Drug Misuse warned that "The spread ofHIV is a greater
danger to individual andpublic health than drug misuse. Accordingly, we believe
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that services which aim to minimise HIV risk behaviour by all available means
should take precedence in development plans. "8. Thus it is important to develop
drug therapies and care systems that address the problems of IDU related HIV and to
reconsider the approach to drug use in the light ofHIV. This new position was
recently summarised by John Strang and Gerry Stimson "We are at apoint of
change - apoint ofcrisis between old ways ofviewing drugproblems and new ones
forced on us by HIV'
Before the advent ofHIV infection, drug use itself had a relatively low mortality with
alternating periods of abstinence and drug use together with natural recovery 10-13
In New York however there was a rapid increase in both AIDS and non AIDS
narcotic related deaths such that by 1986, for every AIDS related death in a drug
user, there was one other as a consequence of such conditions as tuberculosis,
endocarditis and bacterial pneumonia^. Similar data have been reported from
Europe 15,16 Jh;s increase in mortality for drug users is the driving force behind
harm reduction and the reason society can no longer rely on spontaneous recovery for
drug users.
Harm reduction has recently been described thus "the harm minimisation approach
echoes the safer-sex campaigns...people will not want to abstain from sexual activity,
therefore they must be encouraged to engage in safer sex. The idea has now been
extended to drug injectors - ifthey won't stop injecting, they should and could inject
drugs in a safer way^. There are legitimate but unproved concerns however that
harm reduction for IDU related HIV will help to initiate new drug users. Similar
concerns are voiced over increasing the availability of injecting drug equipment or
teaching safer injecting techniques.
Perhaps one reason for this concern is the difficulty of demonstrating that harm
reduction is an effective method of preventing the spread ofHIV amongst drug users.
However the intense debate over injection equipment availability, especially in the
USA, has interesting parallels with the debate that surrounded Methadone
Maintenance Treatment Programmes (MMTP) in the management of drug
dependency. In 1957 the Council on Mental Health of the American Medical
Association concluded that "The advisability ofestablishing clinics... to dispense
opiates to addicts cannot be settled on the basis ofobjective facts'This debate
was in fact primarily centred on the health of society rather than around an
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individuals physical health and is still continuing^. Can society wait however, for
the arrival of definitive proof where HIV is concerned?
Previous reviews of harm reduction have tended to concentrate on only one modality
such as methadone or injection equipment availability20,21. By comparison this
review seeks not to examine the evidence for and against harm reduction with regard
to the treatment of drug dependency, but whether harm reduction can have a
substantial impact on the spread ofHIV. It is necessarily biased because the author is
an Infectious Disease physician concerned with the problem ofHIV and AIDS rather
than a specialist in drug dependency.
The History of Harm Reduction
Maintenance Methadone Treatment Programmes
The use ofmethadone, a long acting opiate, allowed the development of maintenance
programmes for drug users based on daily administration because they were no
longer reliant on the self administration of short acting opiates. MMTP for drug use
have been evaluated over a number of years but the these studies have concentrated
upon retention rates, frequency and prevention of illicit drug use, reduction of
criminal behaviour, the return to normal social activities and/or the possibility of
curing drug usel°, 19,22-26 MMTP were very much seen as harm reduction for
society usually in terms of the reduction of crime or reintegration into society. Harm
reduction for the individual was seen in terms of psycho social issues such as
emotional stabilisation, work record and retention in the programme.
Whilst some improvement in physical health was assumed it is rarely mentioned in
reports other than in respect of the safety ofmethadone maintenance18,19,22- 26
For instance the medical side effects ofmethadone such as constipation or the death
rate were published but no other measures of improved physical health^. In
addition the initial criteria for selection into MMTP concentrated on defining
addiction and specifically excluded patients with serious medical problems although
eventually separate programmes for patients with tuberculosis were
established 19,22,26 Lack of venous access or health problems related to
injection drug use were not considered as entry criteria.
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Amsterdam
The concept of harm reduction for a drug users physical health grew out of
Amsterdam's Municipal Health Service Drug Department's (GG&GD) approach to
the drug problem. Amsterdam's approach to IDU recognises the fact that it is a
relapsing disease and that harm reduction means providing medical and social care
whilst waiting for natural recovery from IDU in order to avoid some of the more
harmful consequences of injecting drug use27,28
Amsterdam's programme of drug treatment has been described in Chapter 6. Needle
exchanges in Amsterdam began in 1984 after the Junky Union agitated for and then
initiated the first needle exchange^,28 There were initially 10 centres for
distributing needles and included the Methadone Bus, Methadone Out-Patient Clinics
and the Junky Union although this latter site has now been discontinued. There was
no enrolment or clinical examination but this was eventually tightened up in order to
evaluate the return rate of equipment.
Amsterdam takes a pragmatic and non-moralistic attitude towards drugs and this has
resulted in a pleuriform system which now offers harm reduction and/or drug free
treatment. The prime goal was to make contact, to provide information on a personal
level and to try and produce attitudinal and behavioural change by the use of
condoms, drug free treatment programmes with short waiting lists, methadone and
needle exchange systems.
The link between IDU relatedHIVand equipment availability
Whilst there is as yet no direct evidence on the effectiveness of increased injecting
equipment availability in stemming the tide of IDU related HIV there is evidence of
what happens when the supply is very limited. Edinburgh has perhaps one of the
best documented examples of a temporal relationship between a policy of restricting
injecting equipment during an epidemic of drug use and a subsequent epidemic of
hepatitis B and HIV which started around 1980 and peaked in 1983-8429-31
Further evidence for this IDU epidemic and the associated sharing of injecting
equipment is provided by the concurrent epidemic of injection related medical
conditions including Hepatitis B between 1980-8532. This epidemic of IDU related
medical conditions was associated with a poor supply of injecting equipment and
high levels of sharing (Chapter 4)33-35
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Glasgow had a smaller IDU related HIV problem despite a larger number of drug
users than Edinburgh and comparisons of self reported habits between Edinburgh and
Glasgow or Edinburgh and London reveal considerably more sharing of needles and
syringes in Edinburgh5>30,36,37 The absence of an epidemic cannot necessarily be
used as proof of effectiveness but it is interesting to note that many conurbations in
England and Wales with larger drug populations than Edinburgh did not have an HIV
epidemic. In the main these areas did not restrict equipment availability and some
areas such as Liverpool had a well developed strategy for dealing with drug users
which was able to adapt rapidly to the problem ofHIV^S. In 1986 as a consequence
of the AIDS epidemic the restriction on the sale of needles and syringes imposed by
the pharmacists' professional association was withdrawn^,34 The ACMD in its
report on AIDS and Drug Misuse in 1988 noted that "The opportunity to take
preventative action must be seized now if the tragedy ofEdinburgh is not to be
repeated throughout the UK"%.
Similar restrictions on equipment availability existed in other countries such as
Australia and New Zealand until 1987 and 1988^0,39 They remain in force in many
parts of the USA where the connection with blood borne virus epidemics amongst
drug users has not been so well documented™.
A significant link between needle sharing and the risk of acquisition ofHIV has been
established*^ 1,36,40-46 More recently HIV has been cultured from needles and
syringes collected from a shooting gallery in Miami, Florida confirming the infection
risk47. Less well recognised is the importance of the type of drug used. Links
between HIV infection and the use of intravenous cocaine or amphetamines has been
reported 48-56 [)rug users often inject cocaine intravenously mixed with heroin and
do so far more frequently than when they inject heroin alone^. Additionally the
sharing of equipment is more often associated with cocaine use and the difficulty in
obtaining such equipment57-60
Is Harm Reduction effective?
Whilst there is strong and compelling evidence linking the spread ofHIV amongst
drug users with the use of contaminated equipment, is there any evidence suggesting
that harm reduction measures are effective in preventing the spread of IDU related
HIV or even in changing high risk drug use behaviour?
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Methadone
There are now data which support the effectiveness of oral opiate substitute
programmes in reducing high risk injecting behaviour as well as reducing the risk of
acquisition ofHIV or AIDS.
Modification ofInjecting Behaviour
In a 3 year study ofMMTP in New York, Philadelphia and Baltimore 715 clients
who remained in MMTP for more than 1 year gave up injection drug use^l. By
comparison, 82% of those who left the programme continued to inject drugs.
Additionally, only 10% of clients in MMTP shared equipment during the study
period compared to 27% amongst dropouts. This latter figure increased to 48% once
individuals had been out of treatment for longer than 1 year. In the Treatment
Outcome Prospective Study organised by the National Institute on Drug Abuse
(NIDA) 4184 clients from 12 MMTP, 2891 clients from 14 residential programmes
and 2914 clients from 11 outpatient drug free programmes were interviewed at
admission between 1979 and 1981. One year follow up interviews were reported on
1310 clients from 1979 and 2300 clients from 1980^2. Whilst none of the treatment
approaches had much effect on cocaine use, continuous long term maintenance
methadone was the most effective method of reducing the risk of heroin use, 74%
effective compared to 68% for residential treatment of greater than 3 months but only
56% for outpatient drug free treatment. These differences were statistically
significant at p<0.001 level. The author's conclusion was that the decline in regular
drug use after treatment, particularly for longer treatment stays, indicates that drug
abuse treatment can be effective in reducing major risk behaviour for HIV.
Another New York study looked at clients on the waiting list for MMTp63. These
clients were randomly divided into 2 groups to receive counselling, methadone and
biweekly urine toxicology or, counselling and biweekly urine toxicology only until
they were admitted to the regular MMTP. Initial needle use was identical for each
group at 95 injections per month, but at entry into MMTP only 33% of those on
methadone were injecting compared to 82% of those in the counselling group. In
San Francisco self reported needle sharing amongst 7660 drug users admitted to 28
day out patient methadone detoxification clinics decreased from 50% in 1986 to 28%
in 1988 (p<0.001)60. A study of 42 HIV positive individuals in a San Francisco
MMTP assessed via self reporting as well as urine tests and clinical examination
found that heroin use decreased significantly during the first 3 months and that the
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early gains were generally maintained 12 months after entry (p<0.0001)64. a Seattle
study noted that individuals in a MMTP for longer than six months shared less than
those in treatment for less than six months and a study ofNew York and New Jersey
drug users in MMTP noted that older users with more years in treatment were more
likely to have changed their needle cleaning habits60,65 ]n \\/est Germany the
majority of 30 HIV positive drug users in a MMTP stopped IDU whilst in Vienna of
180 drug users in MMTP more than one third of poly-drug users and more than one
quarter ofHIV positive drug users were consuming only methadone after an average
of 11.2 months of treatment^,67
Effect on HIV acquisition
A survey of 28 MMTP clinics in New York city revealed that HIV seropositivity in
established clients was 27.2% compared to 45.9% in new clients^. in 68 long term
MMTP patients in New York with a mean length of treatment of 16.9 years but 10.3
years of IDU before enrolment none had HIV antibodies^. in San Francisco there
was a significant difference between HIV serostatus for individuals in MMTP for
more or less than 60 months (8% versus 14%, p<0.001) although this difference was
only for White and Hispanic drug users^O. There was no difference however for
black drug users and this is a matter of concern. It further underlines the fact that
behavioural characteristics of drug users vary with race and geographical location
and must be taken into account in harm reduction^ 1.
In Swedish MMTP, the HIV seroprevalance was only 3% for those admitted in 1983,
16% for those admitted in 1984-1986, and 57% for those admitted in 1988,
suggesting a highly protective effect for the acquisition ofHIV related to MMTP22.
In Geneva the HIV seroprevalence for those admitted to MMTP before 1980 was
only 12% compared to 47% between 1980 and 1986 (p=0.02)23. jn addition the HIV
seroprevalence of drug users admitted to MMTP between 1987-89 had fallen to 22%
and this was coincident with a dramatic fall in needle sharing behaviour which fell
from 90% to 5% for HIV seropositives and from 80% to 29% for seronegative
individuals. During this time period only one out of 155 seronegative patients
seroconverted to HIV suggesting that MMTP is able to modify high risk IDU related
behaviour^. Similar results were obtained from another methadone programme
which was able to demonstrate prospectively a reduction in high risk behaviour and a
correspondingly low HIV seroconversion rate for HIV24. HIV serostatus was
recently evaluated for low threshold MMTP in Amsterdam, which enables contact to
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be made but has little in the way of counselling, and showed that long term clients
did not have a lower seroprevalence for HIV75.
Effect on Progression to AIDS and Immune activation
There is a suggestion that continued IDU may accelerate progression ofHIV to
AIDS; one study reported a relationship between the frequency of IDU and the loss
of T4 lymphocytes whilst another study noted a similar increased rate of decline of
T4 lymphocytes amongst a group of injectors compared to a group of non
injectors^,77 There was also a lower probability of disease progression amongst
methadone users or ex users compared to those that continued IDU reported from
Switzerland. In that study progression to AIDS after 3 years was 24% in the
methadone group, 19% in the ex users but 41% in the persistent IDU group (p<0.05).
Multivariate analysis showed a relative risk of 1.76 for persistent users78. However
other groups have not found an increased risk for continued IDU^9-81 The
incidence ofAIDS in the Bronx was reported to be lower (11.4 v 33 per hundred
patient years) for entrance to the Montefiore MMTP before and after 1983^2.
Similarly the proportion of drug users attending MMTP in Italy was inversely related
to the cumulative incidence ofAIDS. The highest AIDS incidence rates were seen in
the regions with the lowest proportions of injection drug users attending MMTP.
Nearly 40% of the variability ofAIDS incidence was explainable by attendance in
MMTP83. The reasons why continued drug use might predispose to accelerated
immune decline are unknown but one suggestion is that the drift in molecular
composition demonstrated in different HIV isolates could result in an individual
acquiring more infection with differing strains ofHIV which might hasten disease
progression®^.
Another possible explanation would be that IDU itselfmight significantly affect the
immune system, for instance frequent IDU is associated with depressed lymphocyte
function irrespective ofHIV serostatus^2,143 jqu has been associated with higher
levels of (3-2-microglobulin and activated T cells and IDU related HIV is associated
with more immune stimulation^5-88 HIV serostatus may not be known for most
patients and therefore measures, such as the cessation of injection drug use if
necessary via MMTP, that are thought to reduce progression to AIDS should be
applied to all drug users.
By August, 1987, 241 patients had been examined at the HIV clinics at the City
Hospital, 196 ofwhom were seropositive. Eighty-eight per cent or 172 of these were
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injection drug users and 55 per cent or 95 were current users at the initial evaluation.
A total of 107 HIV antibody seropositive patients with a history of intravenous drug
misuse had attended two or more follow-up appointments by the time of the
evaluation. The 107 injection drug users attending the RIDU were classified as
follows:
Group 1: Those thought to be persistently using illicit injection drugs and who were
not prescribed methadone.
Group 2: Those considered to have ceased illicit drug use and to have been
prescribed methadone.
Group 3: Those considered to be utilising both oral methadone and illicit injection
drugs.
Group 4: Those who were observed not to be using illicit drugs by injection and not
in receipt ofmethadone either from ourselves or from general practitioners.
Significantly, more patients on methadone were noted to register a net gain in weight
during the follow-up period. Overall, all methadone users were found to have a mean
net weight increase of 2.5 kg. versus 0.2 kg. (p = 0.02) for those patients who
received no methadone. There was no significant difference in the follow-up period
for these patients (8.1 months versus 7.6 months). When the patients were divided
into groups according to their drug use, a significant increase in weight of 3.7 kg.
was noted for Group 2 or methadone only users on two sample analysis (Table 8.1).
Over the short follow up period there was no significant difference in the initial and
final T4 counts, IgG, IgA, IgM levels between the groups.
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Table 8.1: IDU related HIV and the use of methadone









1 (IDU) 19 6.5 (1 - 14) - 0.4 (- 9.3 to
8.0)
= 0.005





12 8.1 (2-20) - 1.2 (-5.8 to
3.4)
= 0.002
4 (Nil) 38 8.1 (2-19) + 0.6 (- 10.5 to
21.5)
= 0.01
Footnote; IDU = continued injection drug use, Methadone = use oforal drugs
including Methadone, Methadone + IDU = use oforal drugs including Methadone
as well as continued injection drug use, Nil = use oforal drugs from general
practitioners but not Methadone or abstinence from drugs, NA = Not applicable
The physical improvement in those patients giving up injection drug use was
impressive but the improvement was difficult to measure and weight gain provided
one objective measure of improvement in general health. The weight gain
associated with methadone use was almost certainly associated with the cessation of
IDU and has been historically reported to us in those patients giving up IDU by other
means. A general improvement in health is important in those infected with HIV and
the regular attendance of those on oral methadone makes them available for other
health education messages.
Although methadone mixture DTF is not the only oral substitute therapy available it
does have a number of advantages. In modest doses of 40-60 ml, it prevents
withdrawal symptoms but does not provide significant euphoria. It is thus suitable
for those not willing to suffer withdrawal symptoms. Whilst the drug may enter the
'Black Market', its dilution and constituents discourage its use by injection. This is in
contra- distinction to opiates in tablet form for which there is a ready 'Black Market'
because of the ease with which tablets may be dissolved and then injected.
Injecting equipment
The most controversial harm reduction measure especially in the USA and certain
parts of Europe is the availability of clean injecting equipment.
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Modification ofInjecting Behaviour
It appears that drug users change their high risk injecting behaviour if given both
information and equipment. In Amsterdam this behaviour change was more effective
and more likely to occur in the context of individual counselling than in the context
ofmass campaigns^9. Specifically over time there was a reduction in risk behaviour
amongst those enrolled in a cohort study but no reduction over the same time period
in the risk behaviour of the new entrants to the cohort. Others have shown that
information and counselling alone can produce risk reduction but equipment alone
seems not to be enough since in New Orleans and Portland, Oregon, areas where
needles are not controlled by prescriptions, needle sharing still occurred90>91,92
Similarly the widespread availability in Italy of sterile injecting equipment and water
which was introduced as a preventative strategy to combat the heroin and hepatitis B
epidemic in the mid 1970's failed to prevent not only hepatitis B but also the spread
ofHIV93.
Behaviour change has however been shown to occur more often amongst those
attending needle exchanges than amongst non-attendees. In Amsterdam only 10% of
exchange attendees were sharing equipment in the previous 6 months compared to
24% of non-attendees. Similarly, 74% of attendees were using equipment only once,
compared to 27% of non-attendees27,94 Comparable results have been reported
from Glasgow, Scotland where less risk reduction occurred amongst individuals
obtaining supplies from pharmacies compared to needle exchanges93. Even
stimulant users are able to change behaviour if they can be retained in treatment
programmes9^.
Partly as a consequence of the Amsterdam experience, UK practitioners began to
exchange injecting equipment and, under pressure from the McClelland report which
called for greater availability of injecting equipment, the UK Government set up 15
experimental needle exchanges in early 1987 which have now been evaluated9?-!".
The final report on 2449 clients concluded that these schemes reached a considerable
number of injection drug users, the majority living within two miles of the schemes.
Forty per cent had never been in a treatment programme and nearly 75% were not in
a current treatment programme. The attendees were however older opiate users with
a mean age of 27.8 years, mostly male (78%) and had an initial lower level of risk
behaviour compared to injectors who did not attend. For instance only 36% had
shared equipment within the previous four weeks and only 19% had shared with
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more than two individuals in the last four weeks. By comparison 62% of a group of
non attendees were injecting in the previous four weeks and 36% with more than two
individuals. Thus non attendees at exchange schemes had riskier injecting behaviour
despite the fact that this sample was interviewed after the Government publicity
campaign. The commonest reason for sharing was difficulty in obtaining equipment
and this did not differ between attendees or non attendees. The non attendees
however paid more attention to the cleaning of equipment than the attendees.
The major problems for needle exchanges were the high turnover of clients which
varied from a low of 25% to a high of 85% returning for a second visit. The average
retention rate was 61% for the second visit falling to 17% for the tenth visit and only
1% returning for more than 40 visits. The exchange rate also varied from 23% to
100% with a mean of 62%. The number of syringes/needles issued per visit varied
from three (the legal maximum per visit in Scotland) to 30, with a mean of nine per
visit.
Amongst clients who continued to attend there was evidence of self reported
reduction in needle related risk behaviour. For instance sharing in the previous four
weeks declined from 34% to 27% and the percent sharing with two or more
individuals declined from 17% to 11%. Over 70% of attendees and non attendees
reported that as a consequence ofAIDS they had made some change in their drug use
usually a reduction in sharing or an increase in using clean equipment.
Interestingly clients in Scotland, possibly because the schemes ran under stricter
legal controls with fewer needles and syringes given out per visit and shorter opening
hours, showed greater sharing compared to their English counterparts. For instance
76% of Scottish injectors had shared equipment in the previous four weeks compared
to only 52% in English injectors. In Scotland injectors found equipment harder to
obtain, were more likely to find the exchanges closed or to share in custody.
An evaluation of a central London exchange scheme was able to demonstrate after 3
months a fall in median injecting from 56 to 48.5 per month (p<0.001), sharing from
15 to 11% of the time, equipment borrowing on two or more occasions from 8 to 6%
and equipment lending on two or more occasions from 10 to 6% 101. This
improvement in high risk behaviour was associated with a self reported decrease in
skin abscesses in the previous 3 months from 14% to 9%101.
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The first North American needle exchange scheme in Tacoma, Washington State was
also able to demonstrate change towards safer injecting practices. Lending equipment
either to a close or casual friend significantly declined from 64 to 44 times/month
and 48 to 32 times/month respectively (p<0.05)102. There are reports that stimulant
users, who are known to inject more often and to be more at risk for HIV, are
additionally more resistant to behaviour change and this is one important area that
requires additional information^.
Effect on Acquisition ofHIV
Interestingly diabetic drug users in Baltimore were noted to have a lower than
expected incidence ofHIV. The explanation offered for this lowered incidence of
HIV amongst diabetics was the fact that these individuals have had preferential
access to clean injecting equipment 103
Needle exchanges are beginning to provide data that they can prevent acquisition of
HIV. This is mostly in the form of stable HIV prevalence rates over time and
unfortunately it is difficult to use the absence of an event as positive data. For
instance in London the prevalence ofHIV in attendees at a needle exchange was 6%
at the beginning and 7% at the end of the year of follow up^ 1. in Australia the
seroprevalence as judged by anonymous testing of returned equipment remained
stable at 1.5% in 1987 compared to 1% in 1986^4,105 seroprevalence rates in
Amsterdam have risen from 3.4% in 1983 to between 27-31% in 1987 even in the
face of harm reduction^. But how fast would the seroprevalence ofHIV have risen
without these measures and how much of this is new infection as opposed to the
movement of infected drug users into Amsterdam? Careful longitudinal studies are
required to answer these questions.
Outreach education, intervention programmes and cleaning ofequipment
One of the major criticisms of harm reduction measures based on treatment facilities
is the fact that many drug users are not in contact with treatment facilities.
Amsterdam's Municipal Health Service Drug Department (GG&GD) is unusual in
being in contact with at least 70% of its estimated 6-8000 drug users27,28 Unlike
the gay community collective organisations with an educational role have not
flourished with the exception of the Junky Union in the Netherlands27,28
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Modification ofInjecting Behaviour
Outreach intervention programmes have been developed most extensively in the
United States probably as a consequence of the early involvement of drug users in the
AIDS epidemic, the paucity of treatment facilities and the political climate in relation
to either increased treatment facilities or other harm reduction measures 106 jn the
early 1980's New Jersey began to hire ex-addicts to teach safer injecting techniques
which had the unexpected result of increasing the demand for drug treatment
facilities. New Jersey had instituted charges for drug treatment in the early 1980's
but then in response to the increased demand began to issue coupons for free
treatment via outreach workers. Of 1884 drug users interviewed by the Newark and
Jersey City Health Behaviour Project 49% subsequently entered methadone treatment
programmes 107. Outreach intervention programmes were also developed in San
Francisco and New York City to provide initially basic information concerning safer
injecting practices and then the distribution of condoms, cleaning solutions and even
injecting equipment despite the fact that this latter event remains illegal 106 jn gan
Francisco the early message of "Don't Share Needles!" utilised by the Haight-
Ashbury Free Medical Clinic in 1983 was extended by the San Francisco Aids
Foundation in 1985 into a larger campaign to raise the general consciousness of drug
users towards AIDS 108. This was then augmented by the use of Community Health
Outreach Workers to develop trusting relationships with drug users and deliver both
the message and simple practical help in the form of bleach 108.
The campaigns to teach cleaning of injection equipment have concentrated on
commonly available disinfectants such as bleach, alcohol, and detergent. Whilst
whole blood is protective against disinfection ofHIV, dilute household bleach, 70%
isopropyl alcohol and dilute detergent remain effective even in the presence of whole
blood and such compounds should be available to the majority of injection drug
users 109,110 street based education, utilising outreach workers and free one ounce
bottles of bleach have successfully improved 'safe' needle hygienelOlM 11,112. in
San Francisco the combination ofCommunity Health Outreach Workers and bleach
raised the use of bleach for equipment cleaning from 3% to 76%. Compliance with
the bleach disinfection protocol was associated with access to a Community Health
Outreach Worker108.
A NIDA funded study of drug users not enrolled in treatment was able to
demonstrate that outreach and intervention could influence entry into drug treatment
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and reduce high risk drug injecting behaviour107 The study enrolled 30,000 drug
users and their sexual partners and the preliminary report was on 1584 injection drug
users, the majority black and male in 5 US cities (Chicago, Houston, Miami,
Philadelphia and San Francisco). The recruitment was via community based
outreach workers and those eligible were those injecting drugs for at least the
previous 6 months and not enrolled in a treatment programme during the previous 1
month. The interventions used included some or all of the following; counselling
both individual and peer counselling, efforts to build peer support for behaviour
change, demonstrations and practice of safer injecting techniques. The safer
injecting practices that were encouraged included; not sharing equipment, use of
sterile equipment and or the cleaning of equipment with disinfectants. At follow up 6
months later 14-35% of the drug users had entered a drug treatment programme and
between 49-75% reported either stopping or reducing their frequency of drug
injecting. Amongst those who continued to inject 20-39% reported an increase in the
use of cleaning of equipment. There are also data to suggest that intervention
programmes improve the behaviour of users not directly involved in the
programmes 107.
However much more in the way of outreach and contact is required because in a
study of over 15000 US drug users whilst 85% of users were aware of the benefits of
clean equipment only 17% always cleaned their equipment and only a further 20%
always used new equipment leaving 63% using high risk injecting techniques! 13.
Effect on Acquisition ofHIV
There is as yet little scientific data to prove that outreach is effective in preventing
IDU related HIV although it is popular with clients. In San Francisco where
individuals self-reported an improvement in risk behaviour this improvement was
noted to coincide with an aggressive prevention campaign directed at drug users
which began in mid-1986. Subsequently a flattening of the Hepatitis B and HIV
seroprevalence curves has occurred since 1986 amongst drug users! 14,115 Similar
flattening ofHIV incidence in drug users has been reported from Baltimore and
Amsterdam! 16,117 p may be that campaigns detailing cleaning techniques could be
used effectively in areas such as prisons where needle exchange is unlikely to occur
because of security reasons. Perhaps the innovative use of graffiti demonstrated to be
effective at reaching drug users in Denver should be considered by others! 18
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Skin cleaning whilst not protective for HIV has been shown to reduce the risks of
endocarditis and skin abscesses. In 110 active drug users in San Francisco reporting
on skin cleaning and past infections only 4.2% of those who skin cleaned some of the
time reported endocarditis compared to 14.5% in those who did not skin clean. Forty
eight percent of those who never skin cleaned had suffered skin abscesses compared
to 24% for those who sometimes cleaned 1'9. In view of the seriousness of these
infections harm reduction measures for bacterial infections are needed and even more
so for HIV seropositive users in view of their increased susceptibility to bacterial
infections ^20-122
Safety ofHarm Reduction
A major concern of harm reduction for HIV is the concern that it may encourage
existing as well as primary or new drug use. There was no evidence for an increase
in the total number of injection drug users as a consequence of one needle exchange
programme'23. Needle exchanges also do not seem to encourage more drug use
amongst existing users. In Amsterdam those attending exchanges were compared
with those recruited from other areas such as hospitals or police stations. Only 29%
of attendees compared to 50% of the non-attendees had increased their injecting
during a 6 month period^,94 Similarly with the UK exchanges increased injection
behaviour in the attendees was not reported20>97-101 The opening of a needle
exchange scheme next door to a MMTP did not increase or decrease the number of
illegal substances found in the urine of the MMTP patients 124
Studies in Amsterdam have also shown that new users, that is people who had never
injected, were not attracted into the system. The mean age of those attending rose
with time from 26.4 years in 1981 to 30.1 years in 1987 and the proportion under 22
years fell from 14.4 to 4.8%27. if new, younger users were being attracted to drug
use one would expect the average age of the group to fall with time. The length of
injection drug use was also greater at 9 years for exchangers compared to 7 years for
non exchanged?. Comparable data has been reported from the underground needle
exchange scheme in San Francisco ' '4. rff,e use of bleach for disinfection of
injecting equipment has met some resistance especially in the UK on the grounds of
safety despite the fact that even full strength bleach has been shown to be relatively
non-toxic when injected in small amounts intravenously'25
Reasonable return rates have been recorded even for underground and illegal
exchanges although static sites were better than mobile sites (60% vs. 30%)'26.
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Return rates and public safety can be assured by public health initiatives such as
disposal bins in public places and providing portable plastic disposal containers to
exchangers. These techniques increased the return rate from 25% to 64% over 14
months in Sydney!27 More importantly there are studies on the infectivity of
discarded needles which suggest that lymphocytes can only be infected with HIV
from needles exposed to room temperature for 4 hours or less!28 Thus discarded
equipment may not be as much a danger as previously imagined for the general
public.
Limitations of Harm Reduction
Harm reduction for injection drug use is not the only solution for IDU related HIV
but it is a useful intermediate goal although for many progression beyond safe
injection drug use or oral opiate therapy is unlikely!23_ p is important to remember
that IDU itself is an immunostimulant which in the context ofHIV is a disadvantage
and that opiates not only increase susceptibility for bacterial infections but also
promote the growth ofHIV in cell cultures^5-88,130
Blanket harm reduction measures applied in the absence of effective counselling and
health education are not effective in achieving behaviour change. Needle sharing
still occurred in New Orleans and Portland, Oregon despite the fact that needles were
not controlled by prescriptions^!^ Similarly the widespread availability in Italy of
sterile injecting equipment and water which was introduced as a preventative strategy
to combat the fast growing heroin and hepatitis B epidemic in the mid 1970's failed
to prevent not only hepatitis B but also the spread ofHIV^. The data from
Amsterdam would suggest that it is not methadone availability alone that is
protective but the programme as a whole whilst the data from New York suggests
that counselling alone is equally ineffective^,75,89
The development and marketing of harm reduction strategies has also to take into
account the particular drug problem prevalent in a community as well as the
demographic and legal characteristics of that community. For example MMTP are
not successful in managing stimulant drug problems or it seems in preventing the
acquisition ofHIV in black drug users in San Francisco. In those circumstances
other measures such as clean equipment or the distribution of stimulants in a non
injectable form might be more effective but one also has to remember the variations
in safe injecting practices in differing racial groups around the USA^2,131,70,71 jn
an assessment of 7835 out of treatment injection drug users in 15 US cities Blacks in
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the Northeast and the West reported significantly (p<0.05) greater use of new needles
than Whites or Chicanos whereas in the Southwest both Blacks and Chicanos were
reporting the use ofmore new needles than Whites^ 1. In the same study the use of
cleaning agents was significantly (p<0.05) more likely amongst Blacks in the
Northeast or Blacks and Whites in the Southwest and West^l. In the UK the original
needle exchanges failed to attract young or female injection drug users and were less
effective at reducing high risk behaviour in Scotland presumably because of greater
legal restrictions^-100 Only time will tell whether behaviour change brought about
by harm reduction campaigns can be maintained although individuals retained in the
UK needle exchanges continued with their behaviourmodification^, 100
Despite major efforts with the homosexual community there is evidence that the
incidence of rectal gonorrhoea is rising again suggesting that the safe sex message
with regard to anal intercourse has not been maintained^2 Harm reduction for IDU
cannot prevent sexual transmission ofHIV and in many communities such as the UK,
the rate of increase in heterosexual AIDS has equalled or overtaken the rate for IDU
related AIDS^3,134 p- appears that the general heterosexual population as judged
by the sexual behaviour of college women in the USA between 1975 and 1989 has
not as yet changed significantly^5 p is not surprising therefore that drug users also
need to take on board the need to modify sexual behaviour.
Outreach programmes especially those based on ex or stable drug users also have
their problems. Whilst outreach may be viewed as work and part of a drug users
reintegration into society it suffers from often being part time, associated with low
pay and a high turnover of staff. There is also the concern that the ex drug user will
be drawn back into drug use as a consequence of the work. There are no estimates of
the risks involved for such workers but it is thought that they are not insubstantial
and this must be considered in the overall cost benefit analysis of such harm
reduction programmes106
Perhaps the major limitation concerning IDU harm reduction concerns the
methodology used to assess its effectiveness. Much of the work quoted here is only
in abstract form and close scrutiny of methodology is impossible although it does
illustrate the speed of change and the recent nature of the work.
The evidence concerning MMTP and the acquisition ofHIV is mostly retrospective
but consistent differences continue to emerge and prospective data on the
effectiveness ofMMTP with regard to low rates of acquisition ofHIV, corroborated
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with a self reported reduction in high risk behaviour, is now
available^,69,70,72,73,74
Much of the data from needle exchanges and outreach intervention programmes on
behaviour change for injecting drug users is however subject to the criticism that it is
based on a purely self reported behaviour change. Such studies often do not assess
the changes that occurred in a control group and are thus unable to attribute general
from specific behaviour change. The evaluation of the UK and Amsterdam needle
exchanges did attempt such assessments^,89,94,98-100 There [s as yet little
prospective data available on the acquisition ofHIV. San Francisco however has
noted a fall of annual seroconversion rates amongst drug users from 9 to 3% as a
consequence of a general media campaign, HIV testing, increased availability of drug
treatment and outreach programmes^6 The newer and hopefully more acceptable
methods of anonymous testing such as salivary or urine HIV testing or HIV testing of
blood from returned injecting equipment need to be utilised to assess the
effectiveness of intervention campaigns^l,104,137-139
Self reported data are used for assessing the sexual behaviour changes of
heterosexuals or homosexuals but are usually backed up by more objective
measurement parameters such as rates of sexually transmitted diseases or of rectal
gonorrhoea^32 IDTJ related research needs to find similar objective measures of
reduced risk behaviour. Frequency of injection drug injuries and or skin infections
can be used as markers of IDU. A self reported decrease in abscesses was associated
with self reported reduction in IDU!0!. Serum (3-2-microglobulin levels have
recently been shown to be increased in HIV negative drug users compared to non
drug users. They are also increased in HIV positive injecting drug users compared to
HIV positive non injecting drug users^6-88 Whilst absolute levels in HIV positive
individuals could not differentiate injectors from non injectors trends would provide
confirmation of self reported behaviour change. Hair analysis has been shown to be
an effective method of detecting drug use and could be utilised on a wider scale to
corroborate self reported behaviour change 140
Another major difficulty is to find objective measures of reduced equipment sharing
as opposed to IDU. Hepatitis B infection rates are sometimes quoted but these data
must be treated with caution because of the saturation effect in a community as a
consequence of the development of immunity! 14 Falling rates ofHepatitis B need
to be quoted together with the prevalence rates for markers of past Hepatitis B
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infection. Studies of returned equipment from needle exchanges have tended to
concentrate on the isolation ofHIV in order to demonstrate the potential for
spread^?. However the detection ofmore than one blood group from such equipment
would provide an objective assessment of sharing and if used randomly could be
used to corroborate self reported behaviour change.
Conclusion
It would appear that harm reduction measures such as oral opiate substitution therapy
and needle exchange when provided in the context of counselling and health
education are able to initiate contact with drug users, to maintain that contact and to
get across health education and prevention messages. There are preliminary data to
show that such measures are safe in that they do not increase drug use or initiate drug
use, are effective in changing high risk drug behaviour and that oral substitute
prescribing such as methadone is protective against acquisition ofHIV and may also
be protective against progression to AIDS. It seems however that methadone or
needles provided without counselling or health education are not effective. The
evidence that needle exchanges are directly protective for acquisition ofHIV is not
yet available. However there is indirect evidence in the form of an improvement in
high risk behaviour and highly suggestive evidence from those localities such as
Edinburgh where needle availability was actively reduced. Not only did reduced
needle availability fail to prevent an IDU epidemic it facilitated IDU related Hepatitis
B and HIV epidemics.
Thus a harm reduction strategy for IDU related HIV should incorporate; outreach
health education and counselling to initiate contact with and reduce high risk
behaviour amongst drug users not in treatment, increased needle availability in the
context of exchanges to reduce the sharing of equipment, increased availability of
oral substitute prescribing to reduce IDU and increased availability of drug treatment
hopefully to achieve eventual abstinence. There would appear at present to be no
overwhelming reasons for society to avoid harm reduction for IDU and in view of the
consequences of IDU related HIV for drug users as well as for vertical and
heterosexual transmission ofHIV every reason to increase such harm reduction
programmes. Those of us involved in the care of individuals infected with HIV
remain extremely concerned over society's continued opposition, either overtly or by
omission, to harm reduction. It is perhaps significant that a recent journal article
concerning the report "Treating Drug Problems" from the Institute ofMedicine of the
National Academy of Sciences dealt with effectiveness, cost benefit and the
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recommendations for both public and private treatment systems^. However there
was no discussion about the importance of drug treatment with respect to the control
ofHIV and what effect the HIV epidemic might have on need for drug treatment
facilities!
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CHAPTER 9
Inpatient Health Care Utilisation for HIV Infection with particular reference to
Injecting Drug Users
Introduction
The published models of health care for HIV and AIDS reflect the experience of
those centres where the majority of patients affected have been homosexual or
bisexual and there is little in the way of experience of injection drug users (IDUs)l>2_
Equally the health service resource utilisation for IDUs such as number of admissions
(NOA), average length of stay (ALOS), annual bed days etc. may be different to
other risk groups. There has also been little published on the health care resource
utilisation for early HIV infection and/or the effect, if any, of drug use.
The epidemic of injection drug use which began in Edinburgh around 1980, peaked
in 1983-84, was associated with intense sharing of injecting equipment and a
concurrent epidemic of injection related medical conditions including Hepatitis B^-6.
In 1985 and 1986 surveys found that between 38% and 52% ofEdinburgh drug users
had been infected with HIV and the Regional Infectious Disease Unit (RIDU) began
to admit increasing numbers of drug users4>7,8. This chapter details the health care
utilisation of patients attending the RIDU with respect to HIV and AIDS between
1985 and 1992.
Method
The voluntary self referral HIV Counselling clinic established in the Edinburgh
Regional Infectious Disease Unit (RIDU) was described in Chapter 5 and the
accompanying out patient services in Chapter 7. Full details of the clinics have been
previously published^. A confidential prospective database containing an
assessment of clinical staging, injection drug use, oral drug use, weight as well as
biochemical, haematological and immunological parameters is maintained on all
patients attending the City Hospital. The patients are identified on the database by
hospital number only and the cross link between hospital number and name is stored
on a separate database file which is kept on a removable "floppy disc". A
retrospective review of the inpatient care ofHIV infected patients at the City Hospital
was undertaken from the start of the epidemic until 31st December 1989. Thereafter
data on admissions were collected prospectively.
The clinical status of the patients was defined by the 1987 CDC definitions of AIDS
(as detailed in Chapter 1) and the immunological status was defined by a CD4 count
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of greater than or less than 200 cells/cumm during any calendar year of attendance.
The criterion for fulfilling a CD200 diagnosis was the first of two consecutive CD4
counts < 200 cells/cumm. If an individual fulfilled the criterion before or during an
admission, or had an AIDS diagnosis before or during an admission, the admission
was classified as such. The average length of stay was calculated by subtracting the
date of admission from the date of discharge.
Analyses of Variance were carried out on all data unless otherwise indicated and
statistical tests were carried out utilising SPSS/PC.
Results
Between the onset of the HIV epidemic in Edinburgh in early 1983 and the end of
the study on 31st December 1992, 624 known HIV seropositive patients had attended
the out patient department at the Regional Infectious Diseases Unit of the City
Hospital, Edinburgh. Of these, 436 (70%) were IDUs. By the end of the study period
373 (60%) of all out-patients had been admitted to the RIDU at some point and 154
had developed AIDS. The 373 patients had been admitted on 2,069 occasions,
(5.5/admitted patient, 3.3/clinic patient or 0.5/clinic patient/year) of which 146 were
one day admissions of day patients. The number of admissions for each individual
ranged from 1 to 35. The total number of bed days utilised was 21,934 (59 bed
days/admitted patient, 35.2 bed days/clinic patient or 5.0 bed days/clinic patient per
year. There were 879 (42.5%) admissions attributable to 141 patients with a
diagnosis of AIDS and accounted for 11,461 (52%) bed days.
The total number of admissions to the RIDU during 1989, were 2,196; 336 or 15%
of which were HIV related. The occupied bed days during this year were 14,860,
3,651 or 25% ofwhich were HIV related. The ALOS for HIV admissions was 10.9
days whilst for non HIV admissions it was 5.8 days. By 1992 the total number of
admissions to the RIDU were 1,999; 423, or 21% ofwhich were HIV related. The
bed days utilised during this year were 14424, 4653 or 32% ofwhich were HIV
related. The ALOS for HIV admissions was 11.0 days whilst for non-HIV admissions
it was 6.2 days.
Two hundred and fifty one (40%) HIV positive patients were not admitted during the
study period, 105 were admitted once, 51 were admitted twice, and 217 admitted
three times or more (maximum number of admissions = 35).
Table 9.1, figures 9.1 and 9.2 shows the characteristics of the HIV positive
population by Risk Activity of Injecting Drug User (IDU), Heterosexual (Het)
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Homo/Bisexual(Ho/Bi) and Transfusion (Tran) and by sex and age at time of
admission. Risk was undetermined for five individuals. Analyses of variance
indicated significant differences between the ages of different transmission categories
(F = 103.3 p< .0001) and gender (F = 117.8 p < .0001).
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Table 9.2 (figures 9.3 and 9.4) shows the Number of Admissions (NOA) per year, the
number of patients attending the clinic each year and the mean number of admissions
per year per patient, by clinical and immunological category. These include the
admissions to the ward which did not result in an overnight stay. The mean number
of admissions per patient gradually increased over time, up to 1990 for all categories,
but particularly for AIDS admissions. Over the time period the percentage of
admissions for AIDS increased from 8.7% before 1987 to about 50% in 1990 and
1991 and decreased in 1992 to 41%. This was probably due to the large increase in
deaths which occurred in 1990 -1991. Similarly, those with a CD200 diagnosis
increased from 7% before 1987 to about 75% from 1990 to 1992. The decrease in the
total number of admissions after 1990 was contributed to by the opening of a separate
facility for respite, convalescence and terminal care (Milestone House).
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Bed Days
The annual number of bed days used for HIV steadily increased over time until 1991,
when there was a decrease, for the reasons already given. The ALOS from 1986 to
1992 are shown in Table 9.3 (figures 9.5 and 9.6). These exclude admissions where
there was no overnight stay. The overall ALOS decreased from 1987 to 1991 (16 vs.
10 days) but increased again in 1992 to 11.3 days. The ALOS of those with a CD200
diagnosis, however, continued to decrease over the study period although the ALOS
for AIDS or HIV (non-AIDS) admissions also showed a nadir in 1991. By
comparison admissions of those without a CD200 diagnosis, however, continued to
decrease in 1992, although non-AIDS admissions did not.
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Over the study period 815 admissions occurred in 140 patients with a diagnosis of
AIDS and accounted for 11,461 bed days with an average length of stay of 14 days.
By comparison there were 1,108 non AIDS but HIV positive admissions of 292
patients, accounting for 10,473 bed days, with an ALOS of approximately 10 days.
Table 9.4 (figure 9.7 and 9.8) shows the ALOS per patient admitted, by clinical and
immunological category, risk activity and gender
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Analyses of variance were carried out examining the effect of risk, sex and AIDS or
CD4 status on average length of stay. There were no significant interactions between
AIDS or CD4 status with either risk or sex. There was a significant main effect of
AIDS status (F = 23.1 p < 0.0001) and a weaker but significant main effect ofCD4
count on ALOS (F = 4.7 p < = 0.05). There was a significant effect of risk (F = 3.8 p
< 0.05) and individual comparisons using the test ofModified Least Significant
Difference showed significantly longer lengths of stay for homosexual/bisexual men
than for drug users. There was no significant effect of sex (F = 0.86).
Annual Bed Day Use
The average annual number of bed days utilised per living patient by clinical or
immunological staging, risk activity and gender are shown in Table 9.5. Drug users
utilised more days than the other risk groups for AIDS and non-AIDS admissions
(59.9 vs. 44.7 vs. 52.0 and 5.4 vs. 3.3 vs. 4.4 days) although not when analysed by
with or without a CD200 diagnosis (20.4 vs. 23.6 vs. 39.8 and 4.2 vs. 1.6 vs. 7.0
days).. Over all and by CD200 diagnosis, homosexual men used more bed days. This
is at least partly a reflection of the fact that homosexual men tended to become
known to the clinic at a later stage than the drug users. The average time from first
visit to the clinic to death or the end of the study for homosexual/bisexual men was
28 months with 40% of that time being with AIDS. This compared to 49 months for
drug users with only 5.5% with AIDS. Females utilised more annual bed days per
year per patient than males for AIDS or HIV (non-AIDS) admissions (64.2 vs. 52.7
and 5.4 vs. 4.8) but not apparently when analysed by with or without a CD200
diagnosis (22.0 vs. 24.1 and 4.5 vs. 3.9).
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First Admissions
The clinical status of patients on their first admission was also investigated. Table
9.6 shows the AIDS and CD200 diagnosis of the transmission categories and genders
on first admission. Significant differences were found on chi square tests between
the transmission categories (IDU, Het and Homo/BI) for AIDS versus Non-AIDS
admissions ( chi^ = 93.9 p< 0.0001), and also between sexes, (chi^ = 7.48, p < 0.01).
Differences were also found between transmission categories for CD200 diagnosis at
first admission (chi^ = 8.8, p < .05), but not between sexes, (chi^ = 1.95).
Further investigation showed that of 41 individuals whose first admission was the
first time that they had been seen at RIDU, 24 were homosexual men, (34% of all
homo/bisexual men seen) 10 were drug users (2.6%) and 7 were heterosexual
(12.7%). Drug users were more likely to be admitted prior to an AIDS or CD200
diagnosis than, particularly, homosexual men. Generally, females were more likely
to be admitted at an earlier stage than males, though there was no gender difference,
when homosexual men were excluded from the analysis.
Sixty eight of the admissions (3.3%) were as a direct result of injecting drugs, (for
instance injection injuries such as abscesses or cellulitis) and were unrelated to HIV
infection or any other medical condition. A further 65 admissions (3.1%) were drug
related (usually detoxification or stabilisation of drug use). The ALOS for both was
12 days; 22.75 days reducing to 7.2 days in 1992. The number of admissions each
year was similar, with twenty admissions in 1988, 22 in 1990 and 28 in 1992.
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In view of the dramatic onset in 1983 of the Edinburgh EIIV epidemic in injection
drug users 4,8; it is not surprising that the utilisation ofHIV inpatient services
increased over time. The early stage of the Edinburgh drug related HIV epidemic is
demonstrated by the fact that 75% of drug users and 62% of homosexuals did not
have a CD200 diagnosis at first admission, though there were other major differences
between these transmission categories, as discussed below. The relatively early stage
of the Edinburgh epidemic, in health care resource terms, is also exemplified by the
fact that 40% ofHIV positive patients in contact with the hospital did not require an
admission, and only 35% had required 3 or more admissions. By the end of 1989
there were still only 51 patients with AIDS attending the clinic, less than 14% of all
HIV positive patients attending in that year. This had risen to 154 (25%) by the end
of 1992.
Clinical Staging: AIDS andNon AIDS
Among the AIDS patients in this study, 141 out of the 154 (92%) had been admitted
at some point and 92 (60%) had three or more admissions. The ALOS for each AIDS
admission in Edinburgh decreased from 35 days to 13.5 days whilst the number of
admissions rose from 1.5 to 2.6 per AIDS patient. The reduction in ALOS is likely to
be as a result of increased familiarity with the disease whilst the increase in the
number of admissions is probably associated with increased survival. These results
are comparable with a study of 863 patients with AIDS from North California where
99.5% had at least one admission and 57.7% had 3 or more admissions 10. The non
profit prepaid group practice in Northern California, which may be closer to NHS
medical practice than other US practices, reported a mean number of admissions of
3.3 and an ALOS of 17 days in 1983 which had fallen to 10.7 days by 1987 for AIDS
patients 10. The reduction in ALOS is likely to be as a result of the increased
familiarity of the treating physicians with the disease and the increase in the number
of admissions may well be associated with increased survival.
Considerable variations in the ALOS for AIDS have been reported between various
geographical areas; the ALOS for 1983-86 was 22.3 days for New York but only
13.5 days for San Francisco whilst in 1988 it was 9.7 days for Washington State, 32
days in Boston and 18.5 days in New Jersey 11~14. The number of admissions and
the ALOS for AIDS are affected by local demography, health care systems, stages of
the HIV epidemic, familiarity with the problems, anti-retroviral therapy and the use
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of newer therapies for opportunistic infections. There is also evidence of the
increasing incidence of conditions such as TB, lymphoma etc., which are likely to
require more protracted hospital stays, as other opportunistic diseases, such as PCP,
cytomegalovirus and toxoplasmosis become more treatable 15.
Without a doubt however, the major difference between New York and San
Francisco or the East and West Coasts of the USA in terms of health care are related
to differences in demography. In New York City, IDU has been implicated in 34%
of the male and 60% of the female patients whereas in San Francisco only 1.7% of
cases have been in drug users although a further 11.5% have involved drug use in
homosexual or bisexuals 16,17
The ALOS in Edinburgh for HIV (non-AIDS) admissions decreased from 14 days to
7 days in 1991 whilst the number of admissions per clinic patient clinic increased by
a factor of 1.6 from 0.47 to 0.75 admissions per patient. It is unclear why the ALOS
in 1992 was longer than in the preceding three years, but may reflect the fact that
prophylaxis for opportunistic infections delays the onset ofAIDS defining illnesses,
but does not prevent immunological decline as indicated by a CD200 diagnosis and
the onset of serious non AIDS ailments.
There were 1,108 (57.6%) HIV (non-AIDS) admissions in 220 patients, accounting
for 10,473 (48%) bed days. The fall in the proportion ofHIV (non-AIDS) admissions
to AIDS admissions from 1987 to 1990 reflects the development of the epidemic in
IDUs. The proportion of bed days used by HIV (non-AIDS) patients also steadily
decreased up to 1990.
There is unfortunately a paucity of data on non AIDS admissions compared to AIDS
admissions. In New Jersey the admission rate for HIV (non-AIDS) was 1.25
admissions/year/patient with an ALOS for HIV admissions of 12.7 days 18. ]n the
Montefiore Methadone cohort for the years 1986 and 1987 the admission rates were
0.22 and 0.27/patient/year 19. AIDS accounted for only 14 and 16% of the
Montefiore Methadone cohort admissions. Only 8% of the Edinburgh cohorts first
admissions were for AIDS suggesting that the Edinburgh and Bronx cohorts are
broadly comparable. The ALOS for non AIDS, HIV admissions for the whole of the
USA was 17.1 days in 1985 and 14.1 days in 1988 for HIV admissions 20.
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Immunological Staging
CD200 diagnosis based on falling below a level of 200 CD4 cells/cumm was
predictive of the number of admissions and the ALOS. There were nearly three times
as many admissions for those with a CD200 diagnosis than for those without by
1992. There was a significant difference in ALOS between the two groups when
looked at over the whole length of the study (12.1 vs. 10.0). This was less marked
than the difference between AIDS and non AIDS admissions, but became longer over
the last 12 months of the study. It is probable that physicians were more likely to
admit those with a CD200 diagnosis who were exhibiting some symptoms for
investigation than those with a higher count with similar symptoms. Such
admissions, where no opportunistic infection was found, would be of short duration
compared with admissions of those who were known to have AIDS and this factor
probably explains the relatively small difference in ALOS by CD200 diagnosis.
These admissions could be considered as a form of "prophylaxis" for opportunistic
infections in a population with poor compliance for standard prophylactic treatment
for Pneumocystis Pneumonia and who have a high incidence of bacterial pneumonia
and chronic obstructive airways disease.
Both clinical and laboratory staging of immunodeficiency provide useful indications
of health care resource utilisation, but the fact that those who have a relatively
healthy status with regard to their immunology and clinical status consume
significant health care resources in terms of in patient care cannot be ignored. It is
also important to note that, in Edinburgh by 1992, whilst HIV patients accounted for
21% of the admissions they occupied 32% of the bed days utilised in the Unit. This
increased length of stay compared to other patients and the increased likelihood of
admission with advancing immunodeficiency must be taken into account in health
care planning terms.
Gender
There was no significant difference for gender in ALOS whether analysed by AIDS
or CD200 diagnosis but females were more likely than males to have their first
admission prior to an AIDS diagnosis. This difference disappeared when drug users
alone were examined suggesting that the result has more to do with times at which
the different risk groups accessed health care rather than a gender difference.
Women with AIDS used more bed days per year per living patient than men (64.2 vs.
52.7) but the difference was not statistically significant. The situation in Edinburgh is
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in stark contrast to that in the USA where there are studies demonstrating that US
women present late for medical care; 39% ofwomen had a CD4 count of less than
200/cumm mm at presentation and in Minnesota two thirds ofwomen with HIV were
detected by neonatal screening rather than as a result ofmedical care 21,22 [n New
Jersey women presented with more advanced disease, with more symptoms and a
greater duration of symptoms (59.75 versus 24.5 weeks) than did men 23.
RiskActivity
Between 6-7% of both admissions and bed days in HIV positive patients could be
identified as being solely related to the effects of drug use rather than to HIV
infection. By comparison a similar survey amongst the Montefiore Methadone
programme revealed that 30-40% of the admissions in 1986-87 were drug related,
suggesting perhaps that our cohort are less chaotic in terms of drug use than in the
Bronx 14.
Drug users and those infected heterosexually had a shorter ALOS than homosexual
men (15.4 vs. 10.4 vs. 12.1 days). This may be related to the finding that drug users
were more likely to be admitted at an earlier stage in their illness than homosexual
men; only 8% of IDUs had AIDS on their first hospital admission compared with
70% of homosexuals. IDUs attend earlier in the illness, are more familiar with the
clinic and may be more likely to attend at an early stage when ill. The reasons for
this are unclear, but contributory factors may have been the early knowledge ofHIV
status in the IDU related HIV patients following massive publicity about the
epidemic in drug users in Lothian Region. Such local factors need to be taken in to
account in evaluating resource utilisation. Another local factor which may have
affected the presentation of individuals was advice about testing among the gay
community and the fact that some received their care as out patients from the GUM
clinic but transferred to the RIDU when they became more ill. The fact that the
counselling and medical clinics at RIDU were particularly associated with IDU
patients and offered a prescribing service in the early stages of the epidemic no doubt
also facilitated access of IDU patients at an earlier stage of disease. Certainly the
IDU population attending RIDU is over represented within the tested population
within Edinburgh. The Official Scottish figures 24 show that IDUs were 60% of the
tested population in 1992 but they have constituted between 70 and 80% of clinic
attenders in most years. It is clear from an earlier study that hospital admissions for
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drug users, prior to an AIDS diagnosis, can be largely accounted for by admissions
with bacterial chest infections 25.
A more difficult question to answer is what effect concurrent drug use or risk activity
has on health care resource utilisation since the main risk groups are usually not
comparable socio- economically. In 1989 and 1992 AIDS patients attending RIDU
on average utilised 15 and 13.5 bed days per admission, compared to 5.8 and 6.2 for
non HIV patients. In Switzerland, where only 31% were drug users, AIDS patients
utilised 23.3 days compared to 12.4 days per admission 26? suggesting that drug use
per se does not have a major effect. The effect of lower socio-economic status on
non HIV admissions has been shown in the USA to increase ALOS by 3 to 30% 27.
Two US studies have compared ALOS for AIDS for various risk groups;
homosexuals (16.23 days), heterosexuals (21.54 days) and drug using heterosexuals
(19.27 days)14. A further report^ showed an ALOS for homosexuals (13.8 days),
drug using homosexuals (11.1), heterosexuals (17.0 days) and drug using
heterosexuals (19.4 days). In Switzerland by comparison no significant difference
could be detected between the ALOS for homosexuals (18.5 days) or drug users (21
days) with AIDS 26.
In Edinburgh, when considering equivalent clinical or immunological stages, IDUs
did not use excessive resources as judged by ALOS compared with other groups.
Drug users were shown to make up 70% of the total population and, in any one year,
they constituted from 70% to 84% of the cohort. Over all they constituted 72% of all
those persons admitted and 69% of all days spent in hospital. However the average
number of bed days used per living AIDS patient was greatest for drug users (60 days
vs. 52 days for homo/bisexuals). It seems that drug users overall do utilise more bed
days per year than other risk groups although each admission tends to be shorter than
other risk groups.
Conclusion
By 1992 each member of the clinic was on average utilising 1 admission per year and
11.6 bed days per year. In Edinburgh, both clinical and immunological staging, were
predictive of resource utilisation. Gender however was not predictive and the effect
of risk activity was complex possibly because of differing socio-economic status.
The extra hospital resources for drug use related HIV appears to be in the form of
more frequent admissions at all stages ofHIV disease rather than in an increased
ALOS per admission.
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Whilst the increased use of resources with AIDS or CD200 diagnosis is not
unexpected it does underline the fact that the allocation of resources needs to be
based on both clinical and laboratory measures of immunodeficiency since neither
are sufficient to predict all the health care needs of a population.
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CHAPTER 10
The health service problems of IDU related health care
Introduction
By the end of 1991 35% of the AIDS cases and 50% of those infected with HIV in
Scotland were related to IDU1. Some 52% of Scottish HIV reports have come from
Lothian where 57% of the Lothian HIV cases have involved drug use, the highest
percentage in the UK for this particular risk group. The extent of the concentration
of ill patients in Lothian is seen by the fact that 50% of the reported cases ofAIDS in
Scotland and 67% of the CD4 200 cases have come from Lothian. 1
The Regional Infectious Disease Unit has been coping with the injection drug use
related hepatitis problems since 1970 and HIV since 1985. It was designated as a
Regional AIDS Centre in 1987 and new in-patient and out-patient services were
opened in 1991. The initial new facilities provided in London to cope with AIDS
were often based on open or Nightingale wards. These facilities were inappropriate
for a population where one third of the patients were female and a higher incidence
of infectious diseases such as TB and PCP was to be expected. Consequently the
majority of Edinburgh's new accommodation was based on cubicles rather than open
wards.
Characteristics of IDU which affect the Health Service
Since the major risk group in Lothian affected by HIV/AIDS are drug users, caring
for such patients introduces a number of problems, not faced by other AIDS Units in
the UK. One of the major problems for a health service is that drug users typically
have a a crisis type of life style with little planning other than for the next supply of
drugs. On average heroin drug users require 3-4 doses per day and therefore their
horizons are often limited to the next 24 hours. They are not particularly health
conscious as demonstrated by their overwhelming addiction and injection drug use
which is demonstrably a dangerous life choice. Lastly they have a tendency for a
high default rate in terms of the health care system probably because the priorities of
addiction come before all else (Chapter 7).
The characteristics of drug use itself are also important to bear in mind since it is an
illegal activity often associated with violence and unpredictable behaviour. The
accompanying aggression is often as a consequence of excess (e.g. alcohol/opiates)
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or a lack of drugs (e.g. opiates or benzodiazepines). Since recreational drug use
(other than of alcohol and nicotine) is an illegal activity in most countries medical
care for drug users whether HIV infected or not, is difficult to deliver. Since many
individuals come from socio-economically deprived areas there is an associated lack
of support in the community which puts a greater strain on the hospital services.
These characteristics of the drug using patients are important when considering the
problems the RIDU in Edinburgh has had to face. Whilst as a group injection drug
users exhibit poor utilisation of existing services it is important to remember that
some of this chaotic behaviour is as much a characteristic of their community as their
drug use^.
Health Care Service for IDU
In view of all these problems it is not surprising therefore that the health care system
has problems coping with drug users in large numbers. Even more difficulties occur
when one is trying to manage a chronic illness that requires regular attendance over
many years. Traditionally health care for drug users has been based on psychiatric
models developed for the management of addiction rather than the physical aspects
of care.
Health care workers themselves, are concerned over the behaviour associated with
drug use particularly verbal or physical aggression, disruptive behaviour, theft, the
carrying of offensive weapons, drug dealing, selfmedication, day night reversal
(sleeping the day away and being awake all night) etc. Much of the aggression and
the carrying of offensive weapons is however connected with the problems of the
drug culture and fear of their peers rather than a wish to harm health care workers
although they can be caught in the cross fire. An understanding of the reasons for
their behaviour helps in managing it in the wards. Without doubt nurses with both
physical and psychiatric expertise are essential.
Health Care Service for IDU related HIV
Despite the fact that IDU related HIV is becoming more common there are still
relatively few units in the UK with a large enough clinical workload to be able to
provide advice on the management of problems associated with IDU related HIV.
There are two possible methods of delivering care for HIV infected drug users. One
relies on physical restraint and coercion but there are very real concerns over the
possibility of deliberate infection of staff by patients and this has in fact occurred in
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other countries. In addition the system is also interested in increasing harm reduction
for both IDU and sexual behaviour by health education and a coercive system is
unlikely to succeed in this area. The other method of organising care for HIV
patients which was adopted in Edinburgh relies on attracting individuals to the health
care system via the facilities. It is hoped that using this method the chance of
deliberate infection occurring of the staff is reduced. In addition maintaining contact
with the patients over long periods increases the likelihood of harm reduction being
adopted. However as a consequence of the need to maintain contact for long periods
the health care service may have to tolerate more difficult and problematic behaviour
from the patients.
RIDU Edinburgh
The difficulties faced by the RIDU in Edinburgh of having a unique population
attending the Unit have necessitated a number of changes or alterations in the
organisation of the health care system. For outpatients the clinics have been stratified
for chaotic and non chaotic days as well as offering both drug and medical services at
the same site (Chapter 7). In addition higher staffing levels are required to contain
and cope with the problems of this difficult population which stretch from "bad
behaviour" to violent aggression and frank psychosis. It was noticed that more of the
most difficult problems tend to occur at high levels of occupancy whether this is in
the outpatient department or the wards.
Unfortunately only 11 of 15 beds in the new ward dealing with the mainly HIV
patients rather than infectious diseases were in the form of cubicles and the pressure
for cubicles for medical reasons has necessitated the use of cubicles from adjacent
wards. In addition, in order to spread out the different patient populations attending
the RIDU and reduce or avoid problems there has been an additional need to utilise
more than one area. Consequently the patients have been spread over three wards
rather than one in an attempt to reduce behaviour problems. This of course requires
more resources and increases the cost of care. Similar problems exist for the out
patient department and in order to spread out the different patient populations
attending the RIDU and to avoid problems, more clinics are organised to spread the
patient's attendance over the week. This obviously requires a higher staffing level
than if fewer mixed clinics were utilised.
Continuity of care from both nurses and doctors has been one of the most effective
means of reducing problems and incidents. Prior knowledge of the patient by the
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caring team can easily avoid problems. For the new ward dealing mainly with HIV
patients rather than infectious diseases this concept has been extended to night duty
and all the nursing staff rotate from day to night duty.
Problems ofRIDU, Edinburgh
Despite the absence of a serious incident even with the current staffing levels
problems have occurred.
Risk ofInfection and Isolation requirements
There are no students on the new ward and there are reduced student numbers on the
ID wards because of the problem of untrained individuals dealing with the problem
ofHIV. As an example, for a medical ward in the City Hospital the usual
establishment per ward is around 21 WTE but one third of these are student nurses.
By comparison because ofHIV the student numbers in the RIDU vary from 0% in
Ward 14 to around 10% in the other wards.
A large number of patients require isolation in cubicles because of infectious
problems such as salmonella, TB, or infective diarrhoea. Cubicles are also required
because of the nature of the patient population i.e. mixed sexes (one third are female)
and mixed risk groups (20% homosexuals and 70% drug users). The staffing
required for cubicles is higher than for an open ward or Nightingale wards. On an
isolation ward nurses are not immediately available since on leaving the cubicle hand
washing will usually be required. As a consequence more staff are required to cover
an infection ward than a general ward. In 1993 the ratio of the number of staff to the
number of beds is 0.79 for a medical ward in the City Hospital with only one or two
cubicles , between 1.06-1.11 for the general ID wards where 55% of the beds are
single cubicles and 1.7 for our HIV ward where 73% of the beds are single cubicles.
Ideally 2 nurses are required for every cubicle.
Escort duty
Every patient leaving the unit for any investigation is accompanied by a trained
nurse. This was instituted because other units were extremely reluctant to take the
patients, and incidents occurred. Also other departments were concerned over
spillage of body fluids such as vomiting, disconnected intravenous lines etc. A
review of the financial year 1992-3 revealed an average of 2.12 WTE nurses out of
the Unit/month covering escort duties. This is equivalent to 0.53 WTE out of the
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Unit/day. The grade of staff varied from an average of 7 hours/month of a G grade
sister to 33.3 hours of an E grade nurse/month.
Patient dependency
The physical care of the patients with HIV especially IDU related HIV varies from
mildly ill to high dependency (just short of ITU). The mixture of serious physical ill
health combined with serious mental ill health is rarely found in any other area of
medicine and as yet there is no dependency scale that easily reflects the problems.
This lack of an appropriate indicator for care levels has led to difficulties in justifying
resources. Whilst there is a dedicated HIV team, both medical and paramedical and
psycho-social, there are no other specialised drug dependence staff as for instance
might be available in other centres.
The dependency of the patients is both physical and psychological. On a physical
scale it can vary from just short of assisted ventilation because of respiratory failure
to the walking well with numerous psychological problems. On the psychological
scale the patients can be entirely well or have agitated psychotic states with physical
assault on staff (one of the episodes described above).
A 6 month survey of inpatients during 1992 revealed that on average 35.5% of the
patients in the wards each day had HIV infection; 89% of the patients in the wards
each day required total care (attention every 2 hours) whilst 0.9% of the patients in
the ward each day required constant care (one nurse in constant attention). In
addition 7% of the HIV patients in the ward each day or 0.8 patients/day in the ward
each day required increased supervision as a result ofmedical or drug related
drowsiness or because of psychiatric disturbance (see below).
A survey of dependency was undertaken utilising the Patient Assessment Information
System (PAIS); a scoring system which only accurately reflects acute nursing
interventions and omits the psychological needs of the patient^. An assessment was
made of the nursing hours needed on 12 randomly chosen HIV and ID discharges.
This revealed an estimated requirement for HIV patients of 81.81 hours of nursing on
one day with only 47.5 hours actually available compared to an estimated 52.5 hours
for ID patients with only 32 hours actually available^.
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Psychiatric problems
HIV related disease may present with apparent psychiatric problems such as
psychosis. However the differential diagnosis is extensive including toxic
confusional states from drugs or infections, space occupying lesions or HIV related
dementia. Admission to the RIDU is commonly requested in HIV positive patients in
order to exclude the diagnosis of an organic psychosis.
During a 12 month period (1992) 4 psychotic patients were admitted to the RIDU to
exclude organic psychosis rather than be admitted to the local psychiatric hospital.
The time the patients have remained in the Unit varied from a few days to over a
month and not surprisingly this put considerable strain on the Nursing staff.
Security incidents
Over a 12 month period (from August 1992) the busiest ward for HIV experienced 22
reported security incidents. These consisted of two physical assaults on staff
members by patients, one episode of self harm (slashed wrists) by a patient, 11
episodes of verbal aggression towards staff threatening physical assault, 5 episodes of
serious selfmedication requiring medical attention, one episode of theft of a patient's
valuables, one episode of the fire alarm being set of by patient's children, and one
episode of theft ofward equipment (later returned after lengthy discussions).
The out patient department suffered 12 serious security incidents in the 12 month
period consisting of, three episodes of theft of equipment, 4 episodes of verbal
assault threatening physical assault, one episode of physical assault on a
consultant(RPB), one episode of a fight between two patients which resulted in a
slashed face for one patient, one episode of damage to a consulting room as a result
of a patient being asked to observe the no smoking policy and at least 2 episodes of
unconsciousness requiring several hours of constant care in the day bed area as a
result of excess alcohol and drugs. In every year since 1985 the department has had
to deal with the problem of concealed offensive weapons such as guns and knives.
However the peak of incidents in the out patient department occurred in 1989 when
there were 40 security incidents or 3.3 events per month.
There are obviously many more incidents each week, not serious enough to require
reporting or the attention of the police, which are safely avoided or defused by the
staff. These which take considerable time to manage.
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Selfmedication
Continued use of non prescribed drugs taken either orally or by injection cannot be
totally eliminated in a Unit whatever the level of supervision. Unlike Drug
Detoxification Units, restricted visiting and body searches are not possible for
visitors nor for patients who are seriously ill. This results in episodes of excess
sedation requiring at the least constant care or infusions with antidotes and or the
risks of fire from smoking.
Fire incidents
The majority of the patients smoke heavily and since they also prefer excessive
sedative drugs there is a constant danger of fires started by careless cigarette
smoking. Much of the day and night is spent re-enforcing the ward rules with regard
to smoking; for instance repeatedly requesting patients not to smoke in bed or when
drowsy.
Over a 20 month period (10/91-5/93) there were 34 fire incidents in the City Hospital
involving the Fire Brigade. Of these 15/34 or 44% of the fire incidents occurred in
the RIDU area. Ten or 66% of the RIDU fire incidents were related to patients
smoking. Of the 7 ward evacuations that occurred as a result of fire incidents in the
hospital 6 or 86% of the evacuations occurred in the RIDU area. Four or 57% of the
RIDU evacuations were as a consequence of smoking. Unfortunately since the
patient's addiction to cigarettes is probably greater than or at least equal to opiates it
is impossible to enforce a total no smoking policy for the inpatient areas. Smoking is
restricted to patients and only in their rooms but problems still arise. Not
surprisingly the enforcement of such as policy and coping with the fires requires
considerable staff especially since 66% occurred out of office hours.
Conclusions
The range of problems which occur with IDU related HIV are not only extensive but
also very different to those usually faced by the health service. The RIDU in
Edinburgh has had to adapt in order to manage drug users with a chronic illness.
This adaptation has required new skills on the part of the staff and the gradual
reduction in problems suggests that not only are the staff adapting but possibly the
patients are also adapting to the health care system.
Despite this improvement, the RIDU is still having to cope with a considerable
amount of disturbed behaviour probably more so than other units managing HIV in
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the UK. As IDU related HIV appears in other areas of the UK these Units will need
to consider how best to cope with the associated disturbed behaviour. Hopefully
Edinburgh's experience of how to adapt and respond to behavioural problems will be
of some help to others.
One might question why should a health care system have to cope with this sort of
behaviour and there seems no doubt that if the patients were not infectious and
capable of infecting other individuals including health care staff it is unlikely that
funds would continue to be made available for the current level of service which is
extremely expensive (in the region of around £3-4 million per year). HIV/AIDS
funds are now being reduced since it appears that the epidemic is about to plateau.
However caution is required in the area of health care since any suggestion of lack of
caring by society may result in a backlash with the possibility of increased levels of
aggression towards the health service. Lower levels of staffing, the use of cheaper
methods of staffing such as temporary ("bank") staff, higher turnover of staff with
reduced continuity of care and or higher occupancy of difficult patients will and may
will lead to an increase of violent behaviour with increased risks for staff.
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IDU related HIV and prison medical care
Introduction
Unfortunately a considerable proportion of drug users, in Edinburgh perhaps as many
as 70%, will spend periods of time in prison. In view of the rising prevalence of drug
use related HIV, prisoners constitute a group who are at high risk ofHIV infection.
Exact figures ofHIV seroprevalence within UK prisons are unavailable as screening
of individuals on entry to or inside prison is not performed. European figures are
available however and give much cause for concern1. In Italy, which screens all
prison inmates, overall seroprevalence is 16.8% and in some reported studies is
around 30%2-3. Small scale studies in other countries have revealed prevalence rates
of 26% in Spain, 12.6% in France and 11% in Dutch and Swiss prisons'. It is not
unreasonable to estimate a United Kingdom seroprevalence of a similar order
especially in Scotland. In one study of two Madrid prisons, an overall
seroprevalence in males of 55% was found with the highest prevalence (77%)
amongst drug users^. In the USA, seroprevalence rates of up to 15% have been
reported^.
One consequence of the high rates ofHIV in drug using prisoners is that new
infections with HIV are bound to occur because injection drug use continues within
the prison environment. Owing to the lack of available injecting equipment, multiple
sharing does occur and it has been anecdotally reported that as many as 30 inmates
can regularly share a single set of injecting paraphernalia. This obviously puts HIV
seronegative drug users at great risk of acquiring HIV. A recent study of prison
inmates in one US prison suggested an annual rate of infection of 0.41% per person,
and the incidence of seroconversion in Stockholm Central Prison has been estimated
to be 1% per year^»^. Obviously higher transmission rates are more likely in regions
with high HIV seroprevalence in drug users.
With time it became apparent that as a consequence ofHIV infection in addition to
trying to reduce the spread ofHIV in prison some alteration in the medical care
arrangements for prisoners was necessary.
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Patients and Methods
As detailed in Chapter 6 during October and November 1988 the author undertook a
travel fellowship to compare and contrast medical services for injecting drug users.
This included visits to the prison medical services available in New York and San
Francisco.
HIVmedical care forprisoners in Edinburgh
Health care in Scottish Prisons is provided by the Prison Medical Service. In some of
the larger prisons this service employs full time medical officers but often it is based
on part time medical officers who are also general practitioners. Daily sick parades
or surgeries are undertaken and specialist medical care is provided by referral to local
hospitals either as in or out patients. HIV referrals to the City Hospital occurred soon
after HIV testing was introduced in October 1985 either because of requests by
prisoners or because known HIV seropositive individuals under care at the City
Hospital had been sentenced. This was not altogether surprising in view of the fact
that in one local study as many as 70% of Edinburgh injection drug users had been in
prison^.
HMP Saughton caters for adult male remand prisoners from South East of Scotland
as well as sentenced prisoners from all of Scotland. It has a maximum occupancy of
600 prisoners who are housed on single cells and only locked up between 20.30 and
6.30 hours. In May 1991 the breakdown of inmates was 20% on remand, 28%
serving sentences for less than 18 months and 52% serving sentences of longer than
18 months. There is no segregation ofHIV infected individuals although they are
excluded from cookhouse duties. The medical facilities consist of one full time and
two part-time medical officers, one principal nurse, 2 senior nurses and 16 nurse
officers. The prison has 11 "hospital beds", a treatment room, a dental suite and 3
rooms which can be used as consulting rooms. All prisoners are examined within 24
hours of admission to the prison and those identified as being at risk ofHIV are
offered counselling and or HIV testing.
The health care system for HIV in Edinburgh had to take into account the fact that a
significant number of patients with HIV and AIDS were spending some of their time
in prison. After discussions with Dr Joliffe, the medical officer and Mr Pearce,
Governor at Saughton Prison Edinburgh a specific HIV medical service for the local
prison was developed with the aim of improving the HIV medical care for prison
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inmates. It was also hoped to reduce the large number of prison inmates and officers
attending the outpatient department. This had produced considerable congestion in
the out patient department since each prisoner had to be accompanied by 2 officers.
Thus on some mornings there were as many as 12 individuals in the waiting room for
4 consultations. The large number of patients having to attend was also causing staff
problems at the prison and the officers accompanying the prisoners were intimidated
by the fact that many of the other patients attending the department were ex inmates.
It was also hoped that a specific service would reduce the number of patients "lost" to
follow up by the department during spells in prison and offer inmates (whether
patients of the City Hospital or not) access to the same treatment, whether standard or
experimental, as available outside the prison.
In August 1989 a twice monthly HIV medical clinic was established in the infirmary
ofHMP Saughton. The establishment of the clinic was preceded by an exchange of
nurses between the RIDU and the prison infirmary. Patients were either individuals
who had already attended the City Hospital HIV clinic or were HIV positive
individuals referred by the medical officers ofHMP Saughton. Equally all patients
known to be HIV seropositive could request a consultation with a visiting consultant
via the medical officer.
The service occupied one morning session every two weeks and was undertaken
except for holidays by Consultant medical staff (RPB and CLSL). The clinic took
place in the prison infirmary but was physically separate from the medical surgery.
All consultations were in private without prison officers or nursing staff although
recommendations for treatment were passed to the medical officers both verbally and
via letters. The hospital notes were used on all occasions to preserve confidentiality
and as before this encouraged fuller disclosures concerning current drug use. This
latter problem is important in differentiating drug use from HIV problems. The
results of the service were assessed up to December 1990.
Results
Between August 1989 and December 1990 41 (8%) of the 501 HIV positive patients
known to the City Hospital had been seen at the 32 prison clinics (117 attendances).
Thirty (73%) of the patients had previously attended the City Hospital outpatient
department clinic but 11 (27%) were new to specialist medical care. Twenty eight
(68%) of the 41 patients were seen after their discharge from prison at the RIDU
outpatient clinic. By comparison in December 1990, 80 or 16% of the City Hospital
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cohort had been lost to follow up. From August 1989 to December 1990 7 (17%) of
the 41 patients had been admitted to the City Hospital for inpatient treatment and one
had been diagnosed with AIDS. This approximates to 11% of the prison population
being admitted each year. By comparison approximately 12% of the patients known
to the City Hospital were admitted each year for inpatient treatment.
By December 1990 294 (59%) of the 501 patients seen at the City Hospital were in
CDC stage II or III and 207 (41%) had progressed to CDC stage IV. The prison
population was similar in terms of clinical staging in that 20 (49%) of 41 patients
were in CDC stage II or III and 21 (51%) were CDC stage IV.
Four patients or 8% of the 50 patients entered into the MRC\Inserm Zidovudine
(Concorde) trial were enrolled from these prison clinics. In addition 14 (9%) of 155
patients who were started on open label zidovudine did so at the prison clinics and
one patient continued on his zidovudine after imprisonment. Seven (11%) of 65
patients were commenced on inhaled pentamidine as prophylaxis for PCP in prison.
Review ofprison services in the USA
New York
In the 1970's a fear arose in the prison service that a lack of medical care could be
regarded as "cruel and unjust treatment". "Cruel and unjust treatment" was
unconstitutional and therefore moves began to provide a better prison medical care
system. It was decided in New York to offer the service out to tender and the
Montefiore Medical Centre provided the only initial bid. Montefiore Rikers Island
Health Service (MRIHS) now provides 80% of medical care for the New York City
correctional service but none for the State prisons^.
Individuals arrested in New York might spend 3-5 days in Precinct prison cells or
"lock ups" where there might be as many as 50 individuals per cell. Prisoners were
then moved to either Rikers Island or to what was called the "Tombs" (Manhattan
House of Correction for Men) which was above the lock ups in downtown
Manhattan. There were 200,000 arrests per year in the lock ups and Rikers Island
catered for 100,000 arrests per year of which 70,000 were separate individuals. At
any one time there were approximately 11,000 individuals (10,000 males and 1,000
females) on Rikers Island, seventy five percent were under 30 years of age, 19% were
under 21 and only 10% were over the age of 40. The mean length of stay on Rikers
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Island was only 40 days and 40% only stayed 7 days. The majority of crime in New
York is related to drugs or crime against property. It was thought that 40% of the
prisoners were drug users and 19% were enrolled in a Methadone Maintenance
treatment Program (MMTP) prior to imprisonment^.
Rikers Island had three types of prisoners, those on remand awaiting trial, those
serving a sentence of less than 1 year and those awaiting transfer to State Prisons.
Prisoners sentenced to serve longer than 1 year were transferred to a State prison and
at any one time there were between 1,000-5,000 (28%) prisoners awaiting transfer as
a result of a lack of accommodation in the State system. Prisoners on remand as in
the UK have more rights which essentially means more space, the right to wear their
own clothes and the ability to move around with fewer restrictions^.
The right to health for prisoners had in fact resulted in access to a better health care
system for those on Rikers Island than for those on the outside. The medical system
employs about 800 staff for 8 clinics which were open from 8am-4pm with
emergency cover at other times provided by part time practitioners. There were
approximately 70 full time doctors and physician assistants, 125 part time doctors
and 200 nurses or mental health staff. Each clinic was run by a Chief of Medicine (a
specialist in Internal Medicine), a Nurse Supervisor, a Social Worker and a
Pharmacist. MRIHS provides 24 hour, 7 day per week health care including 3
"infirmaries". These infirmaries were not able to cope with iv infusions etc. and
patients requiring more intensive medical care were transferred to a number of City
Hospitals with locked wardsd
All new prisoners were examined before they were assigned a cell. The clinics also
provided a comprehensive follow up service of any initial medical problems as well
as emergency medical care, daily walk-in clinics and specialist clinics such as
Dermatology, ENT, Neurology, Ophthalmology, Orthopaedics and Surgery.
The provision of methadone to substance abuse prisoners depended very much on the
sentence. Those awaiting transfer to a State prison were enrolled in a 7 day
detoxification programme whilst those already in a MMTP with a discharge date
within 21 days were enrolled in a 21 day detoxification programme in order to enable
them to return to their programme on discharged Lastly there was a new programme
called "keep" which provided maintenance methadone for those with an early
discharge date whilst an attempt was made to enrol them in a MMTP. The prisoners
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had to demonstrate addiction from their past medical or prison history and current
state but on the whole the programme was fairly liberal^* 10.
One infirmary had recently been converted to an AIDS dormitory because the
correctional system wished to house AIDS patients separately in order to avoid
victimisation. There was no programme ofHIV screening (unlike the federal system)
unless the prisoner requested it but there were probably a lot ofHIV patients in the
system as judged by the medical problems being treated. The medical officers were
seeing an increasing amount of TB and from the medical examinations they
concluded that continued drug use was occurring^. Eight per cent of females were
pregnant on admission^. Six per cent ofAIDS cases in inmates in New York have
concurrent TB and AIDS now accounts for 70% of inmate deaths^.
The MRIHS clinics were based on an open plan construction with 5 feet high
partitions to provide the necessary confidentiality whilst ensuring security for the
staff. There were dentists on site and facility for X-rays but not at all of the clinics.
The nurse practitioners and clinic doctors treated patients but not necessarily the
chief of the clinic who basically could do only administration if he so wished^.
San Francisco
The SFGH had a separate locked medical ward (Ward 7D) which was part of the
county jail. Access was regulated by the police and all acute medical cases,
psychiatric cases etc., in police custody needing acute care were admitted there under
the general medical teams. There appeared to be no system equivalent to the
Montefiore Medical Centres on Rikers Island in San Francisco. Consequently they
had little experience ofHIV related medical problems in drug users and there was no
methadone programme for prisoners 1 k
Discussion
Unfortunately to date most of the medical interest has been in the transmission of
HIV in prison rather than the medical care for individuals infected with HIV. There
are suggestions especially from the USA that prisoners are disadvantaged as far as
medical care for HIV is concerned. For instance one study from New York State on
the medical care of prisoners revealed that inmates with PCP arrived in a worse
physical state than community patients with PCP; only 5% of inmates admitted were
on zidovudine compared to 20% for community patients and the mortality for PCP
was 23% for the inmates compared to 5% for community patients^. in addition
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prisoners have considerable medical problems relating to their HIV infection; six per
cent ofAIDS cases in inmates in New York have concurrent TB and AIDS now
accounts for 70% of inmate deaths^.
The system used in New York whereby medical care is tendered for by health care
organisations seems to provide a better health care system than is available to an
individual via the municipal health care system when he or she is not in prison. This
situation may not of course apply to the UK but it does raise concerns over the access
of inmates to specialised HIV medical care.
Efforts to improve inmate's access to specialist care have been tried. For instance in
Rhode Island, USA a collaborative effort between the Brown University AIDS
Program and the Department of Health and Corrections had managed to evaluate 204
newly diagnosed HIV positive inmates (a policy of mandatory testing is in place) or
3.9% of all male inmates and 12% of all female inmates. They achieved 65% follow
up after discharge, improved access of inmates to expert medical care, significantly
reduced health care costs by reducing need for specialist consultations outside the
correctional facility^. in France two groups, one in Paris and the other in Bordeaux
have established similar systems to that in Edinburgh in an attempt to make specialist
medical care available to inmates ofprison. In Bordeaux 160 HIV positive inmates
had received medical consultations (7.5% with AIDS), 13% were on treatment with
zidovudine and 6% were receiving inhaled pentamidine^. in Paris over 1000
inmates are HIV positive, 75 already have AIDS and access to zidovudine for
advanced disease or PCP prophylaxis has been arranged^. After discharge from
prison 20% continued in medical care 16.
In Edinburgh approximately 10% of the current HIV clinic population are in
Saughton prison at any one time and the clinical stage of these patients reflects that
of the population as a whole. It is particularly important to note that the prison
population are no sicker than the clinic population and this is in part because of the
relatively short sentences that many of the patients had received. One can therefore
consider the prison HIV population as a small sample of the Edinburgh HIV
population and the results demonstrate that they have access to similar health care to
those patients in the community. For instance 8% of the zidovudine trial patients, 9%
of the open label zidovudine patients and 11% of the inhaled pentamidine treated
patients have been enrolled from the prison HIV population. Disappointingly 32% of
inmates were lost to follow up after discharge from prison compared to a lost to
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follow up rate of 16% for the City Hospital clinic by December 1990. Thus at
present the system is achieving its aims of providing prisoners access to specialised
HIV care although it is not yet maintaining that contact. The results are as good as
the best of the centres in the USA and apparently better than the French system with
respect to follow up 12,16 whilst these centres have reported delivering PCP
prophylaxis and zidovudine to inmates to date no other centres have reported
enrolment of inmates in clinical trials. In the USA there has been considerable
criticism of the HIV/AIDS therapeutic trial programme in not recruiting
disadvantaged groups such as women, ethnic minorities and drug users^.
The system adopted in Edinburgh is without doubt expensive in terms of consultant
time but it has ensured that patients in prison have the same availability ofmedical
care as those in the community. Whilst not suggesting that the rest of the UK prison
service should follow the same system consideration should be given to the
Edinburgh model.
Conclusions
To date transmission ofHIV in prisons has been ofmore concern than the medical
care for individuals infected with HIV. In Edinburgh approximately 10% of the
current HIV clinic population are in the local prison at any one time and their clinical
stage ofHIV reflects that of the HIV population as a whole.
The services instituted have provided inmates with similar access to health care as
patients in the community. Thus at present the system is achieving its aim of
providing prisoners with access to specialised HIV care although it is not as yet
maintaining that contact after the inmate leaves prison. The system adopted in
Edinburgh is without doubt expensive in terms of consultant time but it has ensured
that patients in prison have the same availability ofmedical care as those in the
community.
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